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Aggressive Non-Hodgkin lymphomas (aNHL) are a heterogeneous group of lymphomas. The 
constellation of oncogenic pathway activities can vary in patients with the same malignant disease. 
The pathological mechanisms behind the current criteria to distinguish individual aNHL subtypes are 
still poorly understood. Molecular models depicting the dynamics of oncogenic signaling and cross 
talk of the pathways can help to obtain a better understanding of lymphoma pathogenesis. Thereby 
the development of future targeted therapies, that will have to intervene with specific signaling 
modules to reverse pathway deregulation, will be enabled. We postulate that the description of a 
time-resolved global gene expression change provides new insights into the dynamics of oncogenic 
signaling and that the intervention into pathway intersections allows identifying new essential 
pathway nodes and cross talks for targeted therapies.  
To gain closer insight into distinct cell signaling networks and their relevance for NHL subtypes, 
firstly, high-dimensional data of time-resolved gene expression changes in BL2 cells induced by BCR 
or CD40 activation were generated. By using a newly established computational method we were 
able to describe 20 disjoint sets of genes to group their time courses. 15 significant sets of genes 
were identified for BCR stimulated samples and 5 significant sets of genes for CD40 activated 
samples, all displaying distinct time courses. We discovered a co-repression of LEF1, PTCH1 and 
NOTCH1 by activation of the B cell receptor. Functional assays revealed that BL cells are not 
responsive to Sonic hedgehog stimulation, but evidence is provided for a c-Myc-driven non-canonical 
regulation of this pathway. Furthermore, a working model for a causality network of BCR induced 
gene expression correlations was compiled. In addition, sustained activated BCR signaling induced a 
change of the gene expression profile towards a certain ‘DLBCL-likeness’. Therefore, a first step to 
develop a model displaying the causative factors for the non-mBL signature is provided. Secondly, 
the gene expression changes of BCR or CD40L stimulated BL2 cells after chemical inhibition of Tak1, 
JNK, p38 and IKK2 were monitored on the whole genome level. In BCR stimulated cells the activity of 
PI3K and Mek1/2 was as well inhibited. Additional biochemical analyses supported the view that 
Tak1 is a pivotal modulator of both CD40 and BCR mediated p38 and NF-κB signaling. Moreover, 
using (5Z)-7-Oxozeanol as well as TAK1-directed siRNA to inhibit Tak1 activity, a corresponding Tak1-
Erk1/2 subnetwork was described.  
Thus, the present study and the herein allocated data provide deep insight into oncogenic 
pathway activities and enable a large variety of continuing studies, which may help to obtain a better 
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Approved living circumstances in the Western World as well as the demographic change and 
prolonged life expectancies have favored cancer becoming a leading cause of mortality worldwide. 
According to the World Health Organization (WHO), cancer accounted for 13 % of all deaths in 
Europe in 2008 (Ferlay et al., 2010). Non-Hodgkin lymphoma (NHL) is estimated to be the tenth most 
common cancer worldwide, with an increasing incidence over the last decades and highest rates 
being reported in the most economically developed countries (Cancer Research UK, 2010). NHLs are 
a subgroup of lymphoma, which comprise a heterogeneous group of hematological malignancies that 
originate mainly from B cells (95 %) and usually form solid tumors. NHL can be divided into indolent 
(slow-growing) and aggressive (fast-growing) subtypes (Jaffe et al., 1998). B cell aggressive NHL 
(aNHL) is a very heterogeneous group of malignancies. In the last decade, clinical and experimental 
investigations complemented by novel molecular genome-wide investigations like gene expression 
profiling and whole-genome sequencing have helped to expand our understanding of the biology and 
diversity of different types of aNHL. 
1.1 Development and transformation of germinal center B cells in lymph 
nodes 
In the past 20 years, exciting progress has been made to elucidate the cellular origin of B cell 
lymphomas as well as the key events leading to transformation. Furthermore, large efforts were 
made to characterize the pathogenesis of lymphoma (reviewed in Klein and Dalla-Favera, 2008; 
Küppers, 2005). The development of B cells as part of the adaptive immune response is strictly 
dependent on their surrounding microenvironment. To achieve optimal antigen recognition by their 
surface antigen receptor, B cells undergo several maturation, differentiation and proliferation steps 
in different compartments of the body. Early B cell development occurs in the bone marrow, consists 
of rearrangement of the heavy and light chain immunoglobulin (Ig) genes and concludes with a B cell 
carrying a functional, non-autoreactive B cell receptor (BCR). Those cells differentiate into mature 
naïve B cells, leave the bone marrow and circulate in the blood and lymphatic system to performe 
the role of immune surveillance. In contrast, precursor B cells, which were unable to maturate a 
functionally active BCR, undergo apoptosis.  
Upon antigen binding to the BCR, mature naïve B cells can be activated. In the T-cell-dependent 
response to exogenous antigens, proliferating B cells form so called ‘germinal centers’ (GCs) in the 
follicles of peripheral lymphoid tissues including lymph nodes. In the early 1990 it was shown that 
GCs are the main site where the immunoglobulins are modified and finalized through somatic 




Today, it is broadly accepted, that the GC microenvironment is the general source of memory B cells 
and plasma cells (Figure 1-1), producing high-affinity antigen receptors and therefore being essential 
for an effective protection against invading microorganisms (MacLennan, 1994). In addition, the GC 
micromilieu seems to play an important role in lymphoma pathogenesis, since several studies 
observed that most types of malignant B cells forming B cell lymphomas reflect their origin by being 
‘frozen’ at that particular differentiation status. In fact, nearly all B cell aNHLs display somatically 
mutated IgV genes, indicating that they are derived from GC or post-GC B cells (Küppers et al., 1999; 
Stevenson et al., 2001). 
 
Figure 1-1 Simplified scheme of B cell differentiation in the germinal center. Antigen-activated B cells enter 
peripheral lymphoid organs and form a germinal center (GC). GCs are polarized into dark and light zones. The 
dark zone mainly consists of proliferating GC B cells, in which somatic hypermutation (SHM) occurs. By this a 
high rate of mutations in the variable (V)-region of Ig genes are introduced. GC B cells with mutated BCRs can 
then enter the light zone (now mainly consisting of resting cells) and are positively selected for high affinity 
antigen receptors. GC B cells exhibiting a BCR with lower affinity for the antigen undergo apoptosis. The 
selection process is presumably controlled through the close contact to T cells and follicular dendritic cells 
(FDCs). A fraction of the positively selected cells encounter class-switch recombination (CSR). Finally, GC B cells 
differentiate into plasma cells or memory B cells and leave the germinal center microenvironment into the 
periphery. Figure taken from (Klein and Dalla-Favera, 2008). 
Indeed, both of the germinal center-intrinsic processes somatic hypermutation and class-switch 
recombination may lead to genetic aberrations promoting lymphomagenesis (reviewed in Küppers et 
al., 1999). Thus, mistakes or malfunctions in the immunoglobulin gene remodeling mechanisms – 
chromosomal translocations and aberrant SHM – can be found as the main causes for genetic lesions 




deregulated expression of proto-oncogenes, because regulatory sequences have been juxtaposed in 
close proximity to the intact coding domain of the target gene from heterologous chromosomes by 
translocations. 
Thus, chromosomal translocations, which involve for example BCL-6 (B cell lymphoma 6), result in 
prevention of gene silencing at the end of the GC reaction and can be frequently found in diffuse 
large B cell lymphoma (DLBCL) (see chapter 1.3.1 for more detail). Enhanced expression of the proto-
oncogene c-MYC results from the translocation into the immunoglobulin heavy chain or light chain 
loci and is associated with 100 % of Burkitt’s lymphoma cases (see chapter 1.3.2 for more details on 
Burkitt’s lymphoma) and up to 10 % of DLBCL cases (Klein and Dalla-Favera, 2008). Moreover, 
additional genetic alterations occur in the different subtypes of aNHL, altogether leading to 





1.2 Paracrine and autocrine signaling influence B cell development and 
transformation 
Proliferation, differentiation and survival of activated B cells in secondary lymphatic organs rely 
tremendously on paracrine signals mediated by the microenvironment. This is provided in the GC, for 
example by T cells and follicular dendritic cells (FDCs). These bystander cells supply the maturating B 
cells with important survival signals, as for example CD40L expressed by CD4+ T cells (see chapter 
1.2.2 for further details) or Sonic hedgehog (Shh) expressed by FDCs in the GC (see chapter 1.2.3 for 
more information). On the other hand, autocrine signaling that is not dependent on surrounding 
microenvironmental cells determines the B cell fate in a similar manner. One central player includes 
the B cell receptor. Normal B cells depend on BCR expression for survival and undergo stringent 
selection for expression of the appropriate BCR throughout their lives. Moreover, the selection for 
expression of a functional BCR also seems to occur in most aNHL subtypes (Gunvén et al., 1980; Segal 
et al., 1991; Yano et al., 1992). Additionally, deregulations of BCR signaling or signaling mediated 
through BCR or CD40 activation seem to operate in BL and DLBCL (chapter 1.2.1 and 1.2.2). In the 
following paragraphs a brief overview will be given of BCR, CD40 and Hedgehog activated signaling 
pathways and the distinct mechanism involved in the respective pathway activations. As NF-κB 
(nuclear factor of kappa light polypeptide enhancer in B cells) and MAPK (mitogen-activated protein 
kinase) signaling are central to most of the here described signaling pathways, they will be described 
in more detail. 
1.2.1 B cell receptor activated signaling and its implications in lymphomagenesis 
Every normal B cell and consequently every lymphoma has a unique BCR, whose signaling results in 
activation of the NF-κB, phosphoinositol 3-kinase (PI3K), MAPK, nuclear factor of activated T cells 
(NFAT) and RAS pathways, which foster proliferation and survival of normal and malignant B cells 
(Dal Porto et al., 2004). The BCR is a multimeric complex, consisting of an antigen-recognition 
structure and a membrane-bound immunoglobulin (Ig), which itself lacks signaling capacity. 
Therefore, the BCR is non-covalently associated with CD79A (Igα) and CD79B (Igβ), each bearing an 
immunoreceptor tyrosine-based activation motif (ITAM) (Cambier, 1995; Reth, 1989), which 
transduces signals intracellularly (Figure 1-2). Antigen induced aggregation of the BCR induces ITAM 
phosphorylation by SRC-family kinases, which in turn leads to recruitment and activation of the 
tyrosine kinase SYK (Rowley et al., 1995; Saijo et al., 2003). The hereupon nucleated multiprotein 
complex consisting of various other kinases and adaptor proteins activates downstream kinases like 
Bruton’s tyrosin kinase (Btk) and phospholipase Cγ2 (PLCγ2) (Takata and Kurosaki, 1996). As 
consequence numerous signal transducers and second messengers are activated. Thus, for example 




calcineurin and the transcription factor NFAT (Antony et al., 2004). Additionally, the increased 
calcium levels activate protein kinase Cβ (PKCβ), which in turn phosphorylates many substrates, 
including caspase recruitment domain-containing protein 11 (CARD11), a key signaling adaptor 
mediating NF-κB activation (Shinohara et al., 2005).  
 
Figure 1-2 Simplified scheme of the basics of B cell receptor signaling. The scheme depicts the BCR, consisting 
of pairs of immunoglobulin heavy (IgH) and light (IgL) chains, whose variable region allows the BCR to bind to 
diverse antigens. The antibody portion of the BCR is coupled non-covalently with CD79A and CD79B, which 
mediate plasma membrane expression, signal transduction and receptor internalization. The ITAM region, 
containing two tyrosine residues (Y) is phosphorylated by SRC-family kinases (SFK) upon antigen-induced 
aggregation of the BCR following SYK recruitment. Several signaling mediators are engaged and lead to the 
activation of various downstream signaling pathways, as indicated (refer to main text for details). CIN85, Cbl-
interacting protein of 85 kDa; BLNK, B cell linker protein; BTK, Bruton tyrosine kinase; PLCγ, phospholipase Cγ; 
PIP2, phosphatidylinositol-4,5-biphosphate; PIP3, phosphatidylinositol-3,4,5-triphosphate; IP3, inositol 
triphosphate; DAG, diacylglycerol; PKCβ, protein kinase Cβ; PI3K, phosphoinositol 3-kinase; CARD11, caspase 
recruitment domain-containing protein 11; CBM, CARD11-BCL-10-MALT1; IKK, inhibitor of NF-κB. The asterisks 
indicate recurrently mutated protein regions in human lymphoma. Figure taken from (Young and Staudt, 2013). 
Furthermore, PI3K is activated through BCR crosslink and catalyzes the phosphorylation of 
phosphatidylinositol-4,5-biphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3), which 
acts as docking site for Akt (also known as protein kinase B, PKB) and phosphoinositide-dependent 
kinase 1 (PDK1). PDK1 phosphorylates Akt at threonine-308 in its kinase domain and subsequent 
phosphorylation of serine-473 by the mTor-rictor complex (mTORC2) leads to full activation of Akt 
(Sarbassov et al., 2005). Akt is the main mediator of the PI3K pathway. Through subsequent 
activation of mTor and resulting phosphorylation of ribosomal S6 kinases as well as the eukaryotic 
initiation factor 4E (eIF4E)-binding protein 1, components of ribosomal biogenesis and mRNA 




addition, Akt influences the transcription factor FOXO (forkhead box transcription factor), thus 
inactivating cell cycle inhibitors and promoting cellular proliferation (reviewed in Burgering and 
Medema, 2003). PI3K activity is counteracted by phosphatase and tensin homologue (PTEN), which is 
a PIP3 3-phosphatase (Di Cristofano et al., 1998; Salmena et al., 2008). Aberrant activation of the 
PI3K/Akt-pathway can be found in a wide array of cancers, including hematological malignancies 
(reviewed in Chalhoub and Baker, 2009; Markman et al., 2010).  
In contrast to the ‘activated’, antigen-induced B cell receptor signaling, a second form of BCR 
signaling mainly utilized by mature B cells to ensure B cell survival exists: so-called ‘tonic’ BCR 
signaling (Lam et al., 1997). Although several investigations implicate the PI3K pathway as a key 
component of tonic BCR signaling, the biochemical and biophysical basis of tonic BCR signaling and 
PI3K involvement is still debated (Cambier and Johnson, 1995; Delgado et al., 2009; Kraus et al., 
2004; Lam et al., 1997; Monroe, 2006; Wienands et al., 1996). 
BCR expression is maintained on the cell surface of most B cell lymphomas (reviewed in Küppers, 
2005), although immunoglobulin loci are disrupted in favor of placing oncogenes under the control of 
the immunoglobulin enhancers (reviewed in Nussenzweig and Nussenzweig, 2010). Many B cell 
lymphomas utilize IgM constant regions to form their BCR, because IgM-BCR signaling seems to 
promote the survival and proliferation of B cells, instead of IgG-BCR signaling, which favors 
differentiation into plasma B cells (Dogan et al., 2009; Horikawa et al., 2007; Martin and Goodnow, 
2002).  
1.2.2 CD40 mediated signaling 
CD40, a member of the TNFR (tumor necrosis factor receptor) superfamily, is expressed on the 
cellular surface of virtually all mature B lymphocytes. Upon binding to its ligand CD40L/CD154, CD40 
activates multiple signaling pathways promoting B cell activation, proliferation and survival (reviewed 
in Van Kooten and Banchereau, 2000). CD40L is primarily expressed by activated (CD4+) T cells. The 
CD40-CD40L interaction is regarded as the ‘classical’ co-stimulatory signal, contributing to GC 
formation, memory B cell formation, Ig isotype switching and affinity maturation (DiSanto et al., 
1993; Kawabe et al., 1994; Xu et al., 1994). A soluble form of CD40L exhibiting comparable activating 
features as the membrane-bound ligand has been reported as well (Graf et al., 1995; Mazzei et al., 
1995). 
Upon CD40-CD40L binding a multi-component protein complex is assembled, containing the 
adaptor molecules TNF receptor-associated factor 2 and 3 (TRAF2, TRAF3), ubiquitin conjugating 
enzyme Ubc13, cellular inhibitor of apoptosis proteins 1 and 2 (c-IAP1/2), IKKγ/NEMO and MAPK 




translocation of the ‘cytokine receptor-assembled signaling complex’ to the cytosol and thus to the 
activation of MEKK1-mediated MAPK signaling via p38 and JNK (Gallagher et al., 2007). In addition 
IKK-promoted canonical and non-canonical NF-κB activation can occur. Moreover, recruitment of 
TRAF6 and Tak1 to CD40 upon its engagement was also suggested, providing a second mechanism to 
activate MAPK and NF-κB signaling in response to CD40 activation (Matsuzawa et al., 2008). 
As in normal B cells, CD40 activation induces in certain B cell malignancies an increase in anti-
apoptotic factors such as Bcl-XL (B cell lymphoma-extra large), A20 (tumor necrosis factor, alpha-
induced protein 3 - TNFAIP3), survivin and CFLAR (CASP8- and FADD-like apoptosis regulator) 
(reviewed in Elgueta et al., 2009). Some in vitro investigations suggested that low-level constitutive 
engagement of CD40 may facilitate malignant cell growth. Studies with non-Hodgkin’s lymphoma 
cells including Burkitt’s lymphoma cells have shown that these cells express low levels of CD40L, 
which in turn leads to sustained cell proliferation through autocrine pathway activation and 
protection from apoptosis (Challa et al., 2002; Pham et al., 2002). Conversely, transient in vitro and in 
vivo activation of CD40 in Burkitt’s lymphoma, multiple myeloma and primary high-grade B cell 
lymphoma resulted in reduction of tumor cell proliferation (Funakoshi et al., 1994; Pellat-
Deceunynck et al., 1996). Thus, not only the activation status but also the quantitative level of CD40 
activation might play a role in cell fate determination. 
1.2.3 Hedgehog signaling pathway 
The Hedgehog (Hh) signaling pathway was first identified in 1980 in Drosophila melanogaster as 
essential developmental signaling pathway regulating proliferation, differentiation and migration of 
embryonic cells (Nüsslein-Volhard and Wieschaus, 1980). In humans, the Hh family of proteins 
comprises three distinct ligands which are processed from the same precursor protein: Sonic 
hedgehog (Shh), Indian hedgehog (Ihh) and Desert hedgehog (Dhh). In the absence of Hh ligands, the 
transmembrane receptor Patched1 (Ptch1) inhibits the activation of Smoothened (Smo), a 
transmembrane G-like protein coupled receptor and thereby prevents active Hh signaling. Once Hh 
binds to Ptch, the inhibition of Smo is abated, thus allowing Smo to translocate to the cytoplasm. 
Smo activation triggers a cascade of signaling events, leading to the activation of members of the 
glioma-associated oncoproteins (Gli) family of zinc-finger transcription factors (Gli1 and Gli2, which 
function mostly as activators while Gli3 as repressor). Gli then translocates to the nucleus and 
initiates transcription of Hh target genes, including GLI1, GLI2 and PTCH1 as well as regulators of cell 
proliferation and survival (Ikram et al., 2004; Lee et al., 1997). The exact details of these processes 
still have to be further investigated for mammalian cells. Since all Hh signaling via the canonical 




completely abrogate all Hh signaling regardless of the ligand (Incardona et al., 1998; Taipale et al., 
2000). 
The identification of point mutations in PTCH1 and SMO in patients with medulloblastomas, basal 
cell carcinomas and rhabdomyosarcomas (Aszterbaum et al., 1999; Goodrich and Scott, 1998; 
Marino, 2005; Xie et al., 1998) has linked the Hh signaling pathway to cancer. Recent investigations 
suggest that several cancers including B cell lymphoma abnormally express Hh ligands and activate 
the Hh signaling pathway in an autocrine manner (Singh et al., 2010). In addition to Shh production 
by follicular dendritic cells in the lymph node and its necessity for proliferation, survival and antibody 
production of germinal center B cells (Sacedón et al., 2005), another study demonstrated in vitro and 
in vivo secretion of Hh ligands by stromal cells in non-Hodgkin lymphoma, which promoted survival 
of the malignant cells in an inverse paracrine manner (Dierks et al., 2007). 
1.2.4 NF-kB signaling pathway 
The Rel/NF-κB-family of transcription factors plays a central role in the immune system by regulating 
various processes, including development and survival of B and T cells, as well as the control of 
immune responses and malignant transformation (reviewed in Vallabhapurapu and Karin, 2009). The 
NF-κB family comprises five subunits: NF-κB1 (p50 and its precursor p105), NF-κB2 (p52 and its 
precursor p100), p65 (RelA), c-Rel and RelB. These subunits form homo- and heterodimeric 
complexes that can bind to DNA and regulate NF-κB specific target genes. Inhibitors of NF-κB (IκBα, 
IκBβ and IκBε) hold NF-κB complexes in an inactive state in the cytoplasm (reviewed in Yamamoto 
and Gaynor, 2004). The release of NF-κB subunits from the IκBs is controlled by IκB kinases 
(IKKα/IKK1, IKKβ/IKK2 and IKKγ/NEMO) in a signal dependent manner. Many different stimuli activate 
the NF-κB transcription factors to induce their nuclear translocation. Here, two different pathways 
exist: the classical (canonical) and the alternative (non-canonical) pathway. The major and most-well 
studied pathway used by most stimuli (including antigen receptors (see chapter 1.2.1 for more 
detailed description), tumor necrosis factor receptors as CD40 (chapter 1.2.2), toll-like receptors 
(TLRs), IL-1R and others) is the canonical NF-κB pathway, which mainly employs the p65:p50 and c-
Rel:p50 heterodimers. This pathway mainly centers on activation through a trimeric IKK-complex, 
where IKK1 and IKK2 function as catalytic subunits that phosphorylate the IκBs leading to their 
subsequent degradation, while IKKγ/NEMO comprises the regulatory subunit of the IKK complex. The 
IKK2 subunit is referred to exhibit the majority of IκB kinase activity in most cell lines. In the absence 
of IKK2, IKK1 can adopt residual IκB kinase activity (Li et al., 1999), whereas deletion of IKK1 in IKK2-
expressing cells has nearly no effect on classical IKK activity (Hu et al., 1999). An important and 
unique function of IKK1 is the activation of the alternative NF-κB signaling pathway by activation 




processing of the p100 precursor and subsequent activation of RelB:p52 dimers (Yilmaz et al., 2003). 
This alternative pathway is activated in response to a small subset of tumor necrosis factor (TNF) 
family members, including CD40L, but also regulated through the canonical NF-κB pathway, which 
upregulates NF-κB2 expression (Senftleben et al., 2001). 
As mentioned above, NF-κB signaling is induced through a variety of different stimuli and 
positively as well as negatively regulated. Thus, it is not surprising that deregulated NF-κB signaling 
leads to aberrant expression of its target genes, which predominantly regulate cell survival, 
proliferation or growth and occupies an important role in many types of cancer. Hence, constitutively 
active NF-κB signaling can be found in several lymphoma subtypes including ABC (activated B cell-
like) DLBCL (see also chapter 1.3.1) or Epstein-Barr virus positive Burkitt’s lymphoma (chapter 1.3.2). 
1.2.5 Mitogen activated protein kinase (MAPK) signaling pathways 
Mitogen activated protein kinases (MAPKs) are serine/threonine-specific protein kinases directing 
the cellular response to a diverse array of stimuli, such as mitogens, pro-inflammatory cytokines or 
stress signals. Amongst others they regulate proliferation, gene expression, differentiation, mitosis, 
cell survival and apoptosis (reviewed by Pearson, 2001). The best studied MAPKs are extra-cellular 
signal related kinases 1 and 2 (Erk1/2), the Jun-N-terminal kinases (JNKs) and p38 kinases. MAPKs are 
activated by phosphorylation cascades. The two upstream protein kinases MAPK kinase kinases 
(MKKs) and MKK kinases (MAP3Ks) are activated in series and regulate MAPKs. Furthermore, 
additional kinases may be required upstream of this three-kinase module. Erk1/2, JNK and p38 are 
predominantly regulated by different MKKs (Raman et al., 2007), thus resulting in distinct responses 
to a specific stimulus. Another characteristic of the phosphorylation cascade is signal amplification 
provided if the successive protein is more abundant than its regulator. In case of the Erk1/2 pathway, 
Raf and MEK1/2 are the relevant upstream protein kinases. MEK1/2 inhibitors have been used 
extensively to elucidate the biological relevance of Erk1/2 in a wide array of events. One of the most 
often used inhibitors is U0126 (Favata et al., 1998), which interacts preferentially with the inactive, 
unphosphorylated kinase, thus preventing activation of MEK1/2. Upon stimulation Erk1/2 
phosphorylates a large number of substrates (reviewed in Yoon and Seger, 2006), among others the 
transcription factor Elk-1, which is thereby activated and is known to induce expression of immediate 
early response genes such as c-Fos (Gille et al., 1995). 
In contrast to the relatively well-insulated Erk1/2 pathway, p38 and JNK share most of their 
activators at the MAP3K level (MEKK1, MEKK4, Tak1 and others). In addition, some of the MKKs 
directly activate both p38 and JNK (MKK4), whereas others are specific for either p38 (MKK3 and 
MKK6) or JNK (MKK7). Due to this interlacing there are few stimuli that can induce JNK activation 




p38α-specific inhibitor SB203580 (Lee et al., 1994), which was exploited in a huge number of studies, 
revealed the pivotal functions of p38 in immune and inflammatory responses. P38 excerts its 
function through phosphorylation of many substrates in the cytoplasm and the nucleus, thereby 
modulating the activity of kinases as well as transcription factors (reviewed in Cuadrado and 
Nebreda, 2010).  
To elucidate the role of JNK in inflammatory diseases, apoptotic cell death and cancer, the 
reversible ATP-competitive inhibitor SP600125 has been invented (Bennett et al., 2001). The 
transcription factor c-Jun is a well-known target of JNK, as well as other transcription factors 
including p53, Elk-1, JunB, Stat3 and c-Myc (reviewed in Weston and Davis, 2002). 
Both MAPKs, p38 and JNK, are activated through the MAP3K Tak1 (transforming growth factor-β 
activated kinase 1). Tak1 was originally identified as a protein kinase involved in TGF-β (transforming 
growth factor -β) signaling (Yamaguchi et al., 1995), but has emerged in several studies for being 
activated through several external stimuli and thus being a key modulator of the cellular response to 
a variety of signals. These stimuli include IL-1R, TNF, bacterial lipopolysaccharide (LPS), CD40 and its 
viral counterpart LMP1, as well as BCR signaling in various types of cells (Arcipowski and Bishop, 
2012; Irie et al., 2000; Ninomiya-Tsuji et al., 1999; Schuman et al., 2009; Shkoda et al., 2012; 





1.3 Strategies to describe and stratify lymphoma cases based on gene 
expression profiling 
As described before, aNHL comprise a very heterogeneous group of malignancies. This is reflected in 
an increased number of distinct entities specified in the recent WHO classification (Campo et al., 
2011; Jaffe, 2009; Swerdlow et al., 2008). The WHO classifications attempts to define disease entities 
according to their histology, morphology, clinical behavior and molecular characteristics to help 
clinicians and pathologists to recognize the specific entity. In the 1950s, all NHL diversities were 
pooled together and treated – clinically and experimentally – as one disease. With the help of the 
WHO classification and the rise of new molecular methods, multiple novel therapeutic options have 
emerged in the treatment of aNHL and the distinct subtypes of aNHL are treated differentially 
nowadays. 
1.3.1 Diffuse large B cell lymphoma (DLBCL) 
The most common subtype of B cell NHL in Western countries is the diffuse large B cell lymphoma, 
which comprises 25 % to 35 % of new cases annually (Cancer Research UK, 2010). Although 
historically assembled into one category both pathologically and clinically, patients with DLBCL vary 
tremendously in clinical presentation, prognosis and response to current therapies. Patients often 
present with a rapidly progressing lymphadenopathy. Standard chemotherapy regimen includes 
cyclophosphamide, doxorubicin, vincristine and prednisone and the monoclonal antibody rituximab 
(R-CHOP). Response rates in patients with low-risk disease range from 80 % to 90 % (Feugier et al., 
2005), however the 5-year overall survival rate ranges between 30 % and 50 % in all DLBCL patients, 
indicating a large clinical spectrum of sensitivity to the standard treatment (reviewed in Cultrera and 
Dalia, 2012).  
Advances in molecular diagnostics went along with the definition of prognostic factors for DLBCL. 
DLBCL tumors present with large B cells with a very high percentage of tumor infiltrate. Most of the 
tumor cells resemble germinal center centroblasts, carrying complex chromosomal aberrations (Dave 
et al., 2002). Chromosomal alterations leading to aberrant expression of proto-oncogenes as BCL-6, 
c-MYC, BCL-2 and P53 are associated with poor outcome (Friedberg, 2011). The most common 
chromosomal alteration, leading to constitutive activation, is the translocation of BCL-6, a critical 
transcriptional repressor, whose down regulation is essential for the exit from the germinal center 
reaction (Ci et al., 2008, 2009; Fukuda et al., 1997; Iqbal et al., 2007; Kusam et al., 2009; Parekh et al., 






Identification of several subgroups of DLBCLs by global gene expression profiling 
The availability of an ever-growing panel of new genetic technologies, including gene expression 
profiling, array comparative genomic hybridization, methylation profiling, miRNA profiling as well as 
deep sequencing has led to an exponential growth in the discovery of the genetic basics of DLBCL’s 
heterogeneity. Based on gene expression profiling, Alizadeh and colleagues identified a stratification 
for DLBCLs subgroups established by their comparison of healthy B cells from distinct differentiation 
and activation statuses. Thereby two major molecular subtypes have emerged: germinal center B 
cell-like (GCB) DLBCL and activated B cell-like (ABC) DLBCL (Alizadeh et al., 2000). This classification 
helped to underline several diverse signaling properties of DLBCLs in further studies. Based on gene 
expression profiling, ABC DLBCL were identified to be hallmarked by a constitutive active NF-κB signal 
(Lam et al., 2005). Subsequent studies confirmed the activity of NF-κB to be required for ABC DLBCL 
survival in contrast to GCB DLBCLs (Davis et al., 2001). Further studies revealed dependency of ABC 
DLBCL cells on constitutive active BCR signaling, either in form of mutations in CARD11 (Ngo et al., 
2006) or mutations affecting the ITAM motifs of CD79A and CD79B (Davis et al., 2010). Both 
mutations lead to constitutive activation of NF-κB through the CARD11-BCL10-MALT1 (CBM) complex 
(Bidère et al., 2009). Due to these very recent findings, ABC DLBCL are now considered to be 
hallmarked by ‘chronic active BCR signaling’ (Davis et al., 2010) in contrast to other lymphoma 
entities which harbor tonic BCR signaling (compare chapter 1.2.1). Further on, the large number of 
downstream targets of NF-κB contribute to the poor prognosis of ABC DLBCL by collectively 
preventing apoptosis and rendering cells insensitive to chemotherapy (Baldwin, 2001; Rosenwald et 
al., 2002). By blocking the JAK signaling pathway in ABC DLBCL cells in vitro, resulting in apoptosis, it 
was shown that NF-κB signaling also induces cytokines, which act in an autocrine fashion resulting in 
activation of JAK/STAT signaling (Lam et al., 2008). 
1.3.2 Burkitt’s lymphoma (BL) 
In the WHO’s classification of lymphoid tumors, Burkitt’s lymphoma (BL) is listed as an aggressive 
non-Hodgkin B cell lymphoma, characterized by a high proliferation rate of the malignant cells and 
deregulation of the c-MYC gene (Swerdlow et al., 2008). BL was first characterized by Denis Burkitt in 
1958 as the most prevalent childhood lymphoma in Africa mostly localized at the jaw (Burkitt, 1958). 
Nowadays BL is classified in 3 clinical variants, differing in geographical distribution and Epstein-Barr 
virus (EBV) association. The endemic form of BL is found in equatorial Africa and is in 98 % of cases 
associated with an EBV infection (Blum et al., 2004; van den Bosch, 2004; Brady et al., 2008; Ferry, 
2006; Pattle and Farrell, 2006). The immunodeficiency-associated BL is related to an EBV infection in 
30 % of the cases and mainly presents in HIV carriers, where tumors can arise due to the severe 
immunosuppression coincident with the onset of AIDS (Powles et al., 2000). The sporadic form of BL, 




countries and the United States and is rarely associated with EBV infection (Blum et al., 2004; Brady 
et al., 2008; Ferry, 2006; Pattle and Farrell, 2006; Perkins and Friedberg, 2008). However, as the 
central leading event of pathogenesis all three forms share the activation of the c-MYC gene at 8q24, 
usually through translocation with an immunoglobulin locus, which introduces a transcriptional 
enhancer element (reviewed in Hecht and Aster, 2000).  
So far, for management of sporadic BL more intensive chemotherapy regimens are required than 
for treatment of DLBCLs (Blum et al., 2004; Magrath et al., 1996; Mead et al., 2002). Furthermore, 
because of the high risk of involvement of the central nervous system systemic chemotherapy 
crossing the blood-brain barrier is often essential (Bishop et al., 2000). The diagnosis of BL mainly 
relies on morphologic findings, cytogenetic features and immunophenotyping results (Jaffe, 2009; 
Swerdlow et al., 2008). However, the main diagnostic challenge in BL is to distinguish it from DLBCL, 
which may present with similar histological features. Additionally, the characteristic t(8;14) 
translocation of BLs, juxtaposing the c-MYC gene with an immunoglobulin enhancer also occurs in 5 
to 10 percent of DLBCL cases (Kramer et al., 1998). Since the prevalence for DLBCLs is 20 times higher 
than for BL, a lymphoma presenting with a t(8;14) translocation may raise diagnostic challenge. 
Molecular Diagnosis of BL with the index of ‘Burkitt-likeness’ 
In 2006, two major DNA microarray studies were published using whole genome gene expression 
profiling to distinguish BL from DLBCL on the molecular level (Dave et al., 2006; Hummel et al., 2006). 
Using a new statistical approach, Hummel and colleagues developed a molecular classifier to achieve 
a clear discrimination of BL from other mature aggressive B-NHL. Based on the gene expression 
profile of 220 NHL tumors, they identified 58 genes that constituted a molecular Burkitt’s lymphoma 
(mBL) signature. This mBL signature was used to establish a continuous index score (I) of ‘Burkitt-
likeness’ that allows the stratification of aNHL cases either into mBL (I > 0.95), non-mBL (I < 0.05) or 
intermediate lymphomas (0.95 < I > 0.05) (Hummel et al., 2006). Array-based comparative genomic 
hybridization (CGH) further revealed that mBLs had very few genetic alterations in addition to an IG-
MYC translocation (simple karyotype), whereas intermediate and non-mBL cases displayed a higher 
genetic complexity (non-IG-MYC translocations and other genetic aberrations on the background of a 
complex karyotype). At the same time, Dave and colleagues established a classifier for Burkitt’s 
lymphoma based on gene expression profiling with the help of c-Myc target genes identified by 
siRNA-mediated knock down of c-MYC in an ABC DLBCL cell line (OCI-Ly10). Tumor biopsies from 
Burkitt’s lymphomas could be distinguished to a certain extend from DLBCLs by high expression of c-
Myc target genes, the expression of a subgroup of germinal-center B cell genes and decreased 
expression of NF-κB target genes and major-histocompatibility-complex (MHC) class I genes. In 




molecular mechanisms underlying those differences in gene expression are still unclear (Dave et al., 
2006). 
1.3.3 Surrogate markers for oncogenic pathway activation 
Multiple studies demonstrated that DNA-microarray based gene expression profiling (GEP) provides 
the ability to define cancer subtypes, recurrence of disease and response to specific therapies. 
Various studies have also shown the potential of gene expression profiles for the analysis of 
oncogenic pathways. Hence, its stands to reason to use gene expression signatures, obtained 
through specified manipulation of target cells in vitro, to identify and model patterns of oncogene 
activity, which underlie the development of the oncogenic phenotype and reflect the biology and 
outcome of specific cancers (Bentink et al., 2008; Bild et al., 2006). Thus, the gene expression data 
established from ectopic expression of several oncogenes (including RAS, SRC, β-catenin, E2F3 and 
MYC) in primary human epithelia cells (Bild et al., 2006) has been used to model gene modules, 
representing the activity of a defined proto-oncogene (Bentink et al., 2008). These data were then 
combined to so-called ‘pathway activation patterns’ (PAPs), which stratified mature aggressive B cell 
lymphomas into distinct groups. One of the identified PAPs comprised mainly aNHL cases, which 
were characterized as ‘intermediate’ by the mBL index and present mainly cases carrying a complex 
karyotype and being situated in the transitional zone between mBL and non-mBL (Hummel et al., 
2006). The underlying pathway activities were largely undefined. In the meantime, GEP was used to 
demonstrate that outcome in DLBCL patients seems to be influenced by differences in stromal 
factors supplied by the microenvironment of the tumor, such as differences in immune cells, fibrosis 
and angiogenesis (Lenz et al., 2008). 
Driven by these investigations, the group of Dr. Kube started to identify and characterize new 
gene expression patterns that harbor information about relevant oncogenic pathway activities. In 
order to better understand the pathogenesis, implicated diagnostic and therapeutic possibilities of 
lymphomas, gene expression profiling of lymphomas was used to reveal oncogenic pathway 
activities. Therefore, one study focused on the effect of aberrant MYC activity in lymphoma 
precursor cells and its role in aNHL. Schrader and colleagues could later on demonstrate that high c-
Myc activity constitutes a negative prognostic marker in DLBCLs independent of established risk 
factors and of the presence of a MYC translocation (Schrader et al., 2012a). Additionally, A. Schrader 
also investigated the possibility to identify novel pathway activities in malignant lymphoma by 
transferring gene expression data from in vitro perturbation assays performed in lymphoma cell lines 
to primary lymphoma gene expression profiles (Schrader, 2011) and thus was instrumental in 
preparing the present study. 
  
Aim of the Study 
15 
 
Aim of the Study 
A major step fostering the understanding of the clinical heterogeneity of aNHL was the recent 
molecular classification of aNHL based on global gene expression analyses of individual lymphomas. 
These transcriptome based analyses aimed to describe oncogenic events to identify new biomarkers 
and potential targets for individualized therapies of aNHL. However, the mechanisms behind the 
current criteria to distinguish individual NHL subtypes are still poorly understood. A more functional 
characterization of deregulated pathways in aNHL needs to be elucidated in order to improve our 
knowledge of the molecular mechanisms of malignant transformation of B cells. 
We postulate that the description of time-resolved global gene expression changes provides new 
insights into the dynamics of oncogenic signaling. Furthermore, the intervention into pathway 
intersections by chemical inhibitors will allow us to describe the pathways interplay and cross talk. 
Based on in vitro experiments, it was concluded that subsets of aNHLs are characterized by 
aberrantly activated NF-κB and JAK-STAT signals. Using stimulation-mediated gene expression 
changes, specific pathway activities in individual NHL were predicted. Regardless these 
achievements, a number of open questions still exist and need to be answered. 
1) How is the activation of distinct pathway networks by BCR and CD40 activation reflected in 
the gene expression changes occurring over time? 
a. Identify groups of genes which are regulated in a comparable way in response to BCR 
and CD40 activation.  
b. Identify gene expression changes which reflect the immediate early and the late 
pathway activation triggered by BCR / CD40 activation. 
c. Identify networks of genes which reflect a dependency of gene expression 
regulations and could thereby represent regulatory circuits or feedback loops that 
stand in causal relationships within oncogenic pathways. 
2) Is the gene expression profile of DLBCL cells, in contrast to that of BL cells, dominantly 
shaped by constitutive active micromilieu signals?  
a. Evaluate how sustained activation of micromilieu derived signals influences the 
Burkitt-likeness of human transformed germinal center B cells. 
b. Interrogate whether it is possible to resemble the activated gene expression profile 
of DLBCL by stimulating BL cells in vitro.  
3) What is the functional background of the observed pathway activities? 
a. Interrogate which differentially regulated genes could be involved in the oncogenic 
function of the identified gene groups / signatures. 
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b. Identify new functions of signaling molecules that are involved in mediating these 
pathway activities. 
In order to answer these questions, a prototypical cell line characteristic for human transformed 
germinal center B cells was used to analyze the temporal pattern of global gene expression changes 
upon signaling pathway activation by factors of the microenvironment. Secondly, several potential 
oncogenic signaling pathways were inactivated at different levels in the signaling cascade in order to 
dissect intersections in the complex signaling network evolving in a lymphoma cell. 
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2 Material and Methods 
2.1 Biological Material 
2.1.1 Primary Material 
Primary material of human pediatric patients was obtained with consent and ethical approval from 
tonsillectomies performed in the University Medical Center Göttingen, Germany. 
2.1.2 Cell Lines 
Cell lines used in this work are listed in Table 2-1. 
Table 2-1 Cell lines 
Cell line Source Distributor Reference 
BL2 
B cell, Burkitt Lymphoma 
(EBV negative) 
DSMZ 
(Kube et al., 1995; Nilsson and 
Pontén, 1975)  
BL41 
B cell, Burkitt Lymphoma 
(EBV negative) 
DSMZ (Lenoir et al., 1985)  
BL70 
B cell, Burkitt Lymphoma 
(EBV negative) 
DSMZ (Lenoir et al., 1985) 
DG-75 
B cell, Burkitt Lymphoma 
(EBV negative) 
DSMZ (Ben-Bassat et al., 1977) 
HT 
B cell, Diffuse Large B cell 
Lymphoma (GCB) 
DSMZ (Beckwith et al., 1990)  
Ramos 
B cell, Burkitt Lymphoma 
(EBV negative) 
DSMZ (Klein et al., 1975)  
SuDHL4 
B cell, Diffuse Large B cell 
Lymphoma (GCB) 
DSMZ (Epstein et al., 1976)  
SuDHL5 
B cell, Diffuse Large B cell 
Lymphoma (GCB) 
DSMZ (Epstein et al., 1978)  
SuDHL6 
B cell, Diffuse Large B cell 
Lymphoma (GCB) 
DSMZ (Epstein et al., 1978)  
OCI-Ly1 




(Chang et al., 1995)  
OCI-Ly3 




(Tweeddale et al., 1987)  








(Chang et al., 1995)  
U2932 
B cell, Diffuse Large B cell 
Lymphoma (ABC) 
DSMZ (Amini et al., 2002)  
 
2.2 Chemicals and Consumable Supplies 
Chemicals and consumables used in the present study are listed in Table 2-2 and Table 2-3. 
Table 2-2 Chemicals 
Chemical Manufacturer 
α-Thiolglycerol Sigma-Aldrich, Munich GER 
Acrylamid/Bisacrylamid 40% BioRad, Munich GER 
Ammonium persulphate Sigma-Aldrich, Munich GER 
Bradford solution RotiQuant-Roth, Karlsruhe GER 
Bromphenol Blue Sigma-Aldrich, Munich GER 
Bovine serum albumin (BSA) Serva, Heidelberg GER 
Diethylpyrucarbonate (DEPC) Roth, Karlsruhe GER 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Munich GER 
deoxyribonucleoside triphosphates (dNTPs: 100 mM 
dATP, dCTP, dGTP, dTTP) 
PrimeTech LTD, Minsk BY 
Ethanol (100 %) J.T. Baker, Deventer NL 
Ethylenediaminetetraacetic acid (EDTA) Riedel-de Haën, Seelze GER 
Full Range Rainbow Molecular Weight Marker 
RPN800 
GE Healthcare, Munich GER 
Formaldehyde Sigma-Aldrich, Munich GER 
Glycerol Roth, Karlsruhe GER 
Glycine Roth, Karlsruhe GER 
HEPES Sigma-Aldrich, Munich GER 
Hot FIREpol DNA polymerase (5 U/µl) PrimeTech LTD, Minsk BY 
Hydrogen Peroxide Sigma-Aldrich, Munich GER 
Material and Methods 
19 
 
Isopropanol Sigma-Aldrich, Munich GER 
Luminol Sigma-Aldrich, Munich GER 
Magnesium chloride (25 mM) PrimeTech LTD, Minsk BY 
Methanol 100 % (p.a.) J.T. Baker, Deventer NL 
Milk powder Roth, Karlsruhe GER 
Nonidet P-40 Sigma-Aldrich, Munich GER 
Phosphatase inhibitor Phospho- STOP Roche, Mannheim GER 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich, Munich GER 
Proteaseinhibitor-Mix Complete™ Santa Cruz biotechnology, Heidelberg GER 
RPMI-1640 Lonza, Basel CH 
Sodium dodecyl sulfate (SDS) Merck, Darmstadt, GER 
Sodium chloride Merck, Darmstadt, GER 
Sodium deoxycholate Merck, Darmstadt, GER 
Sodiumvanadat Sigma-Aldrich, Munich GER 
Spectra Multicolor Broad Range Protein Ladder Fermentas, Frankfurt GER 
SYBR Green I Nucleic Acid Gel Stain Roche, Grenzach GER 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Munich GER 
Trehalose Roth, Karlsruhe GER 
Trisbase Sigma-Aldrich, Munich GER 
TritonX-100 Roth, Karlsruhe GER 
Trypanblue 0.4 % in PBS GIBCO BRL, Life Technologies, Eggenstein GER 
Tween-20 Merck, Darmstadt GER 
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Table 2-3 Consumables 
Consumables Manufacturer 
ABI PRISM® 384-Well Clear Optical Reaction Plate Applied Biosystems, Foster City USA 
ABI PRISM® Optical Adhesive Covers Applied Biosystems, Foster City USA 
Cell culture flasks Sarstedt, Nümbrecht GER 
Cryo Box Nunc, Wiesbaden GER 
Cryotubes Nunc, Wiesbaden GER 
Diethylaminoethyl-Cellulose Whatman®, International Ltd UK 
Electroporation Cuvettes BioRad, Munich GER 
Falcon Tubes 15 ml Sarstedt, Nümbrecht GER 
Falcon Tubes 50 ml Sarstedt, Nümbrecht GER 
Filter Tips, 10 µl, 100 µl, 200 µl, 1000 µl Starlab, Ahrensburg GER 
Micro Touch Examination Gloves Ansell, München GER 
Pasteurpipettes Sarstedt, Nümbrecht GER 
Pipette Tips w/o filters Sarstedt, Nümbrecht GER 
Reaction tubes 0.5 ml, 1.5 ml, 2.0 ml Sarstedt, Nümbrecht GER 
Serological pipettes 5 ml, 10 ml, 25 ml Sarstedt, Nümbrecht GER 
Tissue culture dish Sarstedt, Nümbrecht GER 
Tissue culture plates, 6 well, 12 well, 24 well Nunc, Wiesbaden GER 
96 well plate, Round/Flat bottom Nunc, Wiesbaden GER 
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2.3 Buffers, Solutions and Media 
Buffers, solutions and media used for this study are listed in Table 2-4. 
Table 2-4 Buffers, solutions and media 
Liquid Receipt / Manufacturer 
4x loading buffer Roti®-Load Roth, Karlsruhe GER 
Cell culture medium I 
(cell lines - BL) 
RPMI-1640   
10 % (v/v) FBS (Sigma-Aldrich, Munich GER) 
200 U/ml Penicilin + 200 μg/ml Streptomycin + 
4 mM L-Glutamine (PSG) (Sigma-Aldrich, Munich GER) 
50 µM α-Thiolglycerol, 20 nM BCS, 1 mM Sodium pyruvat 
Cell culture medium II 
(cell lines - DLBCL) 
RPMI-1640  
10 % (v/v) FBS  
200 U/ml Penicilin +200 μg/ml Streptomycin + 
4 mM L-Glutamine (PSG) 
Cell culture medium III 
IMDM (PAA) 
10 % (v/v) FBS  
200 U/ml Penicilin +200 μg/ml Streptomycin + 
4 mM L-Glutamine (PSG) 
OCI-Ly3 cells were cultivated with 20 % FBS 
EDTA cell culture grade 0.5 M (Sigma Aldrich, Munich GER) 
Freezing medium 
90 % (v/v) FCS  
10 % (v/v) DMSO  
Nuclear Extract Buffer A 
10 mM HEPES pH 7.9 
10 mM KCl 
10 µM EDTA 
10 µM EGTA 
1 mM DTT 
1 x Complete Mini Protease Inhibitor 
1 x PhosStop 
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Nuclear Extract Buffer B 
20 mM HEPES pH 7.9 
400 mM KCl 
1 mM EDTA 
1 mM EGTA 
1 mM DTT 
1 x Complete Mini Protease Inhibitor 
1 x PhosStop 
PCR buffer (10x) for qRT 
750 mM Tris-HCl pH 8.8 
200 mM Ammonium sulfate  
0.1 % Tween-20 
in depc water  
PBS  
(Phosphate Buffered Saline) 
137 mM NaCl 
10 mM Phosphate 
2.7 mM KCl, pH 7.4. 
PBS pH 7.4 (cell culture grade) Lonza, Verviers BEL 
Ponceau-S 
5 % (v/v) glacial acetic acid 
0.5 % (w/v) Ponceau-S 
ReBlot plus mild Millipore, Schwalbach/Ts. GER 
RIPA buffer 
150 mM NaCl 
1 % NP-40 
0.1 % SDS 
50 mM TrisHCl pH 7,4 
0.25 % Sodium-Deoxycholat  
Running buffer (1x): 
25 mM Tris-Base 
192 mM Glycin 
34.67 mM SDS 
Separation Gel Mix 
31.3 % (v/v) Acrylamid/Bis Solution (40 %) 
332 mM Tris Base, pH 8.9 
3.33 mM EDTA 
Stacking Gel Mix 
15 % (v/v) Acrylamid/Bis Solution (40 %) 
125 mM Tris Base pH 6.8 
0.1 % (w/v) SDS 
5 mM EDTA 
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Solution 1 Chemiluminescence – 
Luminol 
100 mM Tris/HCl pH 8.8 
2.5 mM Luminol (Sigma-Aldrich, Munich GER) 
4 mM 4-IPBA (Sigma-Aldrich, Munich GER) 
Solution 2 Chemiluminescence – 
Peroxide 
100 mM Tris/HCl pH 8.8 
10.6 mM H2O2 
SybrGreenMix 
1 x PCR buffer 
3 mM MgCl2 
1:80000 SybrGreen  
0.2 mM dNTP each 
20 U/ml Hot FIREpol DNA polymerase  
0.25 % TritonX-100  
0.5 mM Trehalose in depc water 
TBS (1x) 
20 mM Tris-Base, 
137 mM  Sodium Chloride, pH 7.6 
TBS-T 
1 x TBS 
0.1 % (v/v) Tween-20 
Transferbuffer (1x): 
 
25 mM Tris-Base 
192 mM Glycin 
15 % (v/v) MeOH 
 
2.4 Equipment 
Table 2-5 lists the equipment used in the present study. 
Table 2-5 Equipment 
Instrument  Manufacturer  
ABI PRISM 7900HT  Applied Biosystems, Foster City USA  
Accu-jet  Brand, Hamburg GER  
Biofuge Pico  Heraeus Instruments, Hanau GER  
Biofuge Primo R  Heraeus Instruments, Hanau GER  
Consort E734 Power Supply  Schütt Labortechnik, Göttingen GER  
CAT RM 5 horizontal roller  CAT M Zipperer, Staufen GER  
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Centrifuge 5451D  Eppendorf, Hamburg GER  
GenePulser Xcell Bio-Rad, Munich GER 
Hera freeze -80°C freezer  Heraeus Instruments, Hanau GER  
IKA KS 260 shaker  IKA, Staufen GER  
IKAMAG RCT magnetic stirrer  IKA, Staufen GER  
Incubator Cytoperm  Heraeus Instruments, Hanau GER  
Incudrive incubator  Schütt Labortechnik, Göttingen GER  
LAS-4000 Image Reader  Fujifilm, Düsseldorf GER  
Microflow Laminar Downflow Workstation  Bioquell, UK  
Microcoolcentrifuge 1-15k  Sigma, Munich GER  
Multifuge 3 L-R  Heraeus Instruments, Hanau GER  
ND-1000 UV/Vis-Spectrophotometer NanoDrop™, Wilmington USA  
Neubauer Counting Chamber Improved  Lo Labor Optik, Friedrichsdorf GER  
Power Pac 300 Power Supply  Bio-Rad, München GER  
Reax2 shaker  Heidolph, Schwabach GER  
SunriseTM Microplate Reader  Tecan, Crailsheim GER  
Thermocycler Mastercycler  Eppendorf, Hamburg GER  
Thermocycler 60  Biomed, Theres GER  
Thermocycler T3000  Biometra, Göttingen GER  
Thermomixer Compact  Eppendorf, Hamburg GER  
Vortex Genie 2  Schütt Labortechnik, Göttingen GER  
Water bath  Köttermann Labortechnik, Hänigsen GER  
 
2.5 Recombinant Proteins 
BL and DLBCL cell lines as well as primary B cells were stimulated with either sCD40L (#ABC159; 
AutogenBioclear, Calne, Wiltshire UK) or goat anti human IgM F(ab)2 fragment (#109006129; Jackson 
ImmunoResearch / Dianova, Hamburg GER). 
 




The chemical inhibitors used in this study are listed in Table 2-6. The final concentration listed for 
each inhibitor was used, if not stated differentially in the text. 
Table 2-6 Chemical inhibitors 
Description (target) Manufacturer Final concentration 
10058-F4 (c-Myc) Sigma-Aldrich, Munich GER 60 µM 
5Z-7-oxozeaenol (TAK1/MAP3K7) Calbiochem/Merck, Darmstadt GER 100 nM 
Akti-1/2 (Akt) Calbiochem/Merck, Darmstadt GER 2.5 µM 
AZ-Tak1 (TAK1) Tocris Biosciences, Toronto, CA 500 nM 
Bisindolylmaleimide I (PKC) Calbiochem/Merck, Darmstadt GER 1 µM 
BKM-120 (PI3K) Selleckchem, Munich GER 1 µM 
BX-912 (PDK1) Selleckchem, Munich GER 250 nM 
Compound 15e (PI3K) Enzo Life Sciences, Lörrach GER 400 nM 
Cyclopamine (SMO) Calbiochem/Merck, Darmstadt GER 5 µM 
Everolimus (mTOR) Sigma-Aldrich, Munich GER 1 µM 
IKK2 inhibitor VIII (IKK2) Calbiochem/Merck, Darmstadt GER 7 µM 
Ly294002 (PI3K) Calbiochem/Merck, Darmstadt GER 10 µM 
SB203580 (p38/MAPK14) Sigma-Aldrich, Munich GER 2 µM 
SP600125 (JNK) Calbiochem/Merck, Darmstadt GER 10 µM 
U0126 (MEK1/2) Sigma-Aldrich, Munich GER 10 µM 
U73122 (PLCγ) Tocris Biosciences, Toronto CA 1 µM 
 
  




Antibodies used for immunoblotting are summarized in Table 2-7. 
Table 2-7 Antibodies used for immunoblotting. 
Antibody Source  Working dilution 




1:5000 in 3 % milkpowder in 
TBS-T 
rabbit anti p-AKT (S473) (#9271) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti p-AKT (S473) (D9E) 
(#4060) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit p-Akt (T308) (C31E5E) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti pan AKT (C67E7) 
(#4691) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti c-myc (#9402) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti c-Rel (G57) (#4774) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti HDAC1 (#2062) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti p-p38 
(T180/Y182)(#9211) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti p38 (#9212) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti p-p44/p42 (p-
ERK1/2) (#4372) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti p44/p42 (ERK1/2) 
(#4695) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti p65 (C22B4) (#4764) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti p-p70 S6 Kinase 
(T389) (108D2) (#9234) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti p70 S6 Kinase (49D7) 
(#2708) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
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rabbit anti p100/p52 (NF-ΚB2) 
(#4882) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti p-IκBα (S32) (14D4) 
(#2859) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti IκBα (44D4) (#4812) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti p-SAPK/JNK 
(T183/Y185) (81E11) (#4668) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti JNK1/3 (C-17) 
(#sc-474) 
Santa Cruz, Heidelberg GER 1:1000 in 5 % BSA  in TBS-T 
rabbit anti RelB (C1E4) (#4922) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti p-S6 ribosomal 
protein (S240/244) (#2215) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti S6 ribosomal protein 
(54D2) (#2317) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
rabbit anti Tak1 (D94D7) 
(#5206) 
Cell Signalling/ New England 
Biolabs, Frankfurt am Main GER 
1:1000 in 5 % BSA  in TBS-T 
goat anti mouse HRP polyclonal 
(D1609) 
Santa Cruz, Heidelberg GER 1:5000 in 5 % BSA in TBS-T 
goat anti rabbit HRP polyclonal 
(E1710) 
Santa Cruz, Heidelberg GER 1:5000 in 5 % BSA  in TBS-T 
 
  




Primers used for qRT-PCR are summarized in Table 2-8. 
































































2.9 Ready to Use Reaction Systems 
In Table 2-9 the Ready to use reaction systems applied during this study are listed. 
Table 2-9 Reaction Systems 
Description Manufacturer 
RNA Isolation Kit Machery+Nagel, Düren GER 
Rneasy® Mini Kit Qiagen, Hilden GER 
SuperscriptII™ RT Kit  Invitrogen, Karlsruhe GER 
SignalBoostTM Immunoreaction Enhancer Kit Calbiochem via Merck, Darmstadt GER 
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2.10 Software used 
If not stated elsewhere the following software products were used: the present thesis was written in 
Microsoft® Office Word 2013 and 2007. Literature-management and bibliography was generated 
using Mendeley Desktop Version 1.8.4. Graphs were created using GraphPad PRISM 5.04 and figures 
were assembled using Adobe® Photoshop® CS2 and Microsoft® Office PowerPoint 2013 and 2007. 
Gene expression data were manually compared and analyzed using VENNY (Oliveros, 2007). 
2.11 Cell Biology 
2.11.1 Cell Culture Techniques 
Burkitt Lymphoma cell lines were cultured in RPMI-1640, 10 % (v/v) FCS, 200 U/ml Penicilin, 
200 μg/ml Streptomycin, 20 nM BCS, 50 µM α-Thioglycerol, 1 mM Sodium pyruvate. Cells were 
cultured at 37°C, 5 % CO2 and splitted daily depending on the observed cell proliferation (cell density: 
0.3x106 cells/ml - 1x106 cells/ml). The day before the experiment 0.3x106 cells/ml were seeded. 
DLBCL cell lines, except OCI-Ly1, OCI-Ly3 and OCI-Ly7, were cultured in RPMI-1640, 10 % (v/v) FCS, 
200 U/ml Penicilin, 200 µg/ml Streptomycin and kept in a cell density of 0.5x106 - 1x106 cells/ml. OCI-
Ly1 and OCI-Ly7 were cultured in IMDM, 10 % (v/v) FCS, 200 U/ml Penicilin, 200 µg/ml Streptomycin, 
4 mM L-Glutamine and OCI-Ly3 were cultured in IMDM, 20% (v/v) FCS, 200 U/ml Penicilin, 200 µg/ml 
Streptomycin, 4 mM L-Glutamine. 
Cells were counted in 0.4 % Trypan blue using a Neubauer counting chamber. To cultivate cells 
from a frozen aliquot, thawed cells were washed with 10 ml of the respective cell culture medium 
(centrifugation 250 x g, 7 min at RT). The cell pellet was resuspended in 5-10 ml medium and cells 
were incubated at 37°C, 5 % CO2. To freeze cells approximately 1x107 cells were sedimented as 
described above and resuspended in 1 ml freezing medium (90 % FCS, 10 % DMSO). Cells were frozen 
in cryo boxes containing isopropanol to obtain a constant cooling of approximately 1°C/min and 
stored immediately at -80°C for 24 hours before permanent storage at -150°C. 
2.11.2 Activation of B cells with Soluble Stimulating Factors 
Burkitt lymphoma cell lines were seeded in fresh media in a density of 3x105 cells/ml (DLBCLs: 
5x105 cells/ml) the day prior to experimental handling. In order to stimulate the cells, they were 
counted, centrifuged at 250 x g for 7 min, resuspended in fresh corresponding medium supplied with 
10 mM Hepes (1x106 cells/ml) and supplemented with sCD40L (200 ng/ml) or anti human IgM F(ab)2 
fragment (13 µg/ml). Cells were incubated at 37°C, 5 % CO2 for 15 min, 30 min, 60 min, 90 min, 
120 min, 150 min, 180 min, 210 min, 240 min, 360 min, 480 min and 24 hours for microarray 
analyses. Cells were harvested (10 min, 300 x g, 4°C) and washed with PBS containing 100 mM 
sodium orthovanadate. Samples were frozen at -80°C and RNA was isolated with the RNeasy Kit 
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(Qiagen) for microarray analyses or with the NucleoSpin® RNA II Kit (Macherey-Nagel, Düren 
Germany). 
2.11.3 Inhibitor Treatment 
16 hours prior to inhibitor treatment cells were seeded in serum-reduced media (0.5 % FCS) at 
3x105 cells/ml (BL cell lines) or at 5x105 cells/ml (DLBCL cell lines). Before inhibitor treatment, cells 
were counted, centrifuged (250 x g, 7 min) and seeded in a density of 1x106 cells/ml in fresh serum-
reduced media containing 25 mM Hepes. For microarray analyses, cells were treated with 100 nM 
(5Z)-7-Oxozeaenol (TAK1/MAP3K7 inhibitor), 7 µM IKK2-VIII inhibitor, 10 µM Ly294002 (PI3K 
inhibitor), 2 µM SB203580 (p38/MAPK14 inhibitor), 10 µM SP600125 (JNK inhibitor) or 10 µM U0126 
(MEK1/2 inhibitor) for 3h prior to BCR or CD40 activation. The stimulation was performed for 3 hours 
to monitor gene expression changes, or for 30 minutes to validate pathway activation via WB 
respectively. Cells were harvested at 300 x g at 4°C for 10 min and resuspended in ice-cold PBS, 
supplemented with 1 mM sodium orthovanadate. Dry pellets were frozen at -20°C for protein 
analyses or -80°C for RNA processing. 
2.11.4 Transfection of siRNA 
Small-interfering RNA (siRNA) is a short (20-25bp) double-stranded RNA molecule, which can be 
theoretically used to knock down any gene of interest when synthetically engineered. siRNA can be 
introduced in mammalian cells by transfection. Transfection can be carried out using calcium 
phosphate by mixing a cationic lipid with the siRNA to produce liposomes, which fuses with the cell 
membrane. Another transfection method is electroporation. For electroporation, the cells are 
exposed to short pulses of an intense electric field, which transiently increases the permeability of 
the cell membrane. 
To achieve a knock down of Tak1, corresponding siRNAs (Silencer® Select, Invitrogen, Darmstadt 
GER) were transfected into Burkitt’s and Diffuse large B cell lymphoma cell lines using the GenePulser 
Xcell (Bio-Rad, Munich GER). 2 µg of corresponding siRNA were transfected by electroporation 
(300 V, 150 µF, 1540 Ω) in 2.5x106 cells/ml lymphoma cell lines in 200 µl Opti-MEM® (Invitrogen, 
Darmstadt GER) and transferred into 5 ml pre-warmed RPMI 1640, supplemented with 10 % (v/v) 
FCS, 200 U/ml Penicilin, 200 μg/ml Streptomycin, 20 nM BCS, 50 µM α-Thioglycerol, 1 mM Sodium 
pyruvate and 25 mM Hepes. Transfected cells were incubated for 24 hours at 37°C, 5 % CO2 and 
subsequently transfected a second time.  A non-sense siRNA without a human target was used as 
control (scrbl). Upon two transfections and subsequent 24 hours of incubation, control-transfected 
cells were subjected to inhibitor treatment and stimulation with sCD40L (200 ng/ml) or α-IgM 
(13 µg/ml). 
Material and Methods 
32 
 
2.12 Protein Biochemistry 
2.12.1 Preparation of Cell Lysates 
Cells were harvested using sedimentation (300 x g, 7 min, 4°C) and washed once with PBS containing 
1 mM Sodium orthovanadate. Dry pellets were stored at -20°C until further preparation. 
Whole cell lysates 
Whole cell lysates were prepared by resuspending a cell pellet corresponding to 1x106 cells in 50 µl 
RIPA buffer. The cell suspension was incubated for 30 min on ice, subsequently residual cell debris 
was sedimented at 13000 rpm for 15 min at 4°C. The supernatant, containing the whole cell lysate, 
was transferred into a fresh tube and protein concentration was determined using the RotiQuant® 
assay (Roth, Karslruhe GER). Protein concentration was measured with a microplate reader (Infinite® 
F50, Tecan, Männedorf CH). 
Cell fractionation 
To demonstrate activation of the NF-kB pathway, nuclear translocation of NF-kB family members was 
monitored. Therefore, separation of cytosolic protein from nuclear protein was necessary. To obtain 
nuclear extracts from freshly harvested cell pellets, cell fractionation according to Schreiber et al. 
(Schreiber et al., 1989) was accomplished. Therefore 1x107 cells were harvested (300 x g, 10 min, 4°C) 
and washed twice with PBS containing 1 mM Sodium orthovanadate. Pellets were lysed in 400 µl 
buffer A and incubated 15 min on ice. 25 µl 10 % NP-40 were added and vigorously vortexed for 10 s. 
Samples were sedimented for 5 min, 4°C at 13000 rpm and the supernatant containing cytosolic 
protein was transferred to a new tube. The pellet was covered with 50 µl buffer B and shaked 
strongly for 25 min at 4°C in the cold room. Upon sedimentation for 5 min at 13000 rpm, 4°C, the 
supernatant containing the nuclear proteins was transferred into a new tube. Protein concentration 
was determined using the RotiQuant® assay (Roth, Karslruhe GER). 
2.12.2 SDS-PAGE and Western Blot 
For separation of proteins depending on their molecular weight sodium dodecyl sulphate 
polyacrylamide gelelectrophoresis (SDS-PAGE) was used (Ahn et al., 2001; Laemmli, 1970). Using the 
BioRad System (Munich, GER), polyacrylamide gels comprised of a 10 % separation gel and a 5 % 
stacking gel were prepared. 20-30 µg of protein samples were loaded with 4x RotiLoad®-loading dye, 
denaturized at 95°C for 5 min and loaded onto the gel. For protein size determination, Rainbow-
FullRange™ marker was loaded additionally. Gels were run with 20 mA per gel for 1 hour and 
subsequently proteins were transferred to a nitrocellulose membrane (Hybond™-C extra, GE 
Healthcare, Munich, Germany) using the Tank Blot System (BioRad, Munich, Germany). The 
separating gel was cut from the stacking gel and equilibrated for one minute in Transfer Buffer. For 
Material and Methods 
33 
 
protein transfer a pile was carefully prepared as follows: cathode (-), foam pad, 2 Whatman™-papers, 
separating gel, nitrocellulose membrane, 2 Whatman™-papers, foam pad, anode (+). Transfer was 
conducted at 100 V for 1 hour at 4°C.  
2.13 Molecular Biology 
2.13.1 mRNA Isolation 
mRNA was isolated from cell pellets using the RNeasy® Mini Kit (Qiagen, Hilden, Germany) or 
NucleoSpin® RNA Kit (Macherey&Nagel, Düren, Germany) according to manufacturer instructions. 
mRNA was eluted using 40 µl RNAse-free water. Concentrations were measured by NanoDrop™ 
measurement. 
2.13.2 Reverse Transcription 
In order to obtain cDNA, 1 - 2 µg mRNA was reversely transcribed using the SuperScriptII™ RT Kit 
(Invitrogen, Darmstadt GER). Reverse transcription was initiated with random hexamer primer. 2 µl 
random hexamer primer (100 µM) and 1 - 2 µg mRNA in 10 µl H2O were added to each cup. The mix 
was denaturated for 10 min at 70°C in a thermocycler (Biometra). Subsequently 8 µl of Master Mix 
(Table 2-10) was added and the complete mixture was incubated in a thermocycler with the 
following program (Table 2-10). 
Table 2-10 Master Mix and thermocycler program for reverse transcription of mRNA 
Master Mix thermocycler program 
4 µl 5x First Strand Buffer  
2 µl DTT (0.1M) 42°C 60 min 
1 µl dNTPs (10 mM each) 65°C 10 min 
1 µl SuperScript RT II 4°C ∞ 
 
2.13.3 qRT-PCR (quantitative Real Time – Polymerase Chain Reaction) 
For the quantification of transcripts, a SYBR® Green based system was used. The cyanine dye SYBR® 
Green intercalates in double-stranded DNA. The resulting DNA-dye-complex absorbs blue light 
(λmax = 488 nm) and emits green light (λmax = 522 nm) and can therefore be used to quantify double-
stranded PCR products over time during a PCR reaction. The number of PCR cycles at which a certain 
threshold of fluorescence intensity is achieved (Ct - value, cycle threshold), directly correlates to the 
number of DNA templates present in the reaction. 
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Transcript quantification was performed with Fast SYBR® Green (Applied Biosystems, Foster City 
USA) for GC B samples and a self-made SYBR Green Mix (see section Materials) for all samples 
obtained from cell lines. To carry out the PCR reaction and fluorescence detection an ABI PRISM 
7900HT sequence detection system (Applied Biosystems, Foster City USA) was used (SDS 2.4). For GC 
B samples, cDNA corresponding to 2.5 µg RNA was used as template. For cDNA obtained from cell 
line experiments a corresponding amount of 10 - 20 µg RNA was used. PCR reactions were performed 
in a 384-well clear optical plate. The relative mRNA expression levels were determined by 
normalizing the mean Ct-values of triplets to the Ct values of a housekeeping gene: 
ΔCt = Ctgene of interest – Cthousekeeping gene 
The ΔCt values of the modified sample and the control sample can then be compared by 
calculating ΔΔCt: 
ΔΔCt = ΔCtmodified sample - ΔCtcontrol 
ΔΔCt is a relative measurement, giving the values for the differences of cycles of the amplicon of 
the gene of interest after treatment in comparison to control. Assuming that the efficiency for both 
genes (household gene and gene of interest) is 100 %, one can calculate the n-fold change = 2-ΔΔCt. As 
housekeeping gene, ABL was chosen in this study. All primers for the qRT-PCR reactions were 
designed with the use of PrimerExpress™ software (Applied Biosystems, Foster City USA) on the basis 
of the published NCBI mRNA sequence (http://www.ncbi.nlm.nih.gov/sites/entrez/). Specificity was 
tested with the help of BLAST software (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). In addition, 
the efficiency of each pair of primers was assessed, running a qRT-PCR on a dilution series of 
template DNA and calculating the slope m of the linear regression of the standard curve. The 
efficiency was calculated by 
E = 10-1/m – 1. 
Thus, an efficiency of 100 % results in a slope of -3.32 which corresponds to a doubling of the 
amount of amplicon with one cycle. Primer pairs with an efficiency lower than 93 % were abolished. 
Analyses were accomplished using Microsoft® Office Excel 2007. 
2.14 Microarray Analyses 
Two different types of Affymetrix GeneChip® microarray platforms were used in the present study. 
For pathway perturbation analyses via inhibitor use (chapter 3.3), the Affymetrix GeneChip Human 
Genome U133 Plus 2.0 array was used to ensure comparability to former derived data sets. The time 
course analyses were hybridized on Affymetrix Human Gene 1.0 ST microarrays. In contrast to the 
classical 3’ gene expression arrays, the Human Gene 1.0 ST microarray platform is a whole-transcript 
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expression array, including approx. 26 probes per annotated gene, spread across the whole length of 
the gene. 
For both microarray platforms, cDNA was synthesized using 1 µg corresponding RNA and including 
Poly-A RNA controls with the help of the Affymetrix GeneChip® Poly-A RNA control Kit. Secondly, 
cRNA synthesis and cleanup was carried out using the Affymetrix GeneChip® IVT Labelling Kit. 
Subsequently, fragmentation and labeling for microarray hybridization was accomplished with the 
corresponding kits according to manufacturer’s instructions. The whole process, including final 
hybridization, washing, staining and scanning was executed in the DNA Micorarray and Deep-
Sequencing Facility of the University Medical Center Göttingen (UMG) with the help of Dr. G. Salinas-
Riester and S. Luthin. Raw data were transferred to the Institute of Functional Genomics, University 
Regensburg, and statistically analyzed by K. Meyer, M. Pirkl and Prof. Dr. R. Spang. 
Microarray data preprocessing - Data analysis was performed using the statistical computing 
environment R and the life-science related extension Bioconductor (http://www.bioconductor.org).  
Gene expression profiles were background corrected and normalized on probe level using a variance 
stabilization method (Huber et al., 2002). Normalized probe intensities were summarized into gene 
expression levels using an additive model described in (Irizarry, 2003) and fitted by a median polish 
routine. Additionally, batch effects were corrected using ComBat (Johnson et al., 2007) by estimating 
additive and multiplicative effects for each batch and normalizing accordingly. 
Differential gene expression - An additive linear model approach (Smyth, 2005) was used to 
calculate effects of experimental conditions on each probe set. The experiments with single 
inhibitors/stimulations are used to calculate the individual effect. Synergetic effects are then inferred 
from the combinatorial experiments. 
Nested Effects Models – The effects of gene perturbation via inhibitor use and subsequent 
stimulation on the whole genome gene expression level were analyzed using a class of probabilistic 
models called ‘Nested Effects Models’ (NEMs) (Fröhlich et al., 2007; Markowetz et al., 2005).  
GO KEGG and GSEA - Gene set enrichment analysis (GSEA) of ranked gene lists was performed using 
the Java implementation of GSEA obtained from http://www.broadinstitute.org/gsea/. GSEA was 
conducted in the mode for pre-ranked gene lists on the C2 set of curated gene signatures from the 
Molecular Signature Database (MSigDB). GO and KEGG pathway enrichment analyses were 





3.1 Temporal pattern of whole genome gene expression changes upon 
signaling pathway activation 
In the last decade, global gene expression analyses have been excessively used for developing 
strategies to describe and stratify lymphoma cases. Hence, a molecular definition of BL was 
identified, distinguishing mBL from non-mBL, including DLBCLs (Dave et al., 2006; Hummel et al., 
2006). However, it remains unclear to which extent distinct signaling pathways of the immune 
response are in charge of the differences in gene expression that distinguish lymphoma. In former 
analyses in the group of D. Kube, BL cells were stimulated with factors known to be involved in B cell 
signaling, microenvironment and lymphoma pathogenesis and subjected to microarray analysis. 
Thereby, distinct in vitro stimuli could characterize individual NHL and signaling pathways dominantly 
involved in these global gene expression patterns have been identified (Schrader et al., 2012b). In the 
present study, two of the stimuli inducing the strongest gene expression changes (CD40 and B cell 
receptor activation) were used in a time-resolved analysis to provide data allowing the prediction of 
regulatory feedback loops of certain oncogenic pathways. 
In order to obtain a defined time course of pathway perturbation at the global level, we used 
human transformed GC B cells as a model system in vitro (BL2). Stimulation of cells in vitro was done 
in triplicates by adding α-IgM F(ab)2-fragment to activate BCR signaling or sCD40L to activate CD40 
mediated signaling, respectively. Samples were collected in defined time intervals until 480 min 
(Figure 3-1 A). The corresponding RNA samples were hybridized to Human Gene 1.0 ST arrays 
(Affymetrix, Santa Clara). Respective bioinformatical and high-dimensional statistical data analysis 
was performed in parallel by several statisticians belonging to the HaematoSys-consortium. Data 
preparation (background correction, normalization, estimation of gene expression levels by a median 
polish routine: Katharina Meyer, Regensburg) exhibited a unique gene expression pattern (Figure 3-1 
B + D). Upon α-IgM stimulation 2509 genes with fold change ≥3 were altered in their expression 
level, while CD40 activation led to change of expression level in 2447 genes (here fold change ≥ 1.5 
was chosen, since the overall variance of expression changes was smaller than in α-IgM stimulated 
cells).  
In parallel, CD40 and BCR mediated signaling was monitored on the protein level by detecting 
changes in protein phosphorylation and degradation (Figure 3-1 C + E). To describe the effects and 
their time courses, activation of the following pathways was monitored by Western Blot analyses: 
MAPK signaling (phosphorylation of Erk and p38), NF-κB signaling (via the degradation of IκBα) and 





Figure 3-1 Time course analyses of gene expression changes on the whole genome level upon stimulation of 
human transformed germinal center B cells. A BL2 cells were stimulated with 200 ng/ml sCD40L or 13 µg/ml 
anti-IgM F(ab)2 fragment respectively and samples were harvested every 30 minutes for up to 4 hours, plus 
additional later time points at 6 and 8 hours, B + D Heatmaps displaying gene expression changes on the whole 




one sample. Three biological replicates of each sample either with BCR (B) or CD40 activation (D) were 
hybridized to HU Gene 1.0 (Affymetrix). Additionally, changes in protein phosphorylation and degradation were 
documented by Western Blot analyses (C + E). 
As shown in Figure 3-1 C, α-IgM stimulation of BL cells induced a rapid and sustained 
phosphorylation of Erk as well as an equally rapid activation of p38 (p-p38). However, the 
phosphorylation status of p38 declined 90 min after BCR crosslink and reached basal level upon 
150 min after stimulation. CD40 activation of BL cells showed a similar phosphorylation course of 
p38, although an activation of MAPK signaling through phosphorylation of Erk was hardly detectable 
upon 15 min after CD40 stimulation, but not at any other time point after stimulation (Figure 3-1 E). 
The activation of NF-κB signaling was detected by monitoring the degradation of the NF-κB inhibitor 
IκBα. CD40L strongly activated canonical NF-κB signaling rapidly after stimulation (15 min – 30 min), 
whereas α-IgM stimulation of BL cells resulted only in a marginal degradation of IκBα at a later time 
point (60 min after BCR activation). In contrast, BCR crosslink led to a pronounced activation of the 
PI3K/Akt pathway (p-Akt, Figure 3-1 C), whereas upon CD40L stimulation a phosphorylation of Akt 
was not detectable. Thus, we confirm that α-IgM and CD40L treatment activate, although with 
distinct kinetics, partially overlapping pathways. 
3.1.1 α-IgM stimulation of BL cells changes the mBL index towards non-mBLs 
To further prove the functional relevance of CD40L and α-IgM stimulated BL cells in vitro, it was 
investigated how the activation of the BL cells influences their mBL index. The mBL index value 
summarizes the expression of the 58 mBL signature genes and represents a measure for ‘Burkitt-
likeness’ (Hummel et al., 2006). Designated mBL and non-mBL patient samples from the MMML 
study were hybridizied to HU Gene 1.0 (Affymetrix, Santa Clara, US) to achieve comparability to the 
time course data. Subsequently, the expression of the 58 mBL signature genes in the experimental 
time course samples was determined and each sample was assigned an mBL-signature index score, 
with a higher score reflecting a higher similarity of gene expression in comparison to the mBL core 
samples (Hummel et al., 2006). One can observe, as expected, that untreated BL2 cells showed a 
similar mBL index as proven BL NHL cases (Figure 3-2). Sustained CD40L stimulation for up to 8 hours 
reduced the mBL index score slightly, but did not change the expression of the mBL signature genes 
in an intense manner. In contrast, anti-IgM stimulation of BL2 cells for up to 8 hours led to a more 
intense reduction in the mBL index score over time. One could conclude that the stimulation of BL2 
cells with α-IgM F(ab)2 fragments shifts the gene expression profile of the former mBL cells towards a 
gene expression profile of DLBCLs. Thus, signaling pathways, which are activated in consequence of B 
cell receptor cross linking, seem to induce gene expression changes, which in turn are relevant for a 




and BL, their clinical manifestations and inevitable therapies, a closer view into BCR mediated 
signaling events in transformed germinal center B cells will be very helpful. 
 
Figure 3-2 Sustained BCR activation in BL cells shifts mBL index towards the index of non-mBLs. mBL index 
(Hummel et al., 2006) of time course microarray data (grey bars) upon (A) CD40L stimulation and (B) BCR 
crosslink was calculated and compared to defined mBL (red bars), intermediate (yellow bars) and non-mBL 
cases (green bars, DLBCL). Each bar represents one sample hybridized to HU Gene 1.0 (Affymetrix). 
3.1.2 Causality Network of BCR induced gene expression correlations 
A time course of signaling events is especially interesting to analyze in order to find interdependent 
groups of genes. Data obtained in the present study were taken for network modeling to display 
correlations and causalities between subsets of genes. Normalized and calibrated raw data were 
taken and data were subsequently pre-filtered in two independent steps to exclude genes, which 
(step 1) can be assigned to noise and which (step 2) don’t show any changes in expression over time. 
Noise-cancellation was accomplished assuming a Gaussian distribution of the expression values and 
modeling the overall signal through heuristic fitting of a two-component-mixture. Thereby, noise was 
cancelled and the signal remained. For anti-IgM stimulated data 8012 out of 21995 genes 
represented on the array remained. Secondly, genes which don’t change their expression level with 
time elapsed, were excluded. Therefore, Fisher’s g-test, testing on white noise of unknown frequency 
was used (Wichert et al., 2003). Using a False-Discovery-Rate of 0.1, 2832 genes remained, 
significantly changing their expression upon BCR crosslink. Using Bayesian Hierarchical Clustering 
(Cooke et al., 2011; Heller and Ghahramani, 2005; Savage et al., 2009) clustering of genes with a very 
similar time course was computed. This method reduced the dimensions to 22 clusters of genes. 
Subsequently, clusters with marginal changes over time were observed. All clusters of genes with an 
expression range less than 0.5 and less than 10 % highly significant genes (FDR < 0.05) were excluded. 
Finally based on an algorithm calculating partial correlation between the clusters (SIMoNe 





Figure 3-3 Causality network displaying anti-IgM stimulated gene expression correlations.  Network modelled 
by B. Klaus (AG Strimmer, IMISE Leipzig), based on partial correlation using the ‘R’ package SIMoNe (Statistical 
Inference for Modular Networks (Chiquet et al., 2009)) displaying causal relationships between clusters of 
genes. Genes combined in one cluster display the same time course (Bayesian Hierarchical Clustering). A 
complete list of genes contained in each cluster can be found in Table A-1. Arrows indicate the causal 
relationship; bold arrows display a strong positive correlation between two clusters, whereas dashed arrows 
indicate a negative correlation. 
In this directed graph, partial correlation between the expression courses of two clusters of genes 
may infer a regulatory link between the clusters. Continuous arrows indicate here a positive 
regulation, whereas dashed arrows represent a negative regulation. Additionally, stronger partial 
correlation between two nodes is depicted with bold arrows, whereas weak partial correlation is 
displayed with narrow arrows.  
Having a closer view to the network, it becomes clear that there is no ‘cluster of initiation’. All 
clusters depicted in Figure 3-3 are conditionally dependent on another cluster. This suggests that the 
anti-IgM stimulation triggered several independent processes at the same time. In contrast, several 
clusters are influenced by others, but do not influence a third cluster. This may be due to the limited 




Interestingly, cluster 6 and 8 seem to influence numerous other clusters. Apparently, cluster 8 is 
only conditionally dependent on one Cluster (#9) and cluster 6 is dependent on cluster 8 and 10. 
Both clusters (6 and 8) contain genes, which are slightly up regulated in the first 30 to 90 minutes 
after stimulation (Figure A-1). Both of the clusters then follow a time course, which depicts a down 
regulation of the harboring genes upon 90 to 240 minutes after BCR stimulation. Cluster 6 comprises 
102 genes and cluster 8 harbors 58 genes. In both clusters, genes being mainly associated with signal 
transduction, protein modifications, transcriptional regulation and metabolic processes can be found. 
Cluster 6 and 8 contain amongst others genes encoding kinases (cl 6: NADK, CAMK2G, PIP4K2B, PXK, 
DCK, FASTK, cl 8: AURKA, P38) and genes encoding G-proteins and related proteins (cl 6: CDC20, 
RASGRP1, ARGHAP35, ERC1, TBC1D14, cl 8: GOPC, FPGT, ARHGEF3) (Table A-2). Both clusters 6 and 8 
seem to influence the expression of genes in cluster 11, which contains 126 genes. Those genes show 
a similar expression course as genes from clusters 6 and 8, but with a higher expression rate, thus 
resulting in a distinct cluster of genes. Cluster 11 comprises genes associated with transcription, such 
as transcriptions factors (MYC, BCL6, ID4), transcriptional cofactors (BCL9, BCL3) and others, being 
involved in regulation of RNA and DNA metabolic processes (Table A-2).  
Apparently, statistical analysis of the here obtained time course data enable the construction of a 
comprehensive causality network. Unfortunately, the biological interpretation of this huge data set 
remains difficult, since the distinct clusters comprise large lists of genes, which cannot be assembled 
to one specific function (a complete overview of the GO-analyses can be found on external CD ROM 
\\time course analyses\Network\GO-Enrichment). Thus, the conflation of our time course specific 
gene expression data set with other sources of high-throughput data may be useful to fathom the 
biological meaning of such a causality network. In order to shed some light on the complexity of the 
gene expression changes and their causal correlation induced through α-IgM stimulation, ongoing 
analyses are supposed to integrate genome-wide chromatin immunoprecipitation assays in our cell 
perturbation assays. Therewith, we aim to use such a causality network for identification of, for 





3.1.3 A mathematically new method to analyze time courses identifies differentially 
expressed clusters of genes 
Simultaneously to the network modeling of causalities and regulations in gene expression changes 
over time, a second group around Prof. Dr. J. Läuter (University Magdeburg) established a new 
method to analyze high-dimensional time course gene expression data. The here presented strategy 
to provide a mathematically stringent and effective procedure to describe time course data is based 
on spherical tests (Läuter et al., 1996, 1998). These aim to select the variables which exhibit a 
statistically firm unsteady distribution over time (Läuter et al., 2012). Thereby, the following 
stabilizing strategy was used: genes with similar time course were pooled in one set or cluster and 
tested for stationarity. Those clusters of genes, which emerged to be significant (multiple Beta-
testing according to (Läuter et al., 1998) with alpha error α = 0.05 and abort of the testing at k = 5 
non-significant non-spherical tests (Hommel and Kropf, 2005)), can be taken for biological 
consideration. Hereby, the algorithm presumes that genes, which exhibit a uniform process, are 
potentially regulated through the same elicitor. In addition, in the case of several distinct clusters of 
genes, the specific shape of the serial data curves may be due to mutual regulatory dependence. 
Via the adaptation and advancement of the test for stationarity, 500 sets of genes were built. 
Upon α-IgM stimulation 21 sets of genes were disjoint and CD40 activation led to 20 disjoint sets of 
genes. 15 significant sets of genes out of 21 displaying disjoint time courses were identified for α-IgM 
stimulated samples and 5 significant sets of genes for sCD40L-stimulated samples. 8 positively 
regulated gene groups and 7 gene groups suppressed through α-IgM are described. CD40 activation 
in turn led to 4 sets of up regulated genes and one gene set showing a suppression of gene 
expression.  
Additionally, a combined analysis of CD40 and BCR induced gene expression changes allows the 
comparison of congenial reactions or differences in response to the distinct stimuli. Here, gene sets 
were identified, in which significant differences of gene expression changes upon BCR or CD40 or in 
both stimulations were observable. In Figure 3-4, the blue dashed line shows the mean gene 
expression changes over time for CD40L-stimulated cells, whereas the red curve shows the changes 
upon anti-IgM antibody stimulation. Group #1 illustrates genes highly up regulated through BCR 
crosslink, but not changed at all through CD40 stimulation. Additionally, group #2 depicts genes, 
which showed the same course of expression changes over time, regardless which stimulus the cells 
experienced. Finally 10 more groups of genes could be computed showing the same directionality of 
gene regulation through the different stimuli, but differentiating in intensity or course after a certain 




All of the computed gene sets display distinct expression changes over time, allowing 
discrimination between immediate-early activated gene sets, late events or immediately up 
regulated and later in time course down regulated gene sets. 
 
Figure 3-4 Comparison of time courses of genes commonly regulated through BCR and CD40. 12 significant, 
distinct groups of genes were computed, when taking commonly regulated genes by CD40L and BCR crosslink 
into calculation. red curve – time course of gene expression changed through anti-IgM stimulation, blue curve – 
time course of gene expressions stimulated through sCD40L. The y-axis displays changes in gene expression 
levels (not scaled), x-axis shows the hours of specific treatment. 
Testing for stationarity in differential gene expression changes from CD40L stimulated BL cells 
computed 5 disjoint and distinct gene sets (Figure 3-5 A). GO analysis was used to characterize the 
sets of genes. A complete overview of the GO results for each cluster of genes is provided as external 
data stored on a CD ROM (\\time course analyses\Stationarity\GoKeggLister). Gene set #2 was the 
only group of genes, which comprised solely repressed genes. Interestingly, the majority of the gene 




gene set #4, including mainly negative regulators of signaling as phosphatases, one can postulate 
that CD40 mediated signaling happens very rapidly on the proteome level, leading to a fast feedback 
loop mediated by gene expression changes. The second group of up regulated genes upon CD40L 
stimulation displayed a late onset of increased expression (> 2 hours) and may represent a second 
wave of target genes. In this group, GO analyses did not reveal enrichment in molecular function of 
different gene products, but the list contains target genes of NF-κB signaling (WNT5a, CFLAR) (Katoh 
and Katoh, 2009) and cytokines as TNFSF4 (OX-40L), providing co-stimulatory signals to T-cells (Akiba 
et al., 1999; Brocker et al., 1999). Thus, activation of target genes affecting proliferation, 
differentiation and paracrine signaling occurs 2 hours after CD40L activation.  
To afford the massive necessity of transcriptional regulators, a second intermediate step is 
imperative. Group #8 displayed a strong increase in gene expression for the first 90 min after 
stimulation paired with a rapid inhibition back to basal level after 180 min after stimulation. This 
gene group comprised mainly DNA-binding and transcription factor activity (Table A-4 and external 
data on CD ROM \\time course analyses\Stationarity\GoKeggLister\CD40.3_cluster_8). In contrast, 
gene group #5, showing a similar bi-phasic course with the highest expression change upon 2 to 
2.5 hours after CD40L stimulation and following decline in expression levels up to basal levels upon 
6 hours after stimulation, illustrated several processes as positive regulation of protein kinase 
activity, response to stress (unfolded proteins etc.) and expression of signaling molecules as CD40 
itself (Table A-4 and external data on CD ROM \\time course analyses\Stationarity\GoKeggLister 
\CD40.3_cluster_5). 
Enhanced gene expression as a response to α-IgM was found in 8 gene sets. Those groups of 
genes can be additionally subdivided in groups, which display an ‘immediately-up’ course (#1, #2, #5) 
or ‘late-up’ gene expression (#3, #9, #11, #13, #19). Additionally genes responding with reduced 
expression to α-IgM treatment (#4, #6, #12, #17) could be computed (Table A-5). Genes in group #1 
were commonly activated upon α-IgM stimulation and reached their highest expression level after 
4 hours of stimulation (Figure 3-5 B, #1). SLAMF7 (also known as CS1, CRACC, CD319), the center 
gene of the set, was strongly up regulated upon BCR crosslink, but did not respond to CD40L 
stimulation (compare Figure 3-4). SLAMF7 is a lymphocyte cell surface receptor, which has been 
shown to be strongly up regulated in response to BCR crosslink in Ramos cells and to induce 
proliferation and autocrine signaling of cytokines in human B lymphocytes (Lee et al., 2007). Genes in 
this group could not be integrated in a specific function or process, but represent the diversity of B 






Figure 3-5 Distinct time courses for anti-IgM and CD40 stimulated BL2 cells can be determined by testing for 
stationarity.  Testing for stationarity by reducing the number of genes in each group to 30 genes leads to (A) 5 
unique and disjoint groups of genes upon sCD40L stimulation, (B) 15 significant unique time courses upon α-
IgM stimulation of BL2 cells. The y-axis displays changes in gene expression levels (not scaled), x-axis shows the 




The set of genes #2 displayed a sharper increase in gene expression, reaching approx. 90% of 
highest expression level upon 2 hours of α-IgM treatment (Figure 3-5 B, #2). Center gene of the set is 
CCR7, a pivotal player in homing tumor cells into lymphoma-supporting niches in secondary lymphoid 
organs (Rehm et al., 2011) and known to be highly up regulated upon BCR stimulation (Calpe et al., 
2011). Additionally this group comprised lots of genes actively sustaining immune response and 
playing part in MAPK signaling and G-protein-coupled signaling (\\time course analyses\Stationarity\ 
GoKeggLister\BCR.3_cluster_2). Set #5 displayed a bi-phasic course of gene expression changes. 
Gene expression was immediately up regulated upon α-IgM stimulation, whereas after 2 hours 
expression of those genes was reduced again. This particular set of genes mainly comprised 
regulators of gene transcription like DNA-binding factors (PRDM2, MFSD2A, JUND, PIM3, E2F3) and 
genes affecting transcription factor activity (one example: NR4A3, the center gene of the set involved 
in steroid hormone receptor activity and positively regulating DNA-binding transcription factor 
activity). This time course perfectly fits with the estimation that upon stimulation of the cell, the 
signal is transduced in the nucleus and gene expression is affected in a very pronounced manner, 
leading to feedback signals negatively regulating transcriptional activity.  
A similarly interesting gene set #10, displaying a bi-phasic time course with a slight induction of 
gene expression in the first hour and subsequent transcriptional repression, harbored the center 
gene FOSB. FOSB, belonging to the FOS gene family, encodes a leucine zipper protein, dimerizing with 
proteins of the JUN family, thereby forming the AP-1 transcription factor complex and regulating cell 
proliferation, differentiation and transformation (Entrez Gene: FOSB FBJ murine osteosarcoma viral 
oncogene homolog B). The proto-oncogene JUNB, dimerizing partner for FosB, was as well regulated 
in gene set #10 and displayed the same time course in gene expression. Additionally, this group 
harbored proto-oncogenes like PIM-1 and PIM-2, both exerting their oncogenic activity through the 
regulation of MYC transcriptional activity (van der Lugt et al., 1995; Shirogane et al., 1999). 
Supporting this issue, the expression of MNT, a MAX-binding protein, seems to be co-regulated 
since it displayed the same time course. The protein encoded by this gene has a basic-Helix-Loop-
Helix-zipper domain, whereby it binds the E-box, following heterodimerization with Max proteins, 
thereby repressing transcription of MYC target genes (Hurlin et al., 1997a, 1997b; Sommer et al., 
1998). Upon BCR stimulation, this repression is likely to be abolished, since MNT expression levels 
were decreasing (Figure 3-5 B, #10). The gene groups #3, #9 and #13 comprise genes whose 
expression was up regulated after α-IgM stimulation later in time. In general, the increase in gene 
expression took a longer period of time than in the groups mentioned above. Gene set #9 displayed a 
continuous gain of gene expression, reaching a saturation level after 4 hours of stimulation with α-




biological process, but their products were mainly membrane- and organelle-bound proteins. One 
example is LRMP (lymphoid-restricted membrane protein, Jaw1), an endoplasmic reticulum-
associated protein, which was originally identified as differentially regulated transcript in B and T 
cells (Behrens et al., 1994). Subsequently, LRMP was reported as marker for diffuse large B cell 
lymphoma of the GCB subtype (Tedoldi et al., 2006). 
In gene set #3, gene expression was constitutively increasing for 2 hours after BCR crosslink 
reaching a point of inflection after 4 hours of stimulation. Genes comprised in this particular gene set 
comprised mainly regulating kinase or transferase activity (\\time course 
analyses\Stationarity\GoKeggLister\BCR.3_cluster_3), thus maybe inducing a “second wave of 
activity”. Such kinases might act as feedback loop for the immediate-early response genes. The 
expression of genes in group #13 increased slowly upon BCR crosslink, reaching the maximum after 
4 hours of stimulation before being reduced again in direction to basal level of expression. The high 
diversity of genes comprised in this group impeded the assignment of one specific function to this 
cluster. Among them, we found genes whose products represent several functions such as Rho 
protein signal transduction (ARAP2), DNA binding components (ZNF165, PHF13, ZNF643), helpers in 
protein unfolding (TOR3A) and others (\\time course analyses\Stationarity\GoKeggLister 
\BCR.3_cluster_13). Finally, group #11 and #19 show the genes, whose expression was increased at 
very late stages in the observation period. In group #11, genes preparing the cellular machinery for 
translational processes were enriched (AGA, TARS, WARS, UGDH), whereas in group #19 the negative 
regulation of the cellular response to growth stimuli was activated (NEK7, CLCC1). Thereby, negative 
feedback loops of early-activated genes are potentially activated. 
Additionally, 6 groups of genes showed a decrease in gene expression upon anti-IgM stimulation. 
The groups #4 and #6 showed a similar course where expression continuously diminished as time 
went on. In contrast, in groups #7, #12, #14 and #17, a bi-phasic expression course could be 
observed. In the first phase, gene expression decreased to be returned after a certain period of time 
to the initial expression level. Since the basal expression level was not reached during the period of 
observation and the gain in expression took place very slowly, one might postulate that this time 
course depicts the time-resolved turnover of mRNA abundance in the cell: after initial regulation 
(here repression), the inhibitory effect is released and slowly mRNA expression is increased again, 
leading back to the point of departure.  
In gene set #7, center gene of the set was HEY2, which encodes a bHLH transcription factor. The 
encoded protein acts as a transcriptional repressor and binds preferentially to the canoncical E box 
sequence 5'-CACGTG-3' (Heisig et al., 2012; Wu et al., 2011). Interestingly, the expression of this gene 




transcriptional repression. GO analysis also showed enrichment for transcriptional regulation and 
negative regulation of cell growth (\\time course analyses\Stationarity\GoKeggLister 
\BCR.3_cluster_7) in gene set #7. A similar enrichment could be found in gene sets #12, #14 and #17. 
Thus, negative regulators of gene transcription were down regulated through BCR crosslink, 
promoting active gene transcription. Interestingly, gene set #17 harbored the genes PTCH1, LEF1 and 
NOTCH1. All three genes are known to be evolutionary important for developmental processes as 
hematopoiesis. Notch1, the transmembrane receptor for the Notch signaling network, plays a pivotal 
role in lymphocyte development, proliferation and differentiation (Anderson and Longnecker, 2009; 
Cheng et al., 2001; Pui et al., 1999; Radtke et al., 2004). Lef1, a transcription factor participating in 
the Wnt signaling pathway, regulates B lymphocyte proliferation (Reya et al., 2000) and is aberrantly 
expressed in BLs (Hummel et al., 2006; Walther et al., 2013). Ptch1 is a transmembrane receptor for 
hedgehog signaling and plays an important role in lymphoid lineage commitment (Uhmann et al., 
2007) and the germinal center reaction of B cells (Sacedón et al., 2005). Furthermore, recent 
publications show deregulations of the Hh signaling pathway in several lymphoma subtypes, 
including DLBCLs (Decker et al., 2012; Lin et al., 2010; Siggins et al., 2009; Singh et al., 2009, 2010). 
The α-IgM stimulation of BL cells led to reduction of expression of NOTCH1, LEF1 and PTCH1, 
suggesting an active signaling in BL. Similarly, gene expression of c-MYC, the hallmark of BL was down 
regulated after BCR crosslink (gene set #14).  
Taken together with the observation, that α-IgM stimulation of BL cells reduced the mBL index 
towards a more DLBCL-like index (compare chapter 3.1.1), the question arose whether the down 
regulation of those signaling pathways may give an explanation for essential differences between BL 
and DLBCLs. For a better understanding of the joint α-IgM mediated suppression of PTCH1, LEF1, 
NOTCH1 and as well of MYC, I focused in this study on the role of PTCH1 in aNHL. Recent publications 
suggest an important, but yet not clearly understood role for Hedgehog signaling in lymphoma 
genesis and progression (Decker et al., 2012; Singh et al., 2009, 2010). The role of LEF1 and MYC in 




3.2 Ptch1 and Hedgehog signaling in lymphoma 
Using qRT-PCR it was verified that the statistically modeled data are correct and that MYC as well as 
PTCH1 and LEF1 expression is down regulated after BCR crosslink. Therefore, RNA used for array 
hybridization (batches I-III, Figure 3-6) as well as independently collected data (data not shown) 
showed a marked down regulation of PTCH1, LEF1 and MYC upon BCR activation. Although not 
postulated through the course of gene set #17, PTCH1 expression showed a two-fold up regulation in 
the first hours after stimulation. This discrepancy between computed time course and time course 
collected through qRT-PCR may be due to the calculation of the mean time course of all genes in 
gene set #17. Additionally, the 3 batches of stimulated BL cells used for array hybridization differed 
strongly in their response to BCR activation regarding PTCH1 mRNA expression especially in the first 
two hours of data collection. For statistical modeling an adaptive 3-point smoothing was applied, 
thus probably removing those differences in favor of the not-elevated mRNA expression data. 
However, an overall agreement of the computed to the experimental data could have been shown. 
PTCH1, MYC and LEF1 mRNA expression was reduced in BL2 cells after 3 hours after α-IgM antibody 
treatment. This reduction lasted until 5 – 6 hours after stimulation and was then abolished (Figure 
3-6). 
 
Figure 3-6 MYC, PTCH1 and LEF1 mRNA expression is suppressed in BL2 cells upon anti-IgM stimulation. 
Relative mRNA expression levels of c-MYC, PTCH1 and LEF1 as a function of time upon stimulation with α-IgM 
F(ab)2 fragment. Data are represented as mean (±SEM) of three biological replicates (batches I-III, which were 





3.2.1 Expression profile of Hedgehog signaling components 
Recent findings suggest that hedgehog signals exerted from the microenvironment are important in 
hematologic malignancies, including lymphomas (Dierks et al., 2007; Hegde et al., 2008). All Hh 
ligands (Sonic hedgehog (Shh), Indian hedgehog (Ihh) and Desert hedgehog (Dhh)) share a common 
signaling pathway, where Patched (Ptch1) and Smoothened (Smo) are the membrane bound 
receptors. In the absence of ligand, Ptch1 exerts an inhibitory effect on Smoothened activity that is 
abrogated upon Hh ligand binding. Subsequent activation of the Gli transcription factors, Gli1, Gli2 
and Gli3, leads to expression of PTCH1 and GLI1 amongst others. Recently, Singh et al. (2010) have 
shown that several DLBCL cell lines express PTCH1, GLI1 and SMO and that inhibition of Hh signaling 
via inhibition of Smo through cyclopamine resulted in cell-cycle arrest and apoptosis in some of the 
tested DLBCL cell lines (Singh et al., 2010). To investigate whether Hh signaling components are 
expressed in a similar manner in Burkitt’s and diffuse large B cell lymphoma cell lines, the mRNA 
expression profile of PTCH1, GLI1, SMO, SHH and IHH was comprehensively analyzed using qRT-PCR. 
Additionally, the reduction in mRNA expression levels of PTCH1 upon 3 hours α-IgM F(ab)2 fragment 
in BL2 cells was counterchecked in several cell lines of Burkitt’s and diffuse large B cell lymphoma 
(Figure 3-7). mRNA expression levels are depicted as fold changes relative to the unstimulated cell 
line with the lowest expression level of the respective mRNA (marked with an asterisk in Figure 3-7). 
As shown in Figure 3-7 A, the observed reduction of PTCH1 mRNA upon α-IgM treatment for 
3 hours in BL2 cells was not reproducible in other Burkitt’s lymphoma cell lines tested, except BL30. 
All Burkitt’s lymphoma cell lines tested did express PTCH1 mRNA (Ct-values around 25 cycles, 
housekeeper ABL 21 cycles), but most of them showed slightly elevated PTCH1 mRNA expression 
levels upon BCR crosslink. Diffuse large B cell lymphoma cell lines showed approximately the same 
overall expression levels as BL cell lines, however, the response to α-IgM treatment for 3 hours in 
terms of PTCH1 mRNA expression levels differed. SuDHL5, SuDHL6 and OCI-Ly3 showed a slight to 
moderate decrease in PTCH1 mRNA expression upon BCR activation, whereas the other DLBCL cell 
lines tested did not change or slightly increased their PTCH1 mRNA expression levels (Figure 3-7E). 
PTCH1 gene expression is amongst others activated through the successful activation of the Hh 
signaling pathway as a target gene of Gli1 transcription factor (Marigo and Tabin, 1996). The 
transcription factor GLI1 itself is also a well-known target gene of Hh signaling (Lee et al., 1997). 
Therefore, the mRNA expression levels of hGLI1 were investigated in BL and DLBCL cell lines before 





Figure 3-7 Differential expression and induction of Hh signaling components in Burkitt’s and diffuse large B 
cell lymphoma cell lines through anti-IgM stimulation. Several Burkitt’s lymphoma (A-D) and diffuse large B 
cell lymphoma (E-H) cell lines were tested for expression of hedgehog signaling pathway components by qRT-
PCR. Additionally, cell lines were stimulated 3 hours with anti-IgM F(ab)2 fragment and gene expression was 




expression and normalized to the cell line with the lowest expression (marked with an *). One representative 
experiment out of 3 biological replicates is shown. Expression of SHH mRNA could not be detected in any of the 
tested cell lines. 
Overall mRNA expression levels were pretty low in most BL cell lines (Ct-values around 30 cycles, 
housekeeper Ct = 21) and differed largely between the cell lines (25-fold more basal hGLI1 mRNA 
expression in BL70 than in BL2, Figure 3-7B). One could observe an increase of mRNA expression 
after BCR crosslink in nearly all BL cell lines (except DG-75), which is not correlated to the response to 
BCR in terms of PTCH1 expression. Both genes are meant to be target genes of activated Hh 
signaling, but in BL2 cells PTCH1 expression was reduced upon anti-IgM stimulation whereas hGLI1 
expression increased. In half of the BL cell lines tested (Ramos, BL70 and CA-46), one could observe a 
concomitant increase in mRNA expression, which would suggest an activation of Hh signaling 
pathway through BCR activation. In contrast, in 3 out of 6 BL cell lines (BL2, DG75, BL30) the 
regulation of these two target genes PTCH1 and hGLI1 was opposed (Figure 3-7 B). Similar 
observations have been made for the target gene expression of activated Hh signaling in DLBCL cell 
lines. The basal expression of hGLI1 mRNA was in all DLBCL cell lines tested pretty low (Ct-values 
around 30 cycles), with differences of 5-fold higher expression in Karpass422 and SuDHL6 than in the 
DLBCL cell line with the lowest expression, OCI Ly3 (Figure 3-7 F). Here, the cell lines with the highest 
basal expression level (3/6) also showed an increase in hGLI1 mRNA expression after 3 hours α-IgM 
stimulation, whereas the others did not respond in terms of GLI1 mRNA expression level changes 
(OCI Ly3 and SuDHL5) or did show reduced levels (HT). Overall, one could not observe a consistent 
regulation of Hh signaling target genes upon BCR activation in the tested cell lines.  
Furthermore, the intracellular signal transducer SMO was expressed in strongly diverse levels 
when comparing different BL cell lines (Figure 3-7 C). In some BL cell lines, expression of SMO was 
barely detectable (BL41, Ramos, Ct-values around 33 – 35 cycles), whereas in other BL cell lines a 60- 
to 100-fold higher basal expression level was observed (BL70, CA-46). The response to BCR induced 
signaling in terms of SMO regulation, regarding the different BL cell lines was comparatively 
differential. 2/7 cell lines (BL2 & DG75) showed an reduced expression level upon 3 hours α-IgM 
stimulation, 2/7 BL cell lines (BL41 & CA-46) did not show a regulation of SMO and the remaining 3 
cell lines (Ramos, BL70 and BL30) increased the SMO expression levels upon BCR crosslink. In 
contrast, DLBCL cell lines, which also showed strong differences in basal SMO mRNA expression, 
showed no response to BCR induced signaling in terms of SMO expression (Figure 3-7 G). 
When investigating the expression profile of Hh ligands, I focused on the expression of SHH and 
IHH, because of their implication in lymphocyte biology (Dierks et al., 2007; Lindemann, 2008; 




all via use of SYBR based qRT-PCR and the expression levels of IHH were very low in BL and DLBCL cell 
lines tested. Investigating the expression changes of IHH mRNA after 3 hours α-IgM stimulation, 
differences ranging from more than 15-fold increase in IHH mRNA (BL70) to no change (DG75, CA-46) 
or reduction in IHH mRNA expression (BL2) were observable in BL cell lines (Figure 3-7 D). Overall, 
Burkitt’s and diffuse large B cell lymphoma cell lines demonstrated very inconsistent basal levels as 
well as a very heterogeneous response to α-IgM stimulation regarding the expression profile of Hh 
signaling components. A clear activation or inactivation of the Hh signaling pathway through BCR 
induced signaling was not detectable.  
Although literature concerning the expression and secretion of Hh ligands in hematologic 
malignancies is somewhat controversy, Dierks et al. showed that hedgehog ligands produced by 
stromal cells support proliferation and survival of B cell lymphomas (Dierks et al., 2007). Additionally, 
Singh et al. reported that DLBCL cell lines (OCI Ly3) expresses and secretes Hh ligands (Singh et al., 
2010). Therefore, we decided to test BL and DLBCL cell lines for responsiveness to Shh and 
activatability of the Hh signaling pathway. 
3.2.2 Lymphoma cell lines neither secrete nor respond to Sonic hedgehog 
The murine B cell hybridoma cell line B9 (kind gift of Prof. Dr. H. Hahn), being highly responsive to 
Shh as Hh ligand, was used to investigate the capability of several lymphoma cell lines to produce 
Shh. A HEK293 cell line constitutively secreting Shh (HEK293SHH, a kind gift of Prof. Dr. H. Hahn) was 
used to produce conditioned media, enriched with soluble Shh. Subsequently, after having cultivated 
the murine B9 cells with conditioned media for 24 hours, the mRNA expression levels of mGLI1 were 
measured using qRT-PCR as a mean of activated Hh signaling. As shown in Figure 3-8 A, expression of 
mGLI1 markedly increased upon cultivation of B9 cells with Shh-containing conditioned media 
obtained from HEK293SHH. Simultaneously, conditioned media from BL2, Ramos and OCI Ly3 cells 
were tested for a comparable potency in activating Hh signaling in murine B9 cells, which would 
suggest a Shh secretion of the lymphoma cells. As clearly depicted in Figure 3-8 A, none of the tested 
B cell lymphoma cell lines was capable of activating mGLI1 expression in B9 cells, thus indicating no 
Shh secretion into the medium. 
To investigate the hypothesis that B cell lymphoma cells are sensitive to stroma-initiated Hh 
signaling, B cell lymphoma cell lines were incubated with Shh-containing media for 24 hours and the 
expression level of hGLI1 was monitored as target gene of activated Hh signaling. As depicted in 
Figure 3-8 B, none of the tested cell lines changed the hGLI1 expression levels upon Shh stimulation. 
Therefore, one can conclude that those B cell lymphoma cell lines are not sensitive to secreted Shh 




Several inhibitors of Hh signaling have been identified and are an extensive field of research for 
pharmaceutical companies and universities. The majority of the Hh pathway inhibitors reported 
today target Smoothened (Mar et al., 2011). One of the first inhibitors discovered is the Smo 
antagonist cyclopamine, which abrogates Hh signal transduction and therefore inhibits target gene 
expression (Incardona et al., 1998). To investigate the ability of cyclopamine to change gene 
expression levels of PTCH1 and hGLI1 upon stimulation with α-IgM antibody, Burkitt’s lymphoma cell 
lines were treated for one hour with cyclopamine and subsequently stimulated for 3 hours with α-
IgM antibody. PTCH1 and hGLI1 mRNA expression levels were subsequently analyzed by qRT-PCR 
(Figure 3-8 C & D). 
 
Figure 3-8 Lymphoma cell lines do not produce Shh, neither do they respond to Shh nor to cyclopamine. A 
Secretion of Shh through lymphoma cell lines was tested using the model cell line B9, being highly responsive 
to Shh. Murine B9 cells were 24 hours incubated with conditioned supernatant of Shh-secreting HEK293 cells as 
positive reference for mGLI1 expression. Conditioned media of Burkitt’s and diffuse large B cell lymphoma cell 
lines was also tested to induce mGLI1 expression by qRT analysis. B Lymphoma cell lines are not responsive to 
secreted Shh in regard to Hh signaling pathway activation. BL2, Ramos and OCI Ly3 cells were incubated with 
conditioned media of Shh-producing HEK293 cells and their expression of hGLI1 was determined by qRT 
analysis. C + D Neither BL2 nor Ramos cells are responsive to Cyclopamine. Cells were treated with 5 µM 
cyclopamine for 1 hour, and additionally stimulated with α-IgM F(ab)2 fragment for 3 hours. Relative mRNA 
expression of PTCH1 (C) and hGLI1 (D) was measured using quantitative real-time PCR. Data were analysed for 
all samples using the ΔΔCt-method. Shown are representative results of at least two experiments, relative to 




As shown in Figure 3-8 C, the response of BL2 and Ramos cells to cyclopamine treatment differed 
with regard to PTCH1 expression. In BL2 cells, basal PTCH1 mRNA expression levels were elevated 
upon cyclopamine treatment (2-fold increase), but the BCR induced repression of PTCH1 mRNA 
expression was not affected through cyclopamine treatment. In Ramos cells contrasting results were 
obtained. The BCR signal led to slight induction of PTCH1 mRNA expression, but the cyclopamine 
treatment did not change the basal PTCH1 expression. Instead an increase of PTCH1 mRNA 
expression upon cyclopamine treatment and subsequent BCR crosslink was observable. This 
observation emphasizes once again the heterogeneity of Hh signaling responsiveness between 
different cell lines of one lymphoma subtype and leads to the overall conclusion that active canonical 
Hh signaling may not play an important role in Burkitt’s lymphoma. 
3.2.3 PI3K-mediated regulation of PTCH1, c-MYC and LEF1 mRNA expression 
Initially, the observation that the α-IgM stimulation in BL2 cells led to a down regulation of PTCH1 
mRNA expression, raised the hypothesis that Burkitt’s lymphoma harbor active Hh signaling. The 
transition of the mBL index from mBL towards DLBCL through BCR crosslink would then suggest an 
inactivation of Hh signaling in DLBCL. However, several publications have reported quite the 
opposite: active Hh signaling promoting lymphoma growth and progression, especially in DLBCLs 
(reviewed in Ok et al., 2012). Indeed, the results presented in the current study, showing enhanced 
GLI1 expression upon BCR activation would favor the hypothesis of active Hh signaling in the 
transition to DLBCL instead of an inactivation. Nevertheless, the observation of reduced PTCH1 
mRNA levels was accompanied by similarly reduced levels in LEF1 and c-MYC mRNA expression. We 
therefore asked whether the regulation of these three genes may be directly targeted by BCR 
crosslink. Indeed, several very recent reports, being published in the course of the present study, 
supported our idea. Schmitz and coworkers reported about tonic BCR signaling and PI3K activity in 
Burkitt’s Lymphoma (Schmitz et al., 2009) and Sander and colleagues established a new murine 
model supporting the view of synergistic action between c-Myc and PI3K signaling (Sander et al., 
2012). 
As shown in Figure 3-9 A, PTCH1 mRNA expression was reduced upon α-IgM stimulation, whereas 
inhibition of the BCR signal transduction through the PI3K-inhibitors Ly294002, Compound15e (C15e) 
and BKM120 did not change PTCH1 mRNA levels in comparison to unstimulated cells. Additionally, 
the PLCγ-inhibitor U73122 as well as the PKC-inhibitor Bisindolylmaleimide I abrogated the BCR 
induced decrease in PTCH1 mRNA expression. Similar observations were made for the regulation of 
c-MYC, although here, an inhibition of the PKC seems to affect the basal c-MYC mRNA expression 
level positively (2.5-fold up regulation of c-MYC upon Bisindolymaleimide inhibitor use) (Figure 3-9 




This led to elevated PTCH1 and c-MYC mRNA levels upon PI3K-inhibitor use (Ly294002, C15e and 
BKM120, respectively) in unstimulated BL2 cells (Schrader et al., 2012 and unpublished own data). To 
reduce these effects, the inhibitor treatment was reduced to 30 min prior to 3 hours stimulation 
together with respective inhibitor treatment.  
 
Figure 3-9 Regulation of PTCH1, MYC and LEF1 is mediated through PI3K-PLCγ-PKC signaling. BL2 cells were 
subjected to 30 min treatment with inhibitors and subsequently 3 hours of stimulation with α-IgM F(ab)2 
fragment. mRNA expression levels of PTCH1 (A), c-MYC (B) and LEF1 (C) were determined using the ΔΔCt-
method, relative to ABL housekeeping mRNA expression levels. Data are represented as mean of three 
biological replicates (± SEM), except for 10058-F4, which was used only twice. 
Additionally, the reduction in MYC mRNA levels after BCR activation is abolished upon Akt 
inhibition. Thus the c-MYC regulation might be situated downstream of Akt-signaling, whereas 
PTCH1-regulation seems to be Akt-independent. Interestingly, none of both is regulated through the 
mTOR-pathway, interrupted by Everolimus. The inhibitor of Myc-Max dimerization 10058-F4 was 
used to investigate the effect of c-MYC regulation onto PTCH1 and LEF1 gene expression. α-IgM 
mediated MYC suppression is reversed by the Myc-inhibitor 10058-F4, whereas PTCH1 repression 
seems to be only slightly affected. For LEF mRNA expression it is difficult to state a clear regulatory 
pathway, since all experiments did not show a strong α-IgM-mediated suppression of the LEF1 gene 




here. Nevertheless, an effect of the PI3K inhibitors Compound15e and BKM120 as well as the Myc-
inhibitor 10058-F4 can be postulated, suggesting a positive regulation of the LEF1 mRNA expression 
by PI3-kinase and c-Myc. 
Overall, one can conclude that the BCR induced down regulation of all three genes is mediated via 
the PI3K-PLCγ-PKC signaling pathway. Although slight differences in the responsiveness to the 
different inhibitors are observable, the results presented here point towards a joint regulation of 





3.3 Analyzing intersections in signaling pathways via use of specific 
chemical inhibitors 
Microenvironmental factors are a dominant source of influence for most B cell lymphomas. It is 
important to know and to understand signaling modules and their effectors, which are involved in 
the tumor-micromilieu interactions. It is likely, that several immune response associated signals, such 
as CD40 and BCR induced signaling events, are specific mediators in B cell transformation. Thus, our 
group was able to mimic oncogenic pathway activities in aNHL by investigating the major patterns of 
gene expression changes in response to different stimuli in vitro and to subsequently identify 
individual aNHL profiles reflecting those patterns (Schrader et al., 2012b). 
We therefore asked whether we could get access to comprehensive insights into potential targets 
for future individually designed therapy, based on gene expression profiles of aggressive non-
Hodgkin lymphoma. Thus, in this study a combination of in vitro stimulation with kinase inhibitors 
was used to delineate respective pathway interactions. 
CD40 and α-IgM activated signaling involves both similar and diverging pathways. However, even 
similar pathways are activated in quantitative different manners (compare Figure 3-1). To investigate 
the branching points in this complex signaling network, several kinases regulating different parts of 
specific signaling pathways were targeted to interrupt CD40 and α-IgM mediated signaling and to 
determine subsequent changes in the gene expression profile.  
As a first attempt, we meant to silence several transcription factors being crucial for signaling 
transduction on the gene expression level. We thought of targeting Bcl-6, c-Myc, Stat3 and p65 by 
RNAi mediated silencing. Unfortunately, previous work in our group showed strong difficulties to 
obtain differential gene expression profiles upon siRNA-mediated knock down of specific key players 
in diverging signaling pathways (unpublished data from K. Matulewicz). Even though an effective 
knock down was achievable in our model system, the Burkitt’s lymphoma cell line BL2, we did not 
succeed to obtain comprehensive lists of specifically regulated genes. Although we could observe 
functional abrogation manifested in reduced proliferation or elevated apoptosis rates, current 
mathematical models did not succeed to exhibit differentially expressed genes. Controversially, we 
could even detect signaling pathway interruption on the protein level, but still the induced changes 
in gene expression were not strong enough to obtain lists of significant differentially expressed 
genes. Due to these complications, we decided to use chemical inhibitors instead of siRNA-mediated 
knock down. The major benefit of small molecule inhibitors is the active inhibition of enzymatic 
function, without inducing secondary effect by influencing the translational machinery. Another 




RNAi, we had to transfect cells twice or even three-times and waited for at least 24 hours to observe 
effects. With the use of inhibitors, changes in signal transduction were rapidly detectable. When 
using inhibitors of specific kinases, we were able to detect changes in following protein 
phosphorylation as early as 5 minutes after treatment (data not shown). Additionally we used the 
advantage of targeting kinases instead of transcription factors to intervene on different levels of the 
signaling tree. Thereby, we aimed to dissect jointly regulated and branching points of the signaling 
network induced through CD40L or α-IgM stimulation. 
3.3.1 Inhibitors in use 
To target kinases involved in both CD40 and BCR mediated signaling modules as well as kinases being 
specifically unique to BCR mediated signaling, we decided to target 6 different kinases in a way that 
we could perturb nearly the complete pathway and with use of a second and third inhibitor affect a 
single downstream effector. Thus, the use of one inhibitor aimed to directly affect the targets of one 
kinase, but the combination of several inhibitors affect the same targets as another inhibitor, 
targeting a more upstream kinase. Thereby, we were affecting only its direct targets, which are a 
subset of the phenotype obtained by blocking the complete pathway. A set of 6 different small 
molecule inhibitors were chosen based on literature and pretests in the group of D. Kube. We tried 
to choose inhibitors being already enrolled in clinical studies or having been described in research 
focused on hematological malignancies, mainly lymphomas.  
The recombinant soluble CD40L, used to stimulate transformed germinal center B cells in this 
study, mimics the CD40L/CD154, that is expressed either at the surface of or as soluble form by CD4+ 
T-helper cells, and activates its specific receptor CD40 (Aversa et al., 1993; Gascan et al., 1991; 
Hermann et al., 1993; Lane et al., 1992; Spriggs et al., 1992). CD40 mediated signaling mainly involves 
MAPK signaling via JNK and p38 and IKK activated canonical and non-canonical NF-κB signaling. The 
MAPKKK family member transforming growth factor-beta-activated kinase 1 (TAK1) has been 
reported to function as an ‘upstream’ molecule in IL-1R-mediated NF-κB and MAPK signaling 
pathways (Yamaguchi et al., 1995). Furthermore, Tak1 can be activated through latent membrane 
protein 1 from Epstein-Barr virus (Wan et al., 2004), which in turn is mimicking CD40 (Eliopoulos et 
al., 1996) and plays a pivotal role in EBV-positive Burkitt’s lymphomas. 
Antigen recognition through the B cell receptor activates protein tyrosine kinases as for example 
Syk, which functions as amplifier of the BCR signal and connects the BCR with multiple signaling 
pathways, such as PI3K/Akt (Pogue et al., 2000). Furthermore, formation of the CBM 
(CARMA1/BCL10/MALT1) complex triggers the activation of NF-κB through IKK linkage (Egawa et al., 
2003; Gaide et al., 2002; Hara et al., 2003; Jun and Goodnow, 2003; Newton and Dixit, 2003; Ruefli-




the IKK activation in response to BCR activation (Schuman et al., 2009; Shinohara and Kurosaki, 
2009).  
Likewise, B cell receptor crosslink also activates the MAPK signaling pathway by engagement of 
the Ras-Raf-mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-
extracellular signal-regulated kinase (ERK) mitogen-activated protein (MAP) kinase pathway 
(DeFranco, 1997; Richards et al., 1996, 2001), thereby affecting MEK1/2, p38 and JNK.  
Thus we chose to target TAK1 as a key diversifier of signaling in both CD40 and BCR mediated 
signaling pathways and to treat our model cell line of transformed germinal center B cells with 
100 nM (5Z)-7-Oxozeanol (Arcipowski and Bishop, 2012; Ear et al., 2010; Ninomiya-Tsuji et al., 2003; 
Schrader et al., 2012b). The inhibitor was tested in BL2 cells for pathway interruption and a 
diminished phosphorylation of p38 upon CD40 and BCR activation could be proven by Western Blot 
analysis (Figure 3-10 B). 
NF-κB signaling was attenuated by inhibiting IκBα kinase (IKK) through 7 µM IKK2 VIII-inhibitor 
(Murata et al., 2003). IKK is a large NF-κB-activating signaling complex, consisting of IKKα (IKK1), IKKβ 
(IKK2) and IKKγ-NEMO, whereby IKK1 and IKK2 serve as catalytic subunits phosphorylating IκBα, 
thereby promoting its degradation. The IKK2 inhibitor has been shown to abrogate phosphorylation 
of IκBα and NF-κB-DNA-binding as well as expression of NF-κB target genes leading to apoptosis in 
myeloma cells (Sanda et al., 2005). The inhibition of CD40 mediated NF-κB activation through IKK2 in 
transformed germinal center B cells was circumstantiated in OCI Ly1 cells. Nuclear translocation of 
p65 as activation characteristic for NF-κB signaling was abrogated upon inhibition with IKK2 inhibitor 
(Figure 3-10 D). 
2 µM SB203580 was used to inhibit p38 activity (Craxton et al., 1998; Cuenda et al., 1995; Horie et 
al., 2007). This compound inhibits the activation of MAPKAP-2 by p38 and subsequent 
phosphorylation of HSP-27 (Cuenda et al., 1995). The efficiency of SB203580 has been shown before 
in pre-tests by other members in the group of D. Kube. Due to non-working antibody solutions a 
proof of principle by showing the inhibition of phosphorylation of HSP-27 through SB203580 in BL 
cells was not successful. Nonetheless, the specificity of this compound inhibiting p38 MAPK has been 
reported in several studies, including BL cell lines too (Birkenkamp et al., 2000; Cuenda et al., 1995; 
Fahmi et al., 2000; Horie et al., 2007; Schrantz et al., 2001; Vega et al., 2005; Vockerodt et al., 2001). 
To inhibit JNK activity 10 µM SP600125 were used as reported from other studies in B cells (Bennett 
et al., 2001; Ke et al., 2006; Nishimura et al., 2009; Schnidar et al., 2009; Wang et al., 2009). This 




accomplished on lymphoblastoid cell lines (LCLs) to investigate the effect of SP600125 (Kutz et al., 
2008).  
 
Figure 3-10 Proof of function of the inhibitors in use. BL2 cells were treated for 3 hours with respective 
inhibitors and subsequently 30 min stimulated with either α-IgM antibody or sCD40L. Samples were subjected 
to Western Blot analysis to detect pathway inhibition upon inhibitor use. A U0126 treatment inhibits MEK1/2 
activity upon BCR crosslink. Cells were treated with 10 µM U0126 or dmso (ctrl) and inhibition of MEK1/2 was 
detected by diminished phosphorylation of Erk through phospho-specific antibodies detecting p-p42/p44. B 
The Tak1 inhibitor (5Z)-7-Oxozeanol reduces p-p38 levels in BL2 cells. Cells were treated with 100 nM (5Z)-7-
Oxozeanol and phosphorylation of p38 was detected using specific antibodies. C 10 µM of the PI3K-inhibitor 
Ly294002 were used to inhibit BCR induced signaling, detected here by inhibited phosphorylation of Akt and 
S6. D IKK2 inhibitor ACHP prevents NF-κB activation. OCI Ly1 cells were pre-treated for 3 hours with 14 µM IKK2 
inhibitor (ACHP) and subsequently CD40 signaling was activated via sCD40L. Nuclear extracts were analyzed for 




To specifically dissect BCR mediated signaling modules, additionally PI3K and MEK1/2 activity was 
inhibited using 10 µM Ly294002 (PI3K) (Curnock and Knox, 1998; Uddin et al., 2006; Vlahos et al., 
1994) and 10 µM U0126 (MEK1/2) respectively (Favata et al., 1998; Zheng et al., 2003). BL2 cells 
were pre-incubated for 3 hours with respective concentrations of specific inhibitor to ensure a 
complete mode of action of the inhibitor. To demonstrate the efficacy of U0126 in BL2 cells, the 
phosphorylation status of Erk1/2 upon α-IgM stimulation was monitored by WB using a phospho-
specific antibody against p42/p44 (Erk1/2) (Figure 3-10 A). The activity of Ly294002 could be shown 
under similar conditions through abrogated phosphorylation of Akt upon inhibitor use as well as 
inhibition of phosphorylation of the downstream effector S6 (Figure 3-10 C). 
 
Figure 3-11 Effects of inhibitors used in microarray analyses. Western Blot analyses of 20 ng protein of 
samples of batch III, subjected to microarray hybridization, but harvested 30 min after stimulation to control 
successful activation of signaling pathways. Due to sample limitations, only one signaling pathway could have 
been analysed. A Samples subjected to α-IgM stimulation were verified for active phosphorylation of Erk upon 
stimulation using specific antibodies. B Samples subjected to CD40 activation were counterchecked for active 
NF-κB signaling via degradation of IκBα.  
To verify the activity of the inhibitors and the successful stimulation of the BL cells in the specific 
samples dedicated for microarray hybridization, part of the samples were harvested upon 30 min 
stimulation to subject them to Western Blot analyses. As exemplified in Figure 3-11, the successful 
stimulation through α-IgM antibody was verified via phosphorylation of Erk (Figure 3-11 A) and the 
stimulation through sCD40L was verified by degradation of IκBα as marker for active NF-κB signaling 
(Figure 3-11 B). Figure 3-11 A depicts a strong phosphorylation of Erk upon α-IgM stimulation, which 
was inhibited by U0126. Additionally, a reduction in phosphorylation of Erk was observable after 
Tak1 inhibition (5Z-7-Oxozeanol). This was not expected, but may be supported by some few indirect 
hints proposing a connection between Tak1 and MEK1/Erk signaling (Ninomiya-Tsuji et al., 2003; 
Ohori et al., 2007; Schirmer et al., 2006). However, the effect of Tak1 inhibition on the 
phosphorylation status of Erk has not been shown before to our knowledge. Similar to Birkenkamp 
and coworkers in AML we observed an induction of phosphorylation of Erk upon p38 kinase 




active NF-κB signaling visualized by the degradation of IκBα (Figure 3-11 B). IKK2 inhibition abrogated 
the degradation of IκBα as expected. No activation of NF-κB signaling by inhibition of p38 or JNK 
(SB203580 or SP600125 respectively) was detected. The activation of NF-κB by the Tak1 inhibitor 
(5Z)-7-Oxozeanol was visible only once in all experiments conducted. Therefore we interpreted this 
as a technical artefact (compare Figure 3-13 A and Figure 3-14).  
To conclude, the herein presented protein studies demonstrate that the chosen inhibitors 
interrupt the distinct signaling pathways they are aiming at. Thus we assume effects on the gene 
expression profile upon use of those inhibitors. 
3.3.2 Differential gene expression on the whole genome level upon inhibitor use 
To investigate the gene expression changes that are induced through specific pathway interruption 
under stimulation in a global way, gene expression profiling was performed. Samples of 3 
independent biological replicates were hybridized to Affymetrix HG U133 Plus2.0 GeneChip arrays. 
Data were analysed with support from K. Meyer, M. Pirkl and Prof. Dr. R. Spang from the Institute of 
Functional Genomics in Regensburg. Differentially expressed genes were identified using linear 
models as implemented in the Bioconductor R package LIMMA (Smyth et al., 2005). Genes which 
show a significant (adj. p-value ≥ 0.05) change in expression were considered.  
The stimulation of BL2 cells through BCR cross linking led to the differential expression of 16540 
probes, mapping 9044 genes. CD40 stimulation of BL2 cells led to differential expression of 54654 
probes, which are mapping 2634 genes. Due to the high number of significantly differentially 
expressed genes, in the following expression changes were sorted according to their absolute 
logarithmic fold changes (logFC) and only probe sets displaying logFC ≥ 0.75 or logFC ≤ -0.75 were 
taken into consideration. This process drops all genes with an expression less than 1.5-fold (0.5-fold 
respectively) of the control value.   
The here conducted study comprises a large amount of comprehensive data. The numbers of 
differentially expressed genes upon each comparison between inhibitor, combination of inhibitors 
and stimulation are summarized in Table 3-1. A complete list of differentially expressed genes after 






Table 3-1 Differential expression in human transformed germinal center B cells in response to inhibition of B 
cell specific stimulations. Summarized are the numbers of differentially expressed genes in response to each 
inhibitor in comparison to unstimulated BL2 cells or BL2 cells stimulated for 3 hours with α-IgM antibody or 
sCD40L. The total number of affected genes comprises all genes significantly differentially expressed (adj. p-
value ≤0.05) and is computed out of affected probes represented on the HG U133 Plus 2.0 microarray. Thus 
several genes are represented through probes which are marginally up as well as down regulated, which 
explains why the sum of up and down regulated genes does not necessarily correspond to the total number of 
affected genes. Due to high amounts of affected genes with very small effective fold change, genes exposing a 
logFC ≥ 0.75 or logFC ≤ -075 were regarded as differentially expressed. 
 total # of affected 
genes (up/down) 
up regulated genes 
(logFC ≥ 0.75) 
down regulated genes 
(logFC ≤ -0.75) 
Inhibitor Vs Ctrl 
Ly294002 (PI3K) 3875 (2025/1888) 73 84 
U0126 (MEK1/2) 303 (234/62) 16 1 
(5Z)-7-Oxozeanol (Tak1) 20 (20/2) 0 1 
ACHP (IKK2) 4561 (2139/2535) 22 66 
SB203580 (p38) 21 (18/3) 3 0 
SP600125 (JNK) 1566 (1175/397) 130 6 
IKK2/p38 4387 (2153/2383) 99 175 
JNK/p38 4150 (2188/2038) 63 32 
IKK2/JNK 5804 (2096/3087) 168 160 
IKK2/JNK/p38 4574 (2609/2099) 151 53 
α-IgM 
ctrl 9044 (3548/5770) 378 974 
Ly294002 (PI3K) 5871 (4387/1558) 409 127 
U0126 (MEK1/2) 6539 (4834/1795) 410 171 
(5Z)-7-Oxozeanol (Tak1) 407 (167/241) 15 30 
ACHP (IKK2) 2220 (1342/900) 56 60 
SB203580 (p38) 36 (11/25) 0 1 
SP600125 (JNK) 860 (690/171) 30 13 
IKK2/p38 3477 (2320/1257) 195 103 
JNK/p38 2513 (2114/410) 44 15 
IKK2/JNK 4886 (3373/1640) 230 106 
IKK2/JNK/p38 5512 (3817/1867) 365 139 
sCD40L 
ctrl 2633 (1352/1323) 129 115 
(5Z)-7-Oxozeanol (Tak1) 1838 (1001/862) 79 85 
ACHP (IKK2) 4549 (2232/2575) 62 257 
SB203580 (p38) 3453 (2137/1404) 198 175 
SP600125 (JNK) 4589 (3051/1668) 280 121 
IKK2/p38 5870 (3405/2929) 120 382 
JNK/p38 6028 (3588/2789) 289 390 
IKK2/JNK 5654 (3305/2765) 285 244 






In the present study, small molecule inhibitors were used to abrogate the function of specific 
kinases in order to obtain gene expression changes upon signaling pathway activation through CD40L 
or BCR cross linking. To investigate the effect of the specific inhibitor on the stimulated BL cells and 
to be aware of potential side-effects or effects without activation of the respective pathway two 
different experimental procedures were analyzed for each inhibitor: (1) cells treated with inhibitor 
alone and (2) stimulated cells treated with inhibitor. So, for each inhibitor or combination of 
inhibitors 3 lists of differentially expressed genes were obtained: (a) INHIBITOR-CTRL (contains all 
genes differentially regulated upon inhibitor use in unstimulated BL2 cells); (b) INHIBITORxBCR-
CtrlBCR (shows all differentially expressed genes between BL2 cells incubated 3 hours with inhibitor 
and subsequently stimulated 3 hours with α-IgM antibody and BL2 cells incubated 3 hours with ctrl 
(dmso) and subsequently stimulated 3 hours with α-IgM antibody) and (c) INHIBITORxCD40-CtrlCD40 
(exhibits all differentially expressed genes between BL2 cells incubated 3 hours with inhibitor and 
subsequent CD40 activation and the respective control: untreated/dmso-treated cells stimulated 
with sCD40L). 
The list of differentially expressed genes upon inhibitor use on unstimulated cells compared with 
the unstimulated control BL2 cells, gives a first overview about the effects of the inhibitor on the cell 
type of Burkitt’s lymphoma cells. Those effects observed here may include unspecific actions of the 
inhibitor as well as the exertion of inhibitory effects on already activated signaling pathways in the 
normal turnover of BL2 cells.  
As shown in Table 3-1, most of the inhibitors used in this study did not exert large effects on the 
unstimulated BL2 cells. Major effects upon inhibitor use on unstimulated BL2 cells were detected 
upon PI3K, IKK2 and JNK inhibition. This may point towards active basal signaling of PI3K, NF-κB and 
JNK in Burkitt’s lymphoma cells. Supporting this, a “tonic BCR signal” including augmented activity of 
PI3 kinase in Burkitt’s lymphoma (Schmitz et al., 2012) and a synergistic action of c-Myc and PI3K 
signaling in Burkitt’s lymphomagenesis (Sander et al., 2012) have been described recently. Although 
BL typically do not exhibit constitutive active NF-κB signaling in contrast to other lymphoma entitites 
(Dave et al., 2006; Klapproth et al., 2009), several hints point towards a sustained NF-κB activity in 
BL2 cells (see also chapter 3.3.4). In addition, our group could recently show a tonic activation of 
PI3K, NF-κB and JNK to regulate aberrant ‘basal’ c-Myc expression in BL (Schrader et al., 2012b).  
This dataset comprises a highly comprehensive amount of data. Therefore, no specific single 
differentially expressed genes will be considered, but network analyses provided by M. Pirkl, K. 




3.3.3 Nested Effects Models propose a controversial role of Tak1 in CD40 and BCR 
mediated signaling. 
One of the main aims of the present study was to provide high-dimensional data to develop, 
establish and further improve computational methods. A key obstacle to infer signaling networks 
from perturbation screens is that gene expression profiles offer only an indirect view of pathway 
structure due to the high number of non-transcriptional regulatory events like protein modifications. 
A recent computational approach especially designed to learn from high-dimensional phenotypes 
and indirect information are Nested Effects Models (NEM) (Markowetz et al., 2005, 2007). NEMs are 
a class of probabilistic models, which reverse engineer upstream/downstream relations of cellular 
signaling cascades and are computed to return pathway structures explaining the perturbation 
effects. 
The present study was designed in order to provide sufficient perturbations as well as 
upstream/downstream relations to infer signaling pathway structures with the use of NEMs. 
As described above, CD40L and α-IgM antibody induce overlapping as well as specific signaling 
pathways in BL2 cells. Based on the high-dimensional gene expression data, consolidating several 
different perturbations in terms of pathway activation via stimulation and pathway interruption via 
kinase inhibition, nested effects models were generated returning pathway structures analyzing and 
comparing the role of Tak1 in CD40 and BCR mediated signaling. Prior knowledge based on literature 
discussed Tak1 as signal diversifier upstream of p38, NF-κB and JNK activation in CD40 activated 
signaling (Sato et al., 2005; Takaesu et al., 2003; Yamashita et al., 2008). Equally, an essential role as 
mediator for BCR induced NF-κB signaling has been reported for Tak1 (Schuman et al., 2009; 
Shinohara and Kurosaki, 2009). Additionally, a very recent report being published throughout the 
work on the present study demonstrates a pivotal role for Tak1 in regulating cell survival of mantle 
cell lymphoma, a lymphoma subtype being dependent on active NF-κB signaling (Buglio et al., 2012). 
However, the role of Tak1 in NF-κB-independent malignancies as Burkitt’s lymphoma remains to be 
elucidated so far.  
As shown in Figure 3-12, NEMs derived two independent pathway structures for CD40 and BCR 
mediated signaling, proposing individual roles for Tak1. The firstly provided nested effects models 
supposed a covalent activation of p38 and Tak1 both exerting effects on the activity of IKK2 (Figure 
3-12 A). Furthermore, computed modeling resulted in an interchangeability of IKK2 and JNK, due to a 
strong overlap of target genes, when perturbing both kinases. However, Tak1 did not present as 
mediator that integrates signaling crosstalks. A similar surprising observation was made for BCR 
mediated signaling. Here, PI3K presented as expected as upstream signaling modifier. Nevertheless, 




described in literature (Schuman et al., 2009; Shinohara et al., 2005). Instead, p38, JNK and NF-κB 
signaling presented to be completely independent of Tak1 kinase function, but vice versa exerting 
effects on the shared target Erk1/2. The results proposed by the computed nested effects models 
were completely surprising, unexpected and contradictory to recent reports in other cell types, thus 
a biochemical proof was needed and several further experiments were conducted. 
 
Figure 3-12 Role of Tak1 in CD40 and BCR mediated signaling proposed by a first generation Nested Effects 
Model. A Nested Effects Model (NEM) of CD40 mediated signaling suggests an influence of Tak1 on IKK2 and 
JNk, but the p38-excerted effect seems to be independent of Tak1. Furthermore are IKK2 inhibition and Jnk 
inhibition indistinguishable with regard to their gene expression profile. B NEM of BCR mediated signaling. p38, 
NF-kB and JNK signaling seem to be completely independent from Tak1 signaling, but PI3K inhibition leads to 
effects on NF-kB signaling. Additionally, Tak1 inhibition is proposed to be connected to Erk-pathway by sharing 
target genes. 
To exclude probabilistic side effects of the used chemical inhibitor (5Z)-7-Oxozeanol, one 
additional small molecule inhibitor of Tak1 (AZ-TAK, Tocris, Bristol UK) and siRNA targeted against 
Tak1 was used in a comparative study (Figure 3-13). BL2 cells were transfected twice with a time 
lapse of 24 hours with control-siRNA (scrbl) or siRNA targeted against Tak1 (Silencer® Select, 
Ambion), respectively. Control-siRNA transfected cells were subsequently splitted and additionally 
pre-treated with (5Z)-7-Oxozeanol or AZ-TAK1 for 3 hours, before all cells were either stimulated 
with sCD40L or α-IgM antibody or left unstimulated. Stimulation was carried out for 30 min to 
analyze pathway activation signals via Western Blot analyses or for 3 hours respectively to analyzing 
target gene expression changes via qRT-PCR. In the following the activation of MAPK signaling (p38, 
Erk) and NF-κB signaling (IκBα degradation) was investigated using Western Blot analyses. JNK 
signaling was not contemplated due to the complexity of the here considered data, and non-working 




As clearly shown in Figure 3-13 A, (5Z)-7-Oxozeanol strongly inhibited CD40 and BCR induced 
phosphorylation of p38. Thus, Tak1 should be presented upstream of p38 both in CD40 as well as in 
BCR activated signaling models. Additionally, protein analyses of IκBα-levels in Tak1-inhibitor treated 
BL2 cells revealed a stabilization of IκBα upon inhibitor use and subsequent CD40 activation. In 
control-treated cells a marked degradation of IκBα after CD40 activation as hint for active NF-κB 
signaling was visible. BCR crosslink did not induce strong NF-κB activation, observable as IκBα 
degradation, in BL2 cells, therefore the effect of the inhibitor on BCR induced NF-κB signaling 
remains unclear upon analyses of protein modifications. The inhibitor AZ-TAK obtained from Tocris 
Bioscience (Bristol UK) did not seem to work properly in our hands. Buglio and coworkers could 
demonstrate reduced phosphorylation levels of p38 in an IL-1-induced HeLa cell line upon AZ-TAK1 
treatment for 1 hour (Buglio et al., 2012), but here the phosphorylation status of p38 was already 
elevated upon AZ-TAK1 treatment of unstimulated BL2 cells compared to untreated BL2 cells. Same 
holds true for the use of siRNA mediated knock down of the gene of interest.  
A strong reduction in protein levels of Tak1 was observable upon siRNA use, but the activation of 
p38 signaling through CD40L is still present. Similarly was the inhibition of NF-κB signaling, as 
visualized by IκBα degradation, most clearly detectable upon use of (5Z)-7-Oxozeanol and less 
convincing (but still observable) upon use of AZ-TAK or TAK1-targeting siRNA.  
As already mentioned above the read out for BCR activated signaling on the protein level is more 
difficult. The p38 activation upon 30 min α-IgM stimulation was not as strong as after CD40L, but was 
nevertheless inhibited through (5Z)-7-Oxozeanol. IκBα degradation was not observable after 30 min 
of BCR crosslink, but a strong activation of Erk signaling was detectable via phosphorylation of 
Erk1/2. Upon use of Tak1 inhibitors and siRNA targeted against TAK1, the phosphorylation status of 
Erk1/2 seemed to be reduced.  
Nevertheless, those analyses of protein modifications upon Tak1 inhibition and subsequent 
pathway activation led to the conclusion that Tak1 should be modeled as a signal modulator being 
situated upstream of p38 and NF-κB signals in CD40 mediated signaling as well as upstream of p38, 






Figure 3-13 Tak1 presents as major signal modulator in CD40 and BCR mediated signaling. A Western Blot 
analysis of BL2 cells transfected twice for 24 hours with 4 µg scrbl siRNA or Tak1 siRNA. Samples transfected 
with scrbl siRNA were splitted 24 hours after second transfection for treatment with either 100 nM (5Z)-7-
Oxozeanol or 250 nM Az-Tak1 for 3 hours and stimulated for 30 min afterwards. B-F qRT-analyses of 
transfected BL2 cells (same treatment as in A, apart from 3 hours of stimulation with either sCD40L or α-IgM 
F(ab)2 fragment). Data are represented as 2-ΔΔCt values relative to ABL housekeeping gene expression. G 
Western Blot analysis of several inhibitors of BCR mediated signaling in BL2 cells: PI3K (Ly294002, 
Compund15e, BKM120), PLC-γ (U73122), PDK1 (BX-912). H Model of CD40 mediated signaling based on 




experimental data places Tak1 downstream of PI3K, but upstream of p38, NF-κB and Erk-signaling. The role of 
JNK in this context was not determined.  
To further elucidate gene expression changes induced through Tak1 inhibition, qRT-PCR analyses 
were accomplished using the same experimental procedure as described above, except 3 hours of 
CD40/BCR stimulation before analysis. First of all, TAK1 mRNA expression level were checked to 
prove a knock down of TAK1 upon siRNA use. The results showed 50 % reduced expression levels 
upon siRNA, but not upon inhibitor use, as the chemicals inhibit kinase activity and not protein 
expression (Figure 3-13 A & B). To further investigate the NF-κB activation through BCR crosslink 
typical NF-κB target genes as NFKB2 and ICAM1 have been analyzed. One can observe an induction of 
NFKB2 expression upon CD40 stimulation, which is much less pronounced upon BCR crosslink (Figure 
3-13 C). However, (5Z)-7-Oxozeanol, but not AZ-TAK1 or Tak1 siRNA reduced the levels of NFKB2 
mRNA expression. Such a reduction in NFKB2 expression level was even in the unstimulated BL2 cells 
detectable. Furthermore, the expression of ICAM1 was markedly elevated upon CD40 activation, but 
not changed after α-IgM stimulation (Figure 3-13 D). The level of ICAM1 activation was similarly 
suppressed through (5Z)-7-Oxozeanol treatment after pathway activation through CD40L as in 
unstimulated BL 2 cells. Figure 3-13 E & F shows the regulation of mRNA expression upon Tak1 
inhibition and subsequent CD40/BCR stimulation of SGK1 and LINC00158. SGK1, the serum- and 
glucocorticoid-induced kinase 1, is activated through the PI3K (Yan et al., 2008), thus SGK1 mRNA 
expression level are highly up regulated upon α-IgM stimulation (Schrader et al., 2012b). LINC00158 
is a long intergenic non-protein coding RNA 158, which was found to be strongly regulated through 
CD40 and BCR activation (Schrader et al., 2012b) as well as IKK2 and Tak1 inhibition in CD40 activated 
BL cells (compare supplemental file \\NEM\combinedAnalyses_201211\IKK2_Tak1xCD40.int.xls on 
the provided CD ROM). For both genes a strong inhibition through the use of (5Z)-7-Oxozeanol was 
detectable, which confirms the microarray data by qRT-PCR and contradicts the proposed nested 
effects model for BCR. Additionally, similar to the NF-κB target genes NFKB2 and ICAM1, a regulation 
by Tak1 inhibition in unstimulated BL2 cells for LINC00158 was observed.  
To further verify the proposed NEM for BCR activated signaling, the role of PI3K signaling in regard 
to its possibility to activate NF-κB signaling in BL cells was investigated. Several small molecule 
inhibitors targeting BCR induced signaling on different levels were used. Thus, BL2 cells were 3 hours 
pre-treated with Ly294002, Compound15e or BKM120 to inhibit PI3K activity with three independent 
inhibitors, as well as with inhibitors for PLC-γ (U73122) and PDK1 (BX-912) before subsequent 
stimulation with α-IgM antibody for 60 min (Kopp et al., 2012; Mogami et al., 1997; Vlahos et al., 
1994; Walsh et al., 2013). As depicted in Figure 3-13 G, we could not detect a BCR induced 
degradation of IκBα in BL2 cells. Upon inhibition of basal (‘tonic’) and BCR induced PI3K activity via 




diminished stabilization of IκBα was also visible upon use of BX-912. The here demonstrated results 
raise the question if basal PI3K activity, as observed in BL (Schmitz et al., 2012), restrains NF-κB 
activatability. Therefore, one can conclude that NF-κB activity is also regulated through PI3K 
activation in BCR signaling. Similarly, a strong reduction in BCR induced phosphorylation levels of Erk 
were observed after PI3K-inhibition.  
Summarizing the data presented in Figure 3-13, one can conclude that in CD40 mediated signaling 
Tak1 may indeed influence p38 and NF-κB signaling as upstream mediator, whereas in BCR mediated 
signaling Tak1 additionally modulates Erk signaling and may be interposed between PI3K influence 
upstream and p38, Erk and NF-κB signaling downstream (Figure 3-13 H & I). To further pinpoint the 
role of Tak1 in CD40 and BCR mediated signaling in BL cells, the experimental procedure as described 
above was expanded on another Burkitt’s lymphoma cell line Ramos (Figure 3-14 B), thereby 
disclosing some particularities. In BL2 cells, p38 is activated upon both CD40L and α-IgM stimulation. 
(5Z)-7-Oxozeanol inhibited this activation markedly, whereas upon AZ-TAK treatment only 
diminished phosphorylation levels of p38 were detectable and the use of Tak1 siRNA did not affect 
the activation status of p38 (Figure 3-14 A). In Ramos cells, the p38 activation strongly appeared after 
CD40 pathway activation, but not upon BCR crosslink. Nevertheless, the effect of (5Z)-7-Oxozeanol 
was much stronger in Ramos cells than in BL2 cells, whereas the effect of AZ-TAK and Tak1 siRNA 
were comparable in both cell lines (Figure 3-14 B).  
 
Figure 3-14 Comparison of two Burkitt’s lymphoma cell lines with regard to signaling interruption upon Tak1 
inhibition. A BL2 cells were transfected with Tak1 siRNA or respective control. Control transfected cells were 
splitted and additionally treated with Tak1 inhibitors (5Z)-7-Oxozeanol or AZ-TAK. After 3 hours of inhibitor 
treatment, cells were stimulated for 30 min with either sCD40L or α-IgM F(ab)2 fragment or left as control. 
Samples were harvested and 20 µg protein were subjected to Western Blot analyses. B The Burkitt’s lymphoma 




NF-κB signaling was in both cell lines strongly activated upon CD40 activation and nearly not 
detectable via WB after 30 min BCR crosslink. In BL2 cells, (5Z)-7-Oxozeanol inhibited the NF-κB 
activation, whereas in Ramos cells still a strong IκBα degradation was detectable. Both AZ-TAK as well 
as Tak1-directed siRNA marginally led to an IκBα stabilization in BL2 as well as in Ramos cells.  
Furthermore, the activation of the Erk pathway after BCR crosslink, displayed here through 
phosphorylation of Erk was much stronger in BL2 cells than in Ramos cells, thus the inhibitory effect 
of (5Z)-7-Oxozeanol is much easier to demonstrate in BL2 cells than in Ramos cells. All these 
observations point to a somehow particular role of BL2 cells, our model cell line for human 
transformed germinal center cells. Preliminary results from others in the group of D. Kube 
investigating further Burkitt’s lymphoma cell lines, tend to confirm an outstanding role of the BL2 cell 
line in the scope of Burkitt’s lymphoma cell lines. Nevertheless, the data used to compute nested 
effects models were obtained on perturbations of the BL2 cell line and in this cell line Tak1 seems to 
play its foretold role as mediator of p38 and NF-κB signaling upon CD40 activation as well as 
diversifier of signaling towards p38, NF-κB and Erk signaling after BCR crosslink.  
Taken together, the biochemically collected data provide strong evidence that the primarily 
proposed nested effects models of the role of Tak1 in CD40 and BCR mediated signaling are 
inadequately describing the underlying signaling functions of Tak1. Thus, further computational 





3.3.4 NF-κB signaling upon BCR crosslink in Burkitt’s lymphoma 
Simultaneously to the question whether Tak1 plays its pivotal role as mediator for NF-κB signaling in 
BLs as well upon BCR signaling, the observation of generally low levels of NF-κB activation after α-
IgM stimulation in BL cells was investigated. Generally, triggering of the B cell receptor leads to the 
activation of NF-κB signaling via protein kinase C (PKC) β and additional signal adaptors like CARMA1, 
Bcl10 and mucosal–associated lymphoid tissue 1 (MALT1) (Egawa et al., 2003; Li and Verma, 2002; 
Ruefli-Brasse et al., 2003; Ruland and Mak, 2003). 
Interestingly, the results reported in the present study exhibit the contrasting observation of a 
reduced activatability of NF-κB signaling through B cell receptor signaling compared to CD40 
mediated signaling in the BL cell lines BL2 and Ramos (compare Figure 3-14). Moreover, taking IκBα-
degradation as a sign for NF-κB activation, the impression of reduced NF-κB signaling after BCR 
activation arises, as visualized by a sustained stabilization of IκBα (Figure 3-13 G and Figure 3-14 A). 
To elucidate the reduced NF-κB signaling upon BCR crosslink in Burkitt’s lymphoma, the different 
NF-κB family members and their activatability through CD40 or BCR were analyzed via WB. Upon 
activation of the NF-κB signaling pathway, the transcription factors belonging to the NF-κB family 
translocate into the nucleus, which can be monitored by extracting nuclear and cytosolic proteins 
separately after giving the stimulus to the cell. Thus, the model cell line for Burkitt’s lymphoma in the 
present study, BL2, as well as a model cell line for DLBCLs, OCI Ly1, were compared with regard to 
the ability to translocate p65, c-Rel, or RelB to the nucleus 1 hour after activation with either sCD40L 
or α-IgM antibody (Figure 3-15 A & B). Yet, a more direct observation of NF-κB activation via nuclear 
translocation of the respective transcription factor was achieved in comparison to the indirect proof 
of NF-κB activation by IκBα-degradation.  
Unexpectedly, in both cell lines, BL as well as DLBCL, a nuclear translocation of the NF-κB family 
members p65, c-Rel and RelB was mainly detectable after CD40 activation, but not after α-IgM 
stimulation. In the BL2 cell line, a remarkably strong nuclear signal for p65 was detectable in the 
unstimulated cells as well, thus favoring a completely new and contradicting theorem of constitutive 
active NF-κB signaling in the BL2 cell line. Indeed, when pre-treating BL2 cells with an IKK2-inhibitor, 
both the basal and the CD40 activated nuclear p65 signal was diminished (Figure 3-15 C). 
Unexpectedly, no BCR induced nuclear translocation of any investigated NF-κB family member was 
detectable in the DLBCL cell line OCI Ly1 (Figure 3-15 F). Instead, the BL cell line BL2 exhibits a faint 
NF-κB activation signal 60 min after α-IgM stimulation, which can be inhibited through either IKK2 or 
Tak1 inhibition (Figure 3-15 E). However, a low grade of NF-κB activation can be guessed in terms of 





Figure 3-15 Differences in NF-kB activatability in Burkitt’s lymphoma and Diffuse large B cell lymphoma. 
Nuclear translocation of NF-kB family member was monitored using specific antibodies against p65, c-Rel and 
Rel b. The nuclear extract was verified using a specific antibody against the nuclear marker HDAC1. To compare 
the differences between Burkitt’ lymphoma and diffuse large B cell lymphoma, experiments were carried out in 
BL2 cells (BL) (A, C, E) and OCI Ly1 (DLBCL) (B, D, F). A + B show the general activatability of nuclear NF-kB 
translocation through CD40 stimulation and BCR crosslink with antibodies specific for NF-κB family members 
p65, c-Rel and RelB. C + D depict WB analyses of BL2 and OCI Ly1 cells upon NF-kB inhibition (IKK2i) and Tak1 
inhibition ((5Z)-7-Oxozeanol) and 60 min CD40 stimulation. E + F show the same analyses as C + D upon 
stimulation with α-IgM F(ab)2 fragment. 10 ng of protein were loaded for each fraction. The purity of the 




To conclude, the nuclear translocation of p65 upon α-IgM stimulation demonstrates that NF-κB 
signaling seems to be slightly activated after BCR activation in the BL cell line BL2. This stands in 
contrast to the observed stabilization of IκBα 30 min and 60 min after BCR stimulation. However, 
CD40 mediated activation of NF-κB signaling is more pronounced when compared to BCR mediated 
NF-κB activation. Additionally, the BL2 cell line harbors high basal levels of nuclear p65 thus 
suggesting a basal NF-κB activity. Moreover, we observed for the first time, that BCR activation could 
not induce nuclear translocation of NF-κB family members in a DLBCL cell line. However, the 






We postulated that the differences between molecular BL and DLBCL are due to specific immune 
response associated signals mediated by the B cell microenvironment. Using in vitro stimulation of 
human transformed germinal center B cells as a model system to investigate pathway activation in 
aNHL, we could already demonstrate that both B cell receptor activation as well as CD40 activation 
lead to gene expression changes, which can be used to discriminate individual DLBCLs (Schrader et 
al., 2012b). However, these data are restricted to a specific time after giving the stimulus and may 
hide additional information about potential oncogenic pathway activities and their regulation. Thus, 
the present study aimed to provide gene expression data, which allow to investigate the relevant 
signaling pathways and their consequences in more detail. Therefore, this study used (a) time-
resolved analysis of gene expression changes upon oncogenic pathway activation and (b) a 
combination of in vitro stimulation and kinase inhibition to provide data allowing the prediction of 
regulatory feedback loops and delineate respective pathway interactions on the whole genome gene 
expression level. 
4.1 Analyzing the temporal pattern of gene expression changes 
It was shown in this study that α-IgM as well as CD40 stimulation activate several signaling pathways 
in the BL cell line BL2. This includes overlapping signaling as the activation of p38 MAPK pathway 
through CD40 and α-IgM as well as distinct pathways, activated specifically through one of both 
stimuli. Thus, CD40 activation induces a strong and rapid activation of NF-κB signaling, whereas the 
BCR mediated NF-κB activation seems to be less pronounced and delayed in comparison to CD40 
mediated activation (compare Figure 3-1 C & E). Activation of ERK/MAPK and PI3K/AKT pathway are 
unique to BCR mediated signaling and not triggered through CD40 induced signaling activation.  
To our knowledge this study provides for the first time a global time-resolved investigation on the 
whole genome level of gene expression changes upon signaling pathway activation through CD40 or 
BCR crosslink on B lymphocytes. Both, BCR activation as well as CD40 activation induced a unique 
gene expression profile as revealed by microarray analyses. As shown before in another study, α-IgM 
stimulation of transformed germinal center B cells led to differential expression of significantly more 
genes than CD40 activation (Schrader et al., 2012b). 
It was shown in this study that especially genes which are differentially expressed upon α-IgM 
stimulation shift the gene expression profile of mBL towards a gene expression profile of DLBCL 
(Figure 3-2). It becomes clear, that sustained activated signaling via the B cell receptor but not 
activation of CD40 mediated signaling leads to changes in gene expression which reduce the mBL 
index. This observation is supported by recent findings, which demonstrate chronic active BCR 




2006), thus defining the molecular profile of ABC DLBCL in comparison to other DLBCL subtypes 
(Alizadeh et al., 2000). In addition, our group could very recently demonstrate that the coherent 
expression of α-IgM affected genes characterizes individual NHL (Schrader et al., 2012b). In line with 
recent advances in the understanding of lymphoma pathogenesis, one can conclude that B cell 
receptor signaling has emerged as a central oncogenic pathway in lymphoma genesis and 
progression. The cascade of effectors downstream of the BCR includes many kinases diversifying the 
signal intensity, amplitude and outcome. Thus, it is not surprising that lymphomas adopt and spoil 
this signaling pathway, rendering it to an essential tool, which bears the potential of targeted therapy 
for patients with aNHL.  
Due to the high-dimensionality and complexity of the generated data, statistical and 
bioinformatical analyses turned out to be challenging. In the present study, two different methods 
were used to analyze the temporal pattern of gene expression changes, thereby aiming at the 
disclosure of regulatory circuits, positively and negatively influencing signaling routes in their top-to-
down signaling cascade. Even though using distinct mathematical models, both analyses are based 
on the integration of gene expression changes with similar time course to clusters of genes. It is not 
surprising that the computed clusters of genes are not identical to each other, since different 
mathematical approaches may result in different major findings, an observation which was 
demonstrated by others as well (de Matos Simoes et al., 2012). Apparently, in both models, BCR as 
well as CD40 activation induce a variety of different gene expression changes, including immediate-
early activated and repressed genes as well as genes being changed in their expression profile after 
long-term stimulation or genes, displaying more-phasic time courses.  
The first approach presented in this study demonstrates a causality network of α-IgM mediated 
gene expression correlations (Figure 3-3) and their conditional dependency, inferring an influence 
between connected clusters of genes (Chiquet et al., 2009). The network nicely demonstrates the 
complexity and connectivity of signaling pathways, which are induced upon crosslinking the BCR. A 
biological interpretation of this comprehensive network still remains to be fully elucidated. A first 
attempt to assign GO-terms and search for significant enrichment of specific biological processes 
identified the hub clusters of the causality network to be enriched for genes encoding kinases, G-
proteins and related proteins as well as genes encoding for transcription factors thus playing crucial 
roles in cell signaling and cell proliferation processes. However, further analyses revealed that several 
clusters resemble each other not only in gene expression course but also in the biological processes 
the genes are encoded for. Furthermore, most clusters are composed of genes, which cannot be 




Tremendous advances have been made in the development of new mathematical and 
bioinformatical methods to construct gene regulatory networks (Friedman, 2004; Lee and Tzou, 
2009; Markowetz and Spang, 2007). These methods often combine gene expression data with for 
example protein-DNA interaction data to recover the underlying networks. However, most methods 
focus on reconstructing networks from static data and do not contain any temporal information. 
Only very recent investigations dealed with time series expression data and provided some 
interesting new methods to engineer gene regulatory networks (Cooke et al., 2011; Darkins et al., 
2013; Gonçalves et al., 2012; Haye et al., 2012; Nascimento et al., 2012; Schulz et al., 2012; Su et al., 
2013; Titsias et al., 2012; Yeung et al., 2011; Zou and Conzen, 2005). Thus, the conflation of our time 
course specific gene expression data set with other sources of prior knowledge may be useful to 
fathom the biological meaning of such a causality network. In order to shed some light on the 
complexity of the gene expression changes and their causal correlation induced through α-IgM 
stimulation, ongoing analyses are supposed to integrate genome-wide chromatin 
immunoprecipitation assays in our cell perturbation assays. Therewith, we aim to use such a causality 
network for identification of, for example, transcription factor targets. 
The mathematically further developed and refined method of testing for stationarity applied by J. 
Läuter and colleagues was used to build sets of genes which display distinct expression changes over 
time. Hereby, the clustering of genes is strictly mathematically justified and the biological 
interpretation relies on the assumption that genes, which exhibit a uniform process are also 
regulated through the same elicitor or display a similar biological function. Combining this method of 
time course analysis with Gene Ontology enrichment allowed the discrete characterization of stimuli-
induced gene expression changes over time on a global level. One can conclude from the present 
study that activation of target genes affecting proliferation, differentiation and paracrine signaling 
occurs 2 hours after CD40L activation and thus, CD40 mediated signaling happens very rapidly on the 
proteome-level, leading to a fast feedback loop mediated by gene expression changes. In contrast, 
BCR mediated signals are also translated rapidly into gene expression changes but seem to induce a 
broader variety of signals. This is justified by the higher number of differentially expressed genes 
when compared to CD40 induced gene expression changes as well as longer lasting changes in gene 
expression. Taken together with the observation of the BCR mediated shift of originally mBL-index-
bearing cells towards a gene expression pattern of non-mBL (chapter 3.1.1), the observations made 
in the present study underpin the particular importance of B cell receptor signaling in lymphoid 
malignancies. This is in line with recent assessments and the related investigations in the field of 




As described in chapter 3.1.3, time series analysis of α-IgM induced gene expression changes 
demonstrated the temporal expression pattern of many well-known and pivotal players in both 
normal and pathological BCR signaling. One example is CCR7, a chemokine receptor shown to be an 
essential regulator of leukemia cell infiltration into the central nervous system (Buonamici et al., 
2009). Its high expression in T-cell leukemias was associated with tumor cell migration and invasion 
in vitro and in vivo (Yang et al., 2011). Further, CCR7 was recently described for regulating homing of 
lymphoma cells to T cell regions in lymph nodes, thus promoting lymphoma cell survival through 
facilitating the cross-talk to other microenvironmental non-tumor cells (Rehm et al., 2011). In 
addition, Rehm and colleagues suggested that T-cell zone location of their mouse-model-derived 
lymphoma cells awards resistance to spontaneous apoptosis through the proximity to fibroblastic 
reticular cells (FRCs), which provide the hedgehog protein Indian hedgehog, as shown by reduced 
viability of lymphoma cells upon use of the Hh signaling inhibitor Cyclopamine. This very interesting 
observation taken together with the simultaneous BCR mediated down regulation of the Hh-signaling 
receptor PTCH1 as well as LEF1 and NOTCH1 (compare Figure 3-5 and Figure 3-6), both pivotal 
players in developmental biology as well as being associated with several types of lymphoid 
malignancies (Cheng et al., 2001; Pui et al., 1999; Radtke et al., 2004; Reya et al., 2000; Walther et al., 
2013), strengthens the importance of paracrine and autocrine signaling in the tumor 






4.2 A non-canonical role of Hedgehog signaling in lymphoma 
The statistical analyses of BCR mediated gene expression changes identified the BCR induced co-
repression of LEF1, NOTCH1 and PTCH1. Lef1, a transcription factor in the Wnt signaling pathway, has 
been shown to regulate normal B lymphocyte proliferation (Reya et al., 2000). Further, LEF1 is one of 
the signature genes defining the mBL index (Hummel et al., 2006) and very recently our group could 
demonstrate an aberrant LEF1 expression as well as its transcriptional activity in BLs (Walther et al., 
2013). Notch1, the transmembrane receptor for the Notch signaling network plays not only a role in 
lymphocyte development, proliferation and differentiation (Anderson and Longnecker, 2009; Cheng 
et al., 2001; Pui et al., 1999; Radtke et al., 2004) but has also been implicated in a variety of 
hematological malignancies including chronic lymphatic leukemia (CLL) (Okuyama et al., 2012; 
Willander et al., 2013), acute lymphatic leukemia (ALL) (Schwanbeck and Just, 2011; Tosello and 
Ferrando, 2013) as well as DLBCL (Lohr et al., 2012). Further on, both genes are connected to c-MYC 
activation (Rakowski et al., 2013; Yochum et al., 2008), which in turn displayed a similar time course 
of mRNA decrease after BCR crosslink. However, the connection of Ptch1 and related hedgehog 
signaling and c-Myc in lymphoma signaling remained elusive so far. Studies in Hh-induced 
medulloblastoma formation suggested that c-Myc activates GLI1 expression in vitro and thus 
promotes tumorigenesis (Rao et al.; Zwerner et al., 2008). Evidence for the role of Hh in lymphoma is 
limited but rapidly developing. Both, healthy germinal center B cells as well as myc-driven lymphoma 
cells have been found to be protected from apoptosis by Hh ligands secreted by stroma cells (Dierks 
et al., 2007; Sacedón et al., 2005). Further, expression of Hh signaling proteins and their contribution 
to survival was described for some DLBCL cell lines (Singh et al., 2010). However, the relevance of Hh 
signaling in BL cells was not determined. In the present study, the analyzed BL cell lines differed 
strongly in their basal expression level of Hh signaling components. Hh ligands as SHH and IHH were 
not or only barely expressed by BL cell lines. Further on, activation of the Hh signaling pathway could 
not be achieved through stimulation of the cells with Shh-enriched medium, thus suggesting that BL 
cells are not responsive to Hedgehog pathway activation. These results are supported by a very 
recent study, confirming that Burkitt’s lymphoma cells do not seem to be Hedgehog responsive 
(Yoon et al., 2013). Instead, this group shows that c-Myc directly regulates GLI1 expression more 
significantly than the canonical Hh signaling pathway. This finding circumstantiates the here 
presented data, which demonstrate no relevance of SMO inhibition on BL cells. Additionally, the BCR 
induced c-Myc repression occurs slightly earlier when compared to the time course of PTCH1. These 
findings suggest a c-Myc driven non-canonical regulation of Hh signaling in BL and implies new 
therapeutic approaches, which include the direct targeting of Gli1 or GLI1 target genes.  
This study could not reveal generally higher expression levels of Hh signaling components in the 




signaling in ABC DLBCL, including expression and secretion of Hh ligands as well as responsiveness to 
Hh-inhibition (Ok et al., 2012; Ramirez et al., 2012; Singh et al., 2009, 2010, 2011). These findings are 
somewhat contradictory, even though they might be explainable by the diversity of the cell lines 
used for the investigations in the present and the recently published studies.  
However, the observation of BCR mediated down regulation of PTCH1 expression raised the initial 
hypothesis that Burkitt’s lymphoma harbor active Hh signaling. As shown in Figure 3-6, the computed 
time course of PTCH1 was verified by qRT-PCR and revealed an activation of PTCH1 gene expression 
after α-IgM stimulation before its expression was down regulated. Thus, the observed reduction of 
PTCH1 mRNA levels after 3 to 4 hours of BCR activation might contribute to a regulatory feedback 
loop, preventing an exaggeratory Hh response. However, activation of BCR signaling in the BL cell line 
BL2 led to reduced levels of PTCH1 gene expression but no changes in expression levels of GLI1 
(Figure 3-7). Taken together with the contrasting results in other BL cell lines, we concluded that 
canonical Hh signaling is not active in BLs. Instead, the observed elevated GLI1 expression levels upon 
BCR activation in most cell lines favor the hypothesis of active Hh signaling in DLBCLs. This especially 
holds true when taking into consideration that BCR activation induces a transition of the mBL index 
from mBL towards DLBCL.  
Activation of Hh signaling in cancer has been attributed to aberrant activation of several signaling 
pathways resulting in the integration of multiple oncogenic signaling inputs. Interplay of TGF-β, NF-
κB, Notch and the ERK/MAPK pathway is supported by multiple lines of evidence (Chang et al., 2010; 
Madhala-Levy et al., 2012; Mangelberger et al., 2012; Qu et al., 2013; Schnidar et al., 2009) 
Furthermore, a synergistic effect between Hh and PI3K signaling was suggested for several cancer 
entities including ALK (anaplastic lymphoma kinase)-positive anaplastic large cell lymphoma cells (Ju 
et al., 2009; Mizuarai et al., 2009; Singh et al., 2009; Wei and Xu, 2011). Very recently, a study 
defining causative factors for activation of Hh signaling in diffuse large B cell lymphoma supported 
this link, by demonstrating reduced Gli1 protein levels after PI3K inhibition in DLBCL cell lines 
(Ramirez et al., 2012). However, they could not reveal the precise mechanism by which PI3K 
regulates Hh signaling. Furthermore, in this study Gli1 protein expression was inhibited by very high 
concentrations of the PI3K inhibitor Ly294002 in GCB DLBCL cell lines, whereas in the ABC DLBCL cell 
line OCI Ly3, which exhibits chronic active BCR signaling (Davis et al., 2010), lower concentrations of 
Ly294002 were sufficient to effectively abrogate Gli1 protein expression (Ramirez et al., 2012). 
Similarly, long-lasting inhibition of PI3K through Ly294002 also increased PTCH1 and additionally c-
MYC expression levels in unstimulated BL2 cells (Schrader et al., 2012b and unpublished own data). 
This not only supports the already suggested link between PI3K and Hh signaling but additionally 




action of c-Myc and PI3K has been recently described for lymphoma pathogenesis (Sander et al., 
2012). Further on, a basal activity of PI3K and tonic BCR signaling was demonstrated in Burkitt’s 
lymphoma (Schmitz et al., 2012).  
Nonetheless, the present study revealed a strong heterogeneity between different BL cell lines 
regarding their BCR mediated Hh signaling activation. Furthermore, cell lines where the BCR 
activation led to PTCH1 expression level reduction not necessarily displayed activation of Hh signaling 
as monitored by GLI1 expression. These findings support a non-canoncial activation of Hh signaling in 
lymphoma cells as recently proposed by others (Yoon et al., 2013). Similarly, the cell lines tested in 
the present study did not show any responsiveness to canonical Hh signaling activation through 
stimulation by Shh. In summary, the here presented investigations could not reveal a clear BCR 
induced activation or inactivation of canonical Hh-signaling in lymphoma cells. Moreover, Burkitt’s 
lymphoma cells as well as the one DLBCL cell line investigated here do not seem to be Hedgehog 
responsive. Above all, the present study could not exclusively determine the same regulatory factor 
behind the simultaneous decrease in expression levels of c-MYC, PTCH1 and LEF1, although the 
regulation of all three genes is clearly dependent on the PI3K-PLCγ-PKC pathway. Taken together, the 





4.3 Analyzing pathway intersections 
Our group was recently able to mimic oncogenic pathway activities in aNHL by investigating the 
major patterns of gene expression changes in response to different immune response-associated 
stimuli in vitro (Schrader et al., 2012b). We were also able to identify individual aNHL profiles 
reflecting those patterns and we concluded that future targeted therapies have to intervene into 
specific signaling modules to reverse pathway deregulations. Therefore it is of crucial relevance to 
understand the constellation of oncogenic activities in the context of their interplay and the cross 
talk of signaling pathways being involved in the pathogenesis of lymphomas. Thus, the present study 
aimed to use a combination of in vitro stimulation with specific kinase inhibitors in order to delineate 
respective pathway interactions. The genome-wide expression profile of BL2 cells was investigated in 
several conditions, depicting oncogenic signaling activation and its abrogation at specified 
intersections. Thus, a large amount of comprehensive data was generated, which is still subject to 
work in progress in order to establish suitable methods for analyzing the complexity, the connectivity 
and the biological relevance of gene expression changes. 
Tak1 as major modulator in CD40 and BCR mediated signaling  
A recent computational approach to infer signaling pathway structures from perturbation 
experiments and subsequent gene expression profiling, Nested Effects Modeling (NEM) (Markowetz 
et al., 2005, 2007), was used to compare the role of Tak1 in CD40 and BCR mediated signaling. In 
CD40 activated signaling in B cells, Tak1 has been described to act as pivotal signal regulator 
upstream of p38, JNK and NF-κB activation (Sato et al., 2005; Takaesu et al., 2003; Yamashita et al., 
2008). BCR signaling also activates those signaling pathways, but the contribution of Tak1 is 
controversially debated. Sato and colleagues demonstrated murine Tak1-deficient B cells to be able 
to still activate NF-κB signaling, but not the kinase JNk in response to BCR stimulation (Sato et al., 
2005), whereas a later study demonstrated that B cell-specific TAK1-deficiency disrupted BCR 
induced NF-κB activation (Schuman et al., 2009).  
However, the NEMs derived from the gene expression data in the present study proposed an 
unexpected dispensable role for Tak1 in CD40 and BCR mediated signaling BL cells (Figure 3-12). Yet, 
subsequently conducted biochemical investigations provided strong evidence that the primarily 
proposed nested effects models are not sufficient to describe the role of Tak1 in CD40 and BCR 
mediated signaling. Comparative analysis of the two independent inhibitors of Tak1 activity, (5Z)-7-
Oxozeanol and AZ-TAK1, as well as Tak1-directed siRNA revealed the indispensability of Tak1 for 
mediation of p38 and NF-κB activation in CD40 mediated signaling. In BCR activated signaling, the 
Tak1 mediated activation of Erk, besides p38 and NF-κB activation was demonstrated. Thus, former 




NF-κB signaling in CD40 as well as BCR activated pathways. This includes a so far not recognized 
regulatory role of Tak1 in Erk1/2-signaling. The present results suggest, that inhibitors targeting Tak1 
activity might be suitable treatment options for lymphoma subtypes, depending on NF-κB, JNK, p38 
or Erk1/2 signaling activity. This is supported by a very recent report, which was published during the 
work on the current study and revealed a pivotal role for Tak1 in regulating cell survival of mantle cell 
lymphoma cells, a subtype of aNHL exhibiting active NF-κB signaling (Buglio et al., 2012). 
The here conducted analysis highlights the limitations of NEMs to handle such complex high-
dimensional data in order to correctly return upstream/downstream relations of cellular signaling 
cascades and demonstrates the need for adaptation of the existing method. The observed 
differences in signal intensity may lead to the construction of dissatisfactory graphs. The gene 
expression changes induced through BCR stimulation were much stronger than those induced 
through CD40 activation. Similar observations were made for use of the different inhibitors. Thus, 
less genes are significantly strong regulated upon p38 inhibition than upon Erk1/2 inhibition. Since a 
very stringent cut-off (p-value) for calculation of the NEMs is used, it is possible that such system-
relevant effects cannot be spotted and lead to the omission of potential p38-exerted effects. 
Therefore, a new method of discretization has now been established to integrate the different signal 
intensities in future modeling processes (personal communication from M. Pirkl, Regensburg). 
Another possible cause for the limitations in the NEMs is lying within the off-target effects of the 
inhibitors. The difficulty in modeling signaling cascades with the help of intervention studies is 
concentrated on the possibility to smartly differentiate off-target effects from real pathway signaling. 
Therefore, we are now primarily interested in establishing new methods for learning regulatory 
networks from compendia of the perturbation expression data and combining this data with data 
sources that provide prior knowledge to the network structure. One source of such prior information 
is our collection of manually curated and experimentally validated data, obtained from Western Blot 
analyses, qRT-PCRs or reporter-gene assays. Additionally, literature-based prior information will also 
be included in the generation of a new model. Thus, adjustement of the existing statistical algorithms 
is in preparation in order to map a biologically comprehensive and perspicuous regulatory network of 
the here analyzed perturbations.  
BCR dependent NF-κB signaling in BLs 
Very recent studies demonstrated a so-called ‘tonic’ BCR signaling of Burkitt’s lymphoma cell lines, as 
shown through killing of BL cells by CD79A- or SYK-knock down  (Schmitz et al., 2012). Consistent 
with these findings, conditional activation of PI3K along with Myc in mouse germinal center B cells 
leads to lymphoma genesis of strong BL phenotype (Sander et al., 2012). This ‘tonic’ BCR signaling in 




signaling-mediators CARD11 or BTK. This demonstrates the qualitative difference to ‘chronic active’ 
BCR signaling in ABC DLBCL (Davis et al., 2010; Schmitz et al., 2012).  
In contrast to other lymphoma entities as DLBCLs or mantle cell lymphoma, Burkitt’s lymphoma 
are generally reported to be characterized through low expression levels of NF-κB activation modules 
(Dave et al., 2006; Hummel et al., 2006). Moreover, constitutive activation of the normally pro-
survival factor NF-κB increased cell death in several BL cell lines (Klapproth et al., 2009).  
Typically, antigen-mediated activation of the B cell receptor leads to activation of NF-κB signaling 
in B cells via activation of PKCβ and subsequent signal adaptors like CARMA1, Bcl10 and MALT1 
(Egawa et al., 2003; Li and Verma, 2002; Ruefli-Brasse et al., 2003; Ruland and Mak, 2003). Contrarily, 
the current study demonstrates a reduced activatability of NF-κB signaling through BCR activation 
when compared to CD40 mediated signaling in the BL cell lines BL2 and Ramos (Figure 3-14). 
Moreover, the GCB DLBCL cell line OCI Ly1 did not exhibit a BCR inducible NF-κB activation either. A 
role for ‘tonic’ BCR signaling has been postulated for GCB DLBCLs as well (Chen et al., 2008), although 
genetic knockdown of BCR components did not affect the survival of various GCB DLBCL cell lines 
(Davis et al., 2010). Therefore, it seems possible that some so far unknown mechanisms of ‘tonic’ 
BCR signaling prevent a profound activatability of NF-κB signaling. Another possibility, which has to 
be elucidated, is a delayed activation of NF-κB signaling upon antigen-mediated BCR activation on the 
background of ‘tonic’ BCR activity, since BL2 cells exhibit low levels of nuclear translocation of NF-κB 
transcription factors after 60 min of α-IgM stimulation. Furthermore, time course analysis of α-IgM 
stimulated BL2 cells revealed a NF-κB activation after 60-90 min of BCR crosslink, as visualized by 
faint degradation of IκBα (Figure 3-1). However, when comparing the nuclear levels of NF-κB family 
members, remarkably high levels of nuclear p65 were detected in unstimulated BL2 cells, which were 
abolished through IKK2-inhibition. Thus, one can conclude that the BL2 cell line exhibits constitutive 
active NF-κB signaling. This completely new and former findings-contradicting hypothesis is sustained 
through preliminary data, which show reduced proliferation of BL2 cells upon IKK2-inhibition (data 
not shown). Further studies in several other BL cell lines should elucidate if the activation of NF-κB, 
including the translocation of its transcription factor molecules into the nucleus, is abrogated at a 
later time in BL signaling or if this phenomenon exclusively holds true for the BL2 cell line. As also 
shown in Figure 3-14, the CD40 mediated NF-κB activation is in Ramos cells not ablated through 
Tak1-inhibition as it is in BL2 cells. In spite of the confirmed pivotal role of Tak1 as major modulator 
of antigen and CD40 induced signaling pathways in BL cells, the direct comparison of the two BL cell 
lines Ramos and BL2 with regard to Tak1 mediated signaling exposed once again the heterogeneity of 
the available BL cell lines and the probably particular role of the BL2 cell line as model cell line for 





The analyses of the time course of global gene expression changes of BCR  or CD40 stimulated human 
transformed germinal center B cells enabled us to describe distinct gene groups affected in a 
comparable way, being either activated or suppressed. Therewith, new regulatory circuits and 
perhaps feedback loops can be postulated. A co-repression of LEF1, PTCH1 and NOTCH1 mRNA 
expression through BCR activation was identified, which is slightly delayed when compared to the 
BCR induced c-Myc repression. This could represent one mechanistic explanation for the observed 
shift of the mBL signature of the BL2 lymphoma cell line towards the non-mBL gene expression 
profile. However, this needs to be proven by additional investigations, as for example testing 
different cell lines with differing c-Myc expression levels. The additional treatment with other factors 
of the DLBCL microenvironment or a combination of stimuli could be helpful to avoid the observed 
reversion of BCR mediated gene expression by so far unknown feedback loops. Furthermore, causal 
relationships within oncogenic pathways for BCR activated human transformed germinal center B 
cells were proposed but need further prior knowledge integration before experimental validation. 
The current study provide evidence that, although PTCH1 mRNA expression levels are changed 
upon BCR activation, active Hh signaling does not seem to be important for Burkitt’s lymphoma. 
Instead, we suggest a non-canonical regulation of Hh signaling in cross talk with aberrant c-Myc 
expression. Furthermore, the biochemical validation of a computationally compiled model of Tak1-
signaling revealed a context-dependent role of Tak1 in the modification of signaling transduction. 
Thus, a direct contribution of Tak1 to the BCR induced phosphorylation of Erk1/2 was demonstrated 
for the first time. In addition, the present study provides evidence for a constitutive active NF-κB 
signaling in the BL2 cell line and suggests reduced NF-κB activatability in tonic BCR signaling.  
These global gene expression analyses offer comprehensive data collections, which can be used in 
lymphoma research but also modeling of oncogenic pathways in general. Therefore, herein created 
data provide a sophisticated basis to develop new bioinformatical and statistical methods fostering a 
better understanding of signaling pathways and their regulatory feedback mechanisms. However, the 
present study also elicits vigorously the balance between prediction of oncogenic pathway activites 
and prior knowledge integration to put forward corresponding new hypotheses for experimental 
validation. In addition, we conclude that isolated global gene expression profiling needs to be 
complemented by additional pathway analyses. As the cell fate is not only determined by gene 
expression changes but also by posttranslational protein modifications as phosphorylations, 
ubiquitinations, degradations and others, the integration with data sets obtained by other –omics 
may be helpful for future characterizations of oncogenic pathways in lymphoma pathogenesis and 
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Table A-1 Clusters of genes identified upon BCR crosslinked BL2 cells (BHC, SIMoNe). Using Bayesian 
Hierarchical Clustering sets of genes were built, which show the same gene expression course after anti-IgM 






1 7902398 SNORD45A 
2 7948908 SNORD26 
3 7993664 CCP110 
4 8043697 ANKRD36B 
5 8068522 TTC3 
6 8117330 HIST1H3A 
7 8117580 HIST1H2AI 
8 8127989 SNORD50B 
9 8159004 SNORD24 
Cluster 5 
1 7900119 THRAP3 
2 7904974 PFN1P2 
3 7908867 TMEM183A 
4 7924923 NUP133 
5 7957540 MRPL42 
6 7959408 KNTC1 
7 7969428 UCHL3 
8 7969703 IPO5 
9 7981335 HSP90AA1 
10 7985829 FANCI 
11 8014650 NPEPPS 
12 8050565 PUM2 
13 8059319 FARSB 
14 8074925 GUSBP11 
15 8085374 RAF1 
16 8087874 WDR82 
17 8091452 TMEM183B 
18 8099926 PDS5A 
19 8105523 KIF2A 
20 8111455 GUSBP1 
21 8112558 GUSBP2 
22 8138670 HNRNPA2B1 
23 8162313 IARS 
24 8162514 FANCC 
Cluster 6 
1 7897648 PEX14 
2 7897849 MIIP 
3 7899134 CEP85 
4 7899244 PIGV 
5 7900699 CDC20 
6 7904812 PIAS3 
7 7905198 TARS2 
8 7907092 MPZL1 
9 7909529 RCOR3 
10 7909586 PPP2R5A 
11 7909898 MIA3 
12 7911591 SLC35E2B 
13 7911600 NADK 
14 7911862 LRRC47 
15 7919825 ARNT 
16 7921806 B4GALT3 
17 7934477 CAMK2G 
18 7941769 KDM2A 
19 7941879 TBC1D10C 
20 7941927 AIP 
21 7945357 SIRT3 
22 7948685 TUT1 
23 7949518 FIBP 
24 7949674 RBM4B 
25 7951752 USP28 
26 7952484 TMEM218 
27 7952988 ERC1 
28 7955217 SPATS2 
29 7959777 BRI3BP 
30 7960702 CDCA3 
31 7961339 LRP6 
32 7963851 KIAA0748 
33 7964203 BAZ2A 
34 7969935 ERCC5 
35 7971039 FAM48A 
36 7973732 KHNYN 
37 7979849 DCAF5 
38 7986186 RCCD1 
39 7987405 RASGRP1 
40 7989759 PARP16 
41 7990757 CTSH 
42 7995492 ADCY7 
43 7996041 COQ9 
44 7996744 NFATC3 
45 7999304 FAM86A 
46 7999596 KIAA2013 
47 8000263 COG7 
48 8000706 CDIPT 
49 8002381 COG4 
50 8002904 ADAT1 
51 8003922 MED11 
52 8005839 TMEM97 
53 8009164 DCAF7 
54 8014551 SYNRG 




56 8016847 TRIM25 
57 8017019 MTMR4 
58 8018694 PRPSAP1 
59 8025053 TNFSF9 
60 8026982 MPV17L2 
61 8029856 ARHGAP35 
62 8032455 PLEKHJ1 
63 8034122 SPC24 
64 8034589 FARSA 
65 8035249 NR2F6 
66 8036483 YIF1B 
67 8038117 DBP 
68 8047288 SGOL2 
69 8048175 SMARCAL1 
70 8051012 PREB 
71 8051298 GALNT14 
72 8060705 MAVS 
73 8065637 COMMD7 
74 8065992 NFS1 
75 8066964 TMEM189 
76 8072529 DEPDC5 
77 8078450 CRTAP 
78 8080781 PXK 
79 8087308 USP19 
80 8089040 MINA 
81 8093976 TBC1D14 
82 8095574 DCK 
83 8095751 PARM1 
84 8098581 SNX25 
85 8118116 MICB 
86 8118863 ANKS1A 
87 8124211 GPLD1 
88 8125470 HLA-DOB 
89 8131957 SNX10 
90 8140107 DNAJC30 
91 8143070 WDR91 
92 8143863 FASTK 
93 8145418 CDCA2 
94 8149389 FAM86B1 
95 8155327 ALDH1B1 
96 8164304 ST6GALNAC6 
97 8164481 C9orf114 
98 8165064 UBAC1 
99 8176245 F8A1 
100 8177955 MICB 
101 8178833 HLA-DOB 
102 8180339 ST6GALNAC6 
Cluster 7 
1 7908147 TSEN15 
2 7911897 C1orf174 
3 7942626 UVRAG 
4 7947784 ARFGAP2 
5 7956401 SHMT2 
6 7968199 CDK8 
7 7991406 PRC1 
8 8002729 GLG1 
9 8021727 CNDP2 
10 8027139 RFXANK 
11 8032525 SLC39A3 
12 8051998 MCFD2 
13 8064156 ZGPAT 
14 8069933 MIS18A 
15 8073379 L3MBTL2 
16 8080645 APPL1 
17 8093112 UBXN7 
18 8093462 MAEA 
19 8096688 GSTCD 
20 8108861 NDFIP1 
21 8110589 CNOT6 
22 8111974 PAIP1 
23 8132539 DBNL 
24 8139356 NUDCD3 
25 8143387 MKRN1 
26 8145586 ELP3 
27 8156897 C9orf30 
28 8160953 PIGO 
29 8164013 STRBP 
30 8180394 POLR2M 
Cluster 8 
1 7899604 ZCCHC17 
2 7901479 ZYG11B 
3 7902308 FPGT 
4 7906652 NIT1 
5 7907353 METTL13 
6 7912292 LZIC 
7 7914809 KIAA0319L 
8 7915775 IPP 
9 7915846 MKNK1 
10 7921738 USF1 
11 7935251 TCTN3 
12 7935647 COX15 
13 7939087 C11orf46 
14 7946089 TRIM5 
15 7948249 SLC43A1 
16 7952914 CCDC77 
17 7955450 LETMD1 
18 7958275 POLR3B 
19 7969374 BORA 
20 7973036 PARP2 
21 7974621 ARID4A 
22 7980403 C14orf133 
23 7982154 HERC2P2 
24 7982723 IVD 
25 7986569 HERC2P2 
26 7986701 HERC2P2 




28 7999889 GDE1 
29 8006715 TADA2A 
30 8007272 COASY 
31 8007799 MGC57346 
32 8053158 MOGS 
33 8054702 CKAP2L 
34 8059838 HJURP 
35 8067167 AURKA 
36 8068460 MORC3 
37 8081362 CEP97 
38 8083063 SLC25A36 
39 8088092 RFT1 
40 8088247 ARHGEF3 
41 8098328 GALNT7 
42 8106429 AGGF1 
43 8119000 MAPK14 
44 8119198 FTSJD2 
45 8119858 POLH 
46 8120251 FBXO9 
47 8121161 UFL1 
48 8126259 C6orf130 
49 8128939 TRAF3IP2 
50 8129181 GOPC 
51 8138091 DAGLB 
52 8140915 PEX1 
53 8142019 ORC5 
54 8143040 SLC35B4 
55 8149673 REEP4 
56 8151066 ARMC1 
57 8168589 ZNF711 
58 8175102 ENOX2 
Cluster 9 
1 7898192 DNAJC16 
2 7898679 NBPF3 
3 7899829 S100PBP 
4 7900833 KDM4A 
5 7902883 LRRC8D 
6 7903827 FAM40A 
7 7904482 SRGAP2 
8 7904755 PEX11B 
9 7915516 MED8 
10 7917120 USP33 
11 7922707 RNASEL 
12 7922823 EDEM3 
13 7923812 RAB7L1 
14 7927955 KIAA1279 
15 7930577 CASP7 
16 7930703 TRUB1 
17 7930882 FAM45A 
18 7931951 SFMBT2 
19 7932703 ACBD5 
20 7936817 C10orf88 
21 7945979 TRIM68 
22 7951422 KIAA1826 
23 7954969 IRAK4 
24 7959563 C12orf65 
25 7960261 RAD52 
26 7963935 DNAJC14 
27 7967240 VPS33A 
28 7969228 ALG11 
29 7976307 GOLGA5 
30 7985053 FBXO22 
31 7985080 ISL2 
32 7988838 LEO1 
33 7991357 AP3S2 
34 7995362 GPT2 
35 7999478 TXNDC11 
36 8000236 CDR2 
37 8009552 C17orf80 
38 8014264 PEX12 
39 8016562 SPOP 
40 8017555 ERN1 
41 8021275 POLI 
42 8021716 TIMM21 
43 8034565 DNASE2 
44 8042310 SLC1A4 
45 8047443 STRADB 
46 8050443 SMC6 
47 8062545 ACTR5 
48 8072108 ASPHD2 
49 8072153 CCDC117 
50 8073513 CCDC134 
51 8080926 ARL6IP5 
52 8081612 ABHD10 
53 8081667 SLC35A5 
54 8081953 GTF2E1 
55 8083282 HPS3 
56 8084360 ABCF3 
57 8085852 NGLY1 
58 8090420 TPRA1 
59 8090577 MBD4 
60 8091737 IFT80 
61 8093936 MRFAP1 
62 8095262 REST 
63 8102745 PGRMC2 
64 8108472 PURA 
65 8109576 THG1L 
66 8111960 C5orf34 
67 8113733 CEP120 
68 8113790 MARCH3 
69 8121886 HINT3 
70 8124280 FAM65B 
71 8127787 IBTK 
72 8132318 ANLN 
73 8133114 VKORC1L1 




75 8136163 KLHDC10 
76 8139244 C7orf44 
77 8139737 PSPH 
78 8140070 TBL2 
79 8141024 BET1 
80 8145652 LEPROTL1 
81 8146159 AP3M2 
82 8146278 SGK196 
83 8152222 AZIN1 
84 8154394 SNAPC3 
85 8155696 FAM122A 
86 8166382 MBTPS2 
87 8166989 ZNF673 
88 8170097 SLC9A6 
Cluster 10 
1 7899087 PDIK1L 
2 7902512 DNAJB4 
3 7904469 SRGAP2 
4 7913883 PAFAH2 
5 7919780 GOLPH3L 
6 7922870 TRMT1L 
7 7928937 MINPP1 
8 7947138 FANCF 
9 7953765 RIMKLB 
10 7979565 WDR89 
11 7993298 ERCC4 
12 8004266 SLC16A13 
13 8011396 SHPK 
14 8037144 DEDD2 
15 8042576 NAGK 
16 8058552 IDH1 
17 8066786 ZMYND8 
18 8083223 C3orf58 
19 8084165 SOX2 
20 8085788 NKIRAS1 
21 8092177 NCEH1 
22 8099696 SEPSECS 
23 8102362 TIFA 
24 8103226 TMEM154 
25 8129590 STX7 
26 8143188 CREB3L2 
27 8171896 CXorf21 
Cluster 11 
1 7897803 PLOD1 
2 7898939 NIPAL3 
3 7899870 ZNF362 
4 7901102 MMACHC 
5 7901592 TCEANC2 
6 7901895 ATG4C 
7 7903565 GPSM2 
8 7904452 FAM72D 
9 7904907 BCL9 
10 7905299 PRUNE 
11 7906671 USP21 
12 7907058 POU2F1 
13 7907079 RCSD1 
14 7909146 FAM72D 
15 7913682 HMGCL 
16 7913694 FUCA1 
17 7914917 LSM10 
18 7915472 SLC2A1 
19 7915787 PIK3R3 
20 7919591 FAM72D 
21 7923662 PIK3C2B 
22 7923792 SLC45A3 
23 7925773 ZNF692 
24 7928491 KAT6B 
25 7929322 CYP26A1 
26 7933228 MARCH8 
27 7938183 ZNF215 
28 7941104 ARL2 
29 7942562 NEU3 
30 7944152 IL10RA 
31 7945132 FLI1 
32 7945875 FAM86B1 
33 7952601 ETS1 
34 7952707 PRDM10 
35 7954717 BICD1 
36 7955195 TROAP 
37 7957167 TMEM19 
38 7957759 APAF1 
39 7958439 USP30 
40 7959298 TMEM120B 
41 7959354 BCL7A 
42 7960910 AICDA 
43 7961983 TM7SF3 
44 7965565 USP44 
45 7968789 RGCC 
46 7971486 KIAA0226L 
47 7974697 DAAM1 
48 7975311 EXD2 
49 7975361 KIAA0247 
50 7975787 JDP2 
51 7977868 C14orf93 
52 7986463 LRRK1 
53 7988426 SLC30A4 
54 7988970 FAM214A 
55 7994655 C16orf53 
56 7997735 FOXL1 
57 8001178 C16orf87 
58 8006345 RHOT1 
59 8007471 NBR1 
60 8008339 RSAD1 
61 8010139 SEC14L1 
62 8011415 P2RX5 




64 8015655 FAM134C 
65 8019018 CBX4 
66 8021565 PHLPP1 
67 8026712 ANKLE1 
68 8029465 BCL3 
69 8031522 ZNF581 
70 8037186 LIPE 
71 8037495 ZNF296 
72 8039928 FAM72D 
73 8040365 TRIB2 
74 8048898 SP140 
75 8052669 SERTAD2 
76 8056766 SLC25A12 
77 8058161 ORC2 
78 8058927 TMBIM1 
79 8060977 C20orf94 
80 8085233 RPUSD3 
81 8087852 TLR9 
82 8089261 CBLB 
83 8092691 BCL6 
84 8096070 BMP3 
85 8097417 PHF17 
86 8097867 KIAA0922 
87 8098423 NEIL3 
88 8102342 ELOVL6 
89 8104901 IL7R 
90 8105878 RAD17 
91 8106107 PTCD2 
92 8108301 KIF20A 
93 8108447 CXXC5 
94 8111136 FAM134B 
95 8111552 NADKD1 
96 8117120 ID4 
97 8117165 SOX4 
98 8117435 BTN3A2 
99 8122013 L3MBTL3 
100 8126018 STK38 
101 8126428 TRERF1 
102 8136341 BPGM 
103 8138030 PMS2 
104 8138088 C7orf70 
105 8142096 ATXN7L1 
106 8148158 WDR67 
107 8148317 MYC 
108 8149387 FAM86B1 
109 8151074 PDE7A 
110 8153935 ZNF252 
111 8155332 C7orf70 
112 8160835 C9orf23 
113 8162438 BICD2 
114 8164252 SH2D3C 
115 8164314 ST6GALNAC4 
116 8170998 F8A1 
117 8171029 F8A1 
118 8171136 P2RY8 
119 8172088 BCOR 
120 8173208 SPIN4 
121 8173232 FAM123B 
122 8177026 P2RY8 
123 8177478 RAD17 
124 8180336 SLC35E2 
125 8180412 ST6GALNAC4 
126 8180413 ST6GALNAC4 
Cluster 12 
1 7897482 PIK3CD 
2 7898677 HS6ST1 
3 7901140 MAST2 
4 7903719 AMPD2 
5 7905831 FLAD1 
6 7906061 SYT11 
7 7906079 RAB25 
8 7906767 FCGR2C 
9 7912224 SLC2A5 
10 7915567 ERI3 
11 7916403 SSBP3 
12 7920877 ARHGEF2 
13 7920912 UBQLN4 
14 7923824 SLC41A1 
15 7925978 FAM208B 
16 7926037 PFKFB3 
17 7926170 DHTKD1 
18 7927425 WDFY4 
19 7929990 PPRC1 
20 7931930 PRKCQ 
21 7933760 CCDC6 
22 7935968 LDB1 
23 7937485 PNPLA2 
24 7937892 PGAP2 
25 7940349 CCDC86 
26 7941302 FAM89B 
27 7941457 CCDC85B 
28 7941694 RBM14 
29 7941743 LRFN4 
30 7941797 ADRBK1 
31 7942342 INPPL1 
32 7944335 CXCR5 
33 7945539 SLC25A22 
34 7948565 CYBASC3 
35 7949146 SF1 
36 7949172 MAP4K2 
37 7949206 MEN1 
38 7949264 EHD1 
39 7949383 SYVN1 
40 7949746 POLD4 
41 7949904 UNC93B1 




43 7950248 FCHSD2 
44 7951873 SIK3 
45 7952132 SLC37A4 
46 7952830 NCAPD3 
47 7953651 PEX5 
48 7953981 ETV6 
49 7954104 ATF7IP 
50 7955019 ARID2 
51 7956220 OBFC2B 
52 7957126 KCNMB4 
53 7958950 C12orf52 
54 7958960 TPCN1 
55 7959025 RNFT2 
56 7962659 HDAC7 
57 7963988 SMARCC2 
58 7964413 R3HDM2 
59 7966542 RASAL1 
60 7967358 PITPNM2 
61 7967588 DHX37 
62 7967789 PXMP2 
63 7968126 LSP1 
64 7969533 SLAIN1 
65 7971015 SMAD9 
66 7973709 NFATC4 
67 7977319 PLD4 
68 7977344 PACS2 
69 7980327 ANGEL1 
70 7980970 ITPK1 
71 7981538 JAG2 
72 7982326 KLF13 
73 7982620 EIF2AK4 
74 7987675 RPAP1 
75 7990033 TLE3 
76 7990487 SIN3A 
77 7992402 NDUFB10 
78 7992474 TSC2 
79 7992775 PAQR4 
80 7993478 ABCC1 
81 7994109 PLK1 
82 7994161 RBBP6 
83 7995976 CPNE2 
84 7996608 RLTPR 
85 7996785 PRMT7 
86 7997427 CMIP 
87 7997680 KIAA0182 
88 7998774 RNPS1 
89 7999102 TFAP4 
90 7999173 FAM100A 
91 8004804 PFAS 
92 8005978 TRAF4 
93 8006063 ANKRD13B 
94 8006298 RAB11FIP4 
95 8006788 MLLT6 
96 8007302 TUBG1 
97 8010673 SLC25A10 
98 8011093 SLC43A2 
99 8011262 MNT 
100 8011516 ATP2A3 
101 8011747 SLC25A11 
102 8012304 TRAPPC1 
103 8012376 VAMP2 
104 8012958 UBE2S 
105 8013179 ATPAF2 
106 8014700 C17orf96 
107 8014706 PCGF2 
108 8015412 JUP 
109 8015526 KAT2A 
110 8016546 ZNF652 
111 8017511 CD79B 
112 8018708 UBE2O 
113 8019280 PCYT2 
114 8019357 DCXR 
115 8019778 PCYT2 
116 8024111 CNN2 
117 8024420 SF3A2 
118 8024485 GADD45B 
119 8024798 CCDC94 
120 8025142 ARHGEF18 
121 8025382 CERS4 
122 8025601 ICAM1 
123 8026047 JUNB 
124 8026533 HSH2D 
125 8026579 TMEM38A 
126 8026830 FCHO1 
127 8028286 SIPA1L3 
128 8028397 FAM98C 
129 8028930 RAB4B 
130 8029521 TOMM40 
131 8030525 PTOV1 
132 8030671 SPIB 
133 8031526 CCDC106 
134 8031913 TRIM28 
135 8032076 RNF126 
136 8032365 KLF16 
137 8032380 BTBD2 
138 8032392 MKNK2 
139 8032530 SGTA 
140 8032755 ZBTB7A 
141 8032899 TICAM1 
142 8033190 SLC25A23 
143 8033362 INSR 
144 8034130 KANK2 
145 8034454 DHPS 
146 8034754 SAMD1 
147 8034783 LPHN1 




149 8038261 GYS1 
150 8039306 RDH13 
151 8039316 PPP1R12C 
152 8039413 PPP6R1 
153 8039491 UBE2S 
154 8040238 HPCAL1 
155 8041617 MTA3 
156 8041763 PRKCE 
157 8041826 TTC7A 
158 8045171 IMP4 
159 8045182 PTPN18 
160 8046815 ZNF804A 
161 8047565 FAM117B 
162 8048257 PNKD 
163 8048452 WNT10A 
164 8049246 INPP5D 
165 8049317 DGKD 
166 8049689 RNPEPL1 
167 8051814 ZFP36L2 
168 8052399 BCL11A 
169 8053009 FBXO41 
170 8055130 HS6ST1 
171 8055208 CCDC115 
172 8058973 ZNF142 
173 8059650 SP110 
174 8060353 RBCK1 
175 8060675 CDC25B 
176 8064100 PPDPF 
177 8064790 RASSF2 
178 8065683 SNTA1 
179 8065693 NECAB3 
180 8066939 B4GALT5 
181 8070503 PRDM15 
182 8070557 ZNF295 
183 8070912 SLC19A1 
184 8071339 ZDHHC8 
185 8071566 PPIL2 
186 8071691 BCR 
187 8072757 CSF2RB 
188 8074003 TRABD 
189 8075430 MORC2 
190 8075493 PATZ1 
191 8075785 FOXRED2 
192 8075910 RAC2 
193 8076056 CSNK1E 
194 8076690 KIAA0930 
195 8077042 SBF1 
196 8078729 MYD88 
197 8079037 TRAK1 
198 8079462 NBEAL2 
199 8079796 RNF123 
200 8080093 RBM15B 
201 8080487 PRKCD 
202 8081465 BBX 
203 8082368 PODXL2 
204 8084100 USP13 
205 8086125 TRANK1 
206 8087935 NT5DC2 
207 8090433 MGLL 
208 8093219 BDH1 
209 8093440 FGFRL1 
210 8093916 MAN2B2 
211 8094240 CD38 
212 8099965 ACOT7 
213 8102232 LEF1 
214 8108321 FAM53C 
215 8109149 PCYOX1L 
216 8112107 PPAP2A 
217 8112940 SSBP2 
218 8114215 PITX1 
219 8114511 MZB1 
220 8115543 EBF1 
221 8115927 RNF44 
222 8117243 LRRC16A 
223 8119016 MAPK13 
224 8119582 KIAA0240 
225 8121076 PNRC1 
226 8122971 ARID1B 
227 8124813 MDC1 
228 8125172 EHMT2 
229 8126371 CCND3 
230 8128818 WASF1 
231 8130185 ZBTB2 
232 8131091 MAFK 
233 8133233 AUTS2 
234 8133331 POM121 
235 8135114 CUX1 
236 8135149 SH2B2 
237 8137225 REPIN1 
238 8138504 RAPGEF5 
239 8139057 ELMO1 
240 8139270 RASA4 
241 8140398 YWHAG 
242 8141768 RASA4 
243 8141803 RASA4 
244 8142981 PODXL 
245 8143327 PARP12 
246 8145977 PLEKHA2 
247 8147040 ZBTB10 
248 8148694 GRINA 
249 8149612 LZTS1 
250 8149979 C8orf80 
251 8152133 RRM2B 
252 8153497 SCRIB 
253 8153790 TONSL 




255 8156452 FAM120A 
256 8158829 PRRC2B 
257 8158839 PRRC2B 
258 8159249 MRPS2 
259 8160682 NOL6 
260 8162533 PTCH1 
261 8162729 TRIM14 
262 8162803 ANKS6 
263 8164131 SCAI 
264 8164810 RALGDS 
265 8165094 QSOX2 
266 8165156 SDCCAG3 
267 8165217 NOTCH1 
268 8165552 NELF 
269 8165711 PLCXD1 
270 8170364 AFF2 
271 8171837 KLHL15 
272 8172471 PIM2 
273 8173457 ZMYM3 
274 8174692 SEPT6 
275 8176286 PLCXD1 
276 8178404 MDC1 
277 8178727 ATF6B 
278 8179884 EHMT2 
279 8180362 MPRIP 
280 8180363 MPRIP 
281 8180411 ELMO1 
Cluster 13 
1 7899192 RPS6KA1 
2 7900426 SMAP2 
3 7900911 DPH2 
4 7901951 PGM1 
5 7904137 HIPK1 
6 7904742 LIX1L 
7 7905444 SNX27 
8 7905631 INTS3 
9 7908779 RNPEP 
10 7909708 CENPF 
11 7912166 RERE 
12 7912257 CLSTN1 
13 7912374 SRM 
14 7912412 MTOR 
15 7913156 AKR7A2 
16 7914603 RNF19B 
17 7915695 MUTYH 
18 7919940 VPS72 
19 7919950 PI4KB 
20 7919971 RFX5 
21 7920000 POGZ 
22 7920707 FAM189B 
23 7921133 HDGF 
24 7924669 PYCR2 
25 7932109 SEPHS1 
26 7935474 MMS19 
27 7935639 SLC25A28 
28 7937802 CD81 
29 7939215 C11orf41 
30 7940372 TMEM109 
31 7940600 INCENP 
32 7941148 TM7SF2 
33 7941179 CAPN1 
34 7941976 NDUFS8 
35 7941985 TCIRG1 
36 7944401 HMBS 
37 7945573 POLR2L 
38 7947861 SPI1 
39 7949798 TMEM134 
40 7950271 FAM168A 
41 7953100 FKBP4 
42 7955736 ESPL1 
43 7956152 PA2G4 
44 7959786 AACS 
45 7963646 AAAS 
46 7966570 DDX54 
47 7966878 CIT 
48 7967544 SCARB1 
49 7968734 SLC25A15 
50 7968890 DGKZ 
51 7969438 LMO7 
52 7972577 RPS26 
53 7973067 PNP 
54 7975459 SIPA1L1 
55 7975815 TTLL5 
56 7977820 PRMT5 
57 7981494 AKT1 
58 7982878 CHP 
59 7983290 SERF2 
60 7983843 TCF12 
61 7985431 AGSK1 
62 7987840 VPS39 
63 7990361 UBL7 
64 7990902 AGSK1 
65 7990952 AGSK1 
66 7991088 LOC388152 
67 7991159 LOC388152 
68 7991714 AGSK1 
69 7992043 FAM173A 
70 7992414 TBL3 
71 7992737 FLYWCH2 
72 7995655 FTO 
73 7996137 KATNB1 
74 7996685 EDC4 
75 7997453 PLCG2 
76 7998063 TUBB3 
77 7998251 C16orf13 




79 7998367 RPUSD1 
80 8000869 SEPT1 
81 8003357 PIEZO1 
82 8003733 SGSM2 
83 8004030 RNF167 
84 8004057 KIF1C 
85 8005407 LLGL1 
86 8005994 ERAL1 
87 8006655 DHRS11 
88 8007188 CNP 
89 8007197 NKIRAS2 
90 8007505 DHX8 
91 8007797 RPS26 
92 8008922 PPM1D 
93 8009382 BPTF 
94 8010248 AFMID 
95 8010664 MRPL12 
96 8010747 GPS1 
97 8011407 TAX1BP3 
98 8013696 KIAA0100 
99 8013788 FLOT2 
100 8014882 MIEN1 
101 8015460 ACLY 
102 8015969 UBTF 
103 8017460 SMARCD2 
104 8018428 GALK1 
105 8018511 MRPL38 
106 8018849 TK1 
107 8024089 WDR18 
108 8024170 HMHA1 
109 8024204 STK11 
110 8024358 CSNK1G2 
111 8024446 SPPL2B 
112 8024497 THOP1 
113 8024660 HMG20B 
114 8024864 HDGFRP2 
115 8025255 STXBP2 
116 8026341 TECR 
117 8026638 MYO9B 
118 8026735 GTPBP3 
119 8026751 FAM125A 
120 8027117 ARMC6 
121 8027621 GPI 
122 8027701 GRAMD1A 
123 8028851 SHKBP1 
124 8028916 SNRPA 
125 8029560 CLPTM1 
126 8029814 PPP5C 
127 8029831 CALM3 
128 8030113 RUVBL2 
129 8030470 AP2A1 
130 8031097 NDUFA3 
131 8031483 RPL28 
132 8032106 MED16 
133 8033479 ELAVL1 
134 8033899 EIF3G 
135 8033956 S1PR2 
136 8034843 NDUFB7 
137 8035553 COPE 
138 8036010 PEPD 
139 8036525 MAP4K1 
140 8036938 ADCK4 
141 8037537 ERCC2 
142 8037647 FBXO46 
143 8037991 LIG1 
144 8038202 BCAT2 
145 8042867 WBP1 
146 8043377 WBP1 
147 8048304 CTDSP1 
148 8048595 GMPPA 
149 8049582 SCLY 
150 8051030 SLC5A6 
151 8052803 AAK1 
152 8053599 WBP1 
153 8054092 TMEM131 
154 8054888 CLASP1 
155 8056545 STK39 
156 8059177 TUBA4A 
157 8059222 DNPEP 
158 8059989 HES6 
159 8060257 STK25 
160 8062319 TGIF2 
161 8064613 SLC4A11 
162 8064739 C20orf27 
163 8065817 GSS 
164 8067361 TAF4 
165 8069026 C21orf33 
166 8071768 SMARCB1 
167 8072744 NCF4 
168 8072870 PDXP 
169 8072979 POLR2F 
170 8074020 SELO 
171 8074388 SLC25A1 
172 8075009 C22orf13 
173 8075217 AP1B1 
174 8076307 RANGAP1 
175 8076393 CENPM 
176 8076792 CERK 
177 8079311 LARS2 
178 8079563 DHX30 
179 8079950 GNAI2 
180 8080168 ACY1 
181 8080714 FLNB 
182 8082422 EEFSEC 
183 8086754 SCAP 




185 8088106 TKT 
186 8092457 ALG3 
187 8093685 HTT 
188 8094501 STIM2 
189 8095216 KIAA1211 
190 8101086 NAAA 
191 8101622 TECR 
192 8103188 PET112 
193 8104506 TRIO 
194 8107750 PRRC1 
195 8108330 KDM3B 
196 8109999 ERGIC1 
197 8110327 RGS14 
198 8110362 GRK6 
199 8110982 DAP 
200 8111286 DROSHA 
201 8115524 CLINT1 
202 8119627 PPP2R5D 
203 8120585 SMAP1 
204 8124828 FLOT1 
205 8125125 LSM2 
206 8125649 VPS52 
207 8125775 MNF1 
208 8127051 TRAM2 
209 8128111 UBE2J1 
210 8130916 PHF10 
211 8131253 FOXK1 
212 8131427 C7orf26 
213 8133413 LIMK1 
214 8134821 MEPCE 
215 8137847 BRAT1 
216 8139281 POLM 
217 8139299 POLD2 
218 8139468 TBRG4 
219 8143988 MLL3 
220 8148772 FAM203A 
221 8148783 HEATR7A 
222 8148799 FAM203A 
223 8153652 SHARPIN 
224 8153776 VPS28 
225 8153838 RECQL4 
226 8155699 FXN 
227 8158123 FPGS 
228 8158961 GTF3C5 
229 8160036 C9orf123 
230 8162462 FAM120A 
231 8162502 FBP1 
232 8165622 ZMYND19 
233 8165630 C9orf37 
234 8167042 RBM10 
235 8167125 USP11 
236 8167656 MAGED1 
237 8167924 UBQLN2 
238 8170865 TAZ 
239 8172119 MED14 
240 8172296 NDUFB11 
241 8173009 PHF8 
242 8175924 NAA10 
243 8176117 FAM3A 
244 8178419 FLOT1 
245 8178641 LSM2 
246 8178917 VPS52 
247 8179688 FLOT1 
248 8179839 LSM2 
249 8180123 VPS52 
Cluster 17 
1 7898549 MRTO4 
2 7899703 TXLNA 
3 7904000 DDX20 
4 7910416 URB2 
5 7913805 RUNX3 
6 7915091 MTF1 
7 7920766 ASH1L 
8 7923503 ADIPOR1 
9 7923778 ELK4 
10 7924969 TAF5L 
11 7928589 PPIF 
12 7946201 ARFIP2 
13 7947969 FNBP4 
14 7948493 SLC15A3 
15 7949916 CHKA 
16 7967736 POLE 
17 7970111 ARHGEF7 
18 7971177 FOXO1 
19 7972548 GPR18 
20 7974455 MAPK1IP1L 
21 7977105 TRMT61A 
22 7980828 CCDC88C 
23 7982185 DEXI 
24 7986685 DEXI 
25 7987584 INO80 
26 7988687 GABPB1 
27 7993148 PMM2 
28 7993973 POLR3E 
29 7994280 IL4R 
30 7999120 CORO7 
31 8000244 USP31 
32 8003249 FBXO31 
33 8004431 POLR2A 
34 8005441 SMCR8 
35 8006148 GOSR1 
36 8006850 CDK12 
37 8013486 USP22 
38 8014214 NLE1 
39 8014925 MED24 




41 8021866 NFATC1 
42 8025458 ZNF317 
43 8025563 PPAN-P2RY11 
44 8027074 UPF1 
45 8028119 WDR62 
46 8028552 NFKBIB 
47 8030035 GRWD1 
48 8032137 C19orf6 
49 8034482 TNPO2 
50 8035007 AKAP8 
51 8035023 AKAP8L 
52 8035980 RHPN2 
53 8037657 DMPK 
54 8038624 C19orf48 
55 8042381 PNO1 
56 8042942 HK2 
57 8052143 GPR75 
58 8055183 SMPD4 
59 8059996 PER2 
60 8062286 C20orf4 
61 8066641 ZNF335 
62 8067563 DIDO1 
63 8067593 YTHDF1 
64 8068289 SON 
65 8068551 DYRK1A 
66 8068810 SLC37A1 
67 8068974 TRAPPC10 
68 8069174 FAM207A 
69 8070194 RUNX1 
70 8073039 GTPBP1 
71 8073345 EP300 
72 8074647 PI4KA 
73 8075406 PES1 
74 8077595 BRPF1 
75 8080878 ATXN7 
76 8083324 TSC22D2 
77 8087271 QRICH1 
78 8087748 VPRBP 
79 8088128 DCP1A 
80 8088642 LRIG1 
81 8088776 FOXP1 
82 8093590 RNF4 
83 8097461 CCRN4L 
84 8108099 SEC24A 
85 8110841 LPCAT1 
86 8115168 RBM22 
87 8118228 LY6G5B 
88 8118580 BRD2 
89 8119712 SRF 
90 8130116 LATS1 
91 8133145 CRCP 
92 8137542 RBM33 
93 8140061 BCL7B 
94 8142730 ZNF800 
95 8145259 CHMP7 
96 8159476 TRAF2 
97 8160647 BAG1 
98 8160722 UBAP2 
99 8161192 RNF38 
100 8162601 ZNF367 
101 8164665 RAPGEF1 
102 8164862 SURF6 
103 8178059 LY6G5B 
104 8179504 BRD2 
Cluster 18 
1 7898602 OTUD3 
2 7923659 PPP1R15B 
3 7924526 TP53BP2 
4 7925823 GTPBP4 
5 7938331 ZNF143 
6 7939839 PTPRJ 
7 7940051 ZDHHC5 
8 7940118 ZFP91-CNTF 
9 7942439 RELT 
10 7948229 SLC43A3 
11 7955425 ATF1 
12 7965918 NT5DC3 
13 8003448 ANKRD11 
14 8009932 SAP30BP 
15 8022404 FAM210A 
16 8031956 ZNF324 
17 8069565 BTG3 
18 8077612 TTLL3 
19 8110734 BRD9 
20 8115681 PANK3 
21 8116548 DUSP22 
22 8117128 E2F3 
23 8119408 NFYA 
24 8141241 SMURF1 
25 8160756 DCAF12 
26 8162850 TEX10 
27 8173615 RLIM 
Cluster 19 
1 7903321 RTCD1 
2 7903619 SARS 
3 7903908 CEPT1 
4 7904340 MAN1A2 
5 7906810 DUSP12 
6 7907135 SFT2D2 
7 7914180 SPCS2 
8 7918255 CLCC1 
9 7918284 TAF13 
10 7922250 SCYL3 
11 7923516 CYB5R1 
12 7929012 STAMBPL1 




14 7930162 C10orf26 
15 7930614 NHLRC2 
16 7932160 FAM107B 
17 7942168 FADD 
18 7942553 SPCS2 
19 7943314 JRKL 
20 7945058 FAM118B 
21 7946742 CYP2R1 
22 7950753 CCDC90B 
23 7953211 C12orf5 
24 7954492 FGFR1OP2 
25 7954711 C12orf35 
26 7958819 ERP29 
27 7959282 RNF34 
28 7964021 RNF41 
29 7964347 TMEM194A 
30 7967881 MPHOSPH8 
31 7969626 GPR180 
32 7969979 ABHD13 
33 7971027 ALG5 
34 7973530 PCK2 
35 7974207 MGAT2 
36 7974576 NAA30 
37 7974725 JKAMP 
38 7976571 C14orf129 
39 7978932 SOS2 
40 7979984 ZFYVE1 
41 7980438 SPTLC2 
42 7983744 TMOD3 
43 7988753 SPPL2A 
44 7989128 CNOT6L 
45 7989224 ADAM10 
46 7999553 CPPED1 
47 8002347 AARS 
48 8002523 FTSJD1 
49 8018600 SRP68 
50 8021187 SKA1 
51 8021453 SEC11C 
52 8035886 C19orf12 
53 8036420 ZFP30 
54 8036813 ZNF780B 
55 8040503 UBXN2A 
56 8041487 CCDC75 
57 8041820 SOCS5 
58 8042161 PEX13 
59 8044613 CBWD1 
60 8050278 PDIA6 
61 8050474 RDH14 
62 8055890 STAM2 
63 8058221 TRAK2 
64 8058985 RNF25 
65 8061373 GZF1 
66 8071274 SEPT5-GP1BB 
67 8077993 TMEM43 
68 8081115 ARL13B 
69 8083310 RNF13 
70 8083757 NMD3 
71 8084016 PIK3CA 
72 8088065 SFMBT1 
73 8088151 ACTR8 
74 8088700 TMF1 
75 8088830 SHQ1 
76 8090840 RYK 
77 8091637 SLC33A1 
78 8091941 PDCD10 
79 8093961 KIAA0232 
80 8095148 TMEM165 
81 8095163 EXOC1 
82 8096251 NUDT9 
83 8097066 METTL14 
84 8097704 TMEM184C 
85 8099797 RELL1 
86 8099834 TLR1 
87 8100318 SGCB 
88 8103834 AGA 
89 8104760 TARS 
90 8105862 CDK7 
91 8106303 POLK 
92 8106702 ZCCHC9 
93 8106784 RASA1 
94 8107520 TNFAIP8 
95 8108847 RNF14 
96 8110678 CCDC127 
97 8111533 LMBRD2 
98 8111952 C5orf28 
99 8112182 MIER3 
100 8112687 COL4A3BP 
101 8114829 YIPF5 
102 8115476 MED7 
103 8116998 JARID2 
104 8118613 SLC39A7 
105 8120215 PAQR8 
106 8120378 KIAA1586 
107 8121525 KIAA1919 
108 8121861 NCOA7 
109 8121927 RNF146 
110 8129254 MAN1A1 
111 8130032 FBXO30 
112 8130438 TFB1M 
113 8130765 FAM103A1 
114 8132292 Sep-07 
115 8133167 KCTD7 
116 8135464 DLD 
117 8137464 PSPH 
118 8137709 ZFAND2A 




120 8142540 FAM3C 
121 8144774 VPS37A 
122 8146000 ADAM9 
123 8146649 MTFR1 
124 8148658 ZNF623 
125 8150219 BRF2 
126 8150565 RNF170 
127 8151436 PEX2 
128 8151788 RBM12B 
129 8155214 MELK 
130 8155422 CBWD5 
131 8155636 CBWD3 
132 8156043 PSAT1 
133 8158513 DOLPP1 
134 8159815 CBWD1 
135 8160405 KLHL9 
136 8161537 CBWD3 
137 8161587 CBWD3 
138 8166098 RAB9A 
139 8166140 MOSPD2 
140 8166442 FAM3C 
141 8169617 PGRMC1 
142 8176230 RAB39B 
143 8177462 CDK7 
144 8178225 SLC39A7 
145 8179525 SLC39A7 
146 8180397 NT5C3 
Cluster 20 
1 7899173 DHDDS 
2 7899377 PPP1R8 
3 7899486 TRNAU1AP 
4 7901662 TTC4 
5 7904883 CHD1L 
6 7907124 TIPRL 
7 7907445 KLHL20 
8 7913242 MUL1 
9 7922008 TADA1 
10 7922391 CENPL 
11 7926319 SUV39H2 
12 7928752 GHITM 
13 7929831 HIF1AN 
14 7933115 SEPT7L 
15 7934852 GLUD1 
16 7939329 PDHX 
17 7943218 PANX1 
18 7943721 FDX1 
19 7943842 C11orf57 
20 7954279 AEBP2 
21 7954382 PYROXD1 
22 7959657 ATP6V0A2 
23 7961829 BCAT1 
24 7962185 AMN1 
25 7967287 ZCCHC8 
26 7970084 CARKD 
27 7970716 LNX2 
28 7971550 MED4 
29 7974473 FBXO34 
30 7975136 FUT8 
31 7977127 KLC1 
32 7978166 TM9SF1 
33 7980523 GTF2A1 
34 7988245 MFAP1 
35 7989516 HERC1 
36 7993833 METTL9 
37 7997230 PSMD7 
38 8001317 N4BP1 
39 8004111 RABEP1 
40 8004144 MIS12 
41 8005512 PRPSAP2 
42 8006477 ZNF830 
43 8007435 RUNDC1 
44 8015456 KLHL11 
45 8017235 APPBP2 
46 8021208 ME2 
47 8023246 C18orf32 
48 8023481 NARS 
49 8026339 SNRPG 
50 8027510 C19orf40 
51 8027521 GPATCH1 
52 8030991 LOC147804 
53 8035193 C19orf42 
54 8042830 MTHFD2 
55 8048847 AGFG1 
56 8053046 DUSP11 
57 8054978 ERCC3 
58 8061129 C20orf72 
59 8061262 NAA20 
60 8070215 SETD4 
61 8073875 TRMU 
62 8079869 RBM5 
63 8084064 MTHFD2 
64 8084904 SDHAP2 
65 8084912 SDHAP2 
66 8087634 TUSC2 
67 8092534 TMEM41A 
68 8092905 LSG1 
69 8093039 SDHAP1 
70 8097570 USP38 
71 8101228 CNOT6L 
72 8104422 MTRR 
73 8113250 ERAP1 
74 8113591 PGGT1B 
75 8116867 TMEM14B 
76 8116969 NOL7 
77 8120698 MTO1 




79 8128650 SEC63 
80 8131356 CCZ1 
81 8132458 MRPL32 
82 8134581 ARPC1A 
83 8134621 ZKSCAN5 
84 8135064 TRIM56 
85 8138128 CCZ1 
86 8141133 SHFM1 
87 8141169 MGC72080 
88 8144528 TNKS 
89 8144931 ATP6V1B2 
90 8146448 MRPL15 
91 8146544 UBXN2B 
92 8146930 TMEM70 
93 8148941 ZNF7 
94 8151118 VCPIP1 
95 8155234 ZCCHC7 
96 8157700 RABGAP1 
97 8158112 CDK9 
98 8162676 TSTD2 
99 8163402 PTBP3 
100 8163784 FBXW2 
101 8163964 PDCL 
102 8169920 RBMX2 
103 8178090 C6orf48 
104 8179326 C6orf48 
105 8180257 CEP170 
Cluster 21 
1 7897370 VAMP3 
2 7905171 PRPF3 
3 7906400 IFI16 
4 7909782 RRP15 
5 7911539 CCNL2 
6 7922432 RC3H1 
7 7925996 FBXO18 
8 7926916 ZEB1 
9 7927233 FAM21C 
10 7927323 FAM21B 
11 7927560 FAM21A 
12 7935425 RRP12 
13 7936596 C10orf46 
14 7946635 ZBED5 
15 7947894 CELF1 
16 7953594 EMG1 
17 7956524 PIP4K2C 
18 7966202 KCTD10 
19 7968999 NUDT15 
20 7970858 HMGB1 
21 7980998 BTBD7 
22 7986411 MEF2A 
23 7993341 BFAR 
24 7998510 CLCN7 
25 7999642 KIAA0430 
26 8003298 SLC7A5 
27 8006183 SUZ12P 
28 8007904 GOSR2 
29 8008530 UTP18 
30 8014738 CWC25 
31 8021228 SMAD4 
32 8031899 ERVK3-1 
33 8039909 CCNL2 
34 8043105 KCMF1 
35 8048940 SP100 
36 8053388 TGOLN2 
37 8053562 CHMP3 
38 8061715 KIF3B 
39 8063211 NCOA3 
40 8063315 DDX27 
41 8063607 RAB22A 
42 8064976 DNAJC9 
43 8067206 CTCFL 
44 8073733 NUP50 
45 8077931 MKRN2 
46 8082408 SEC61A1 
47 8087461 GMPPB 
48 8091764 KPNA4 
49 8099029 TNIP2 
50 8103922 CASP3 
51 8107353 ZRSR1 




54 8109528 CYFIP2 
55 8110169 FAF2 
56 8110894 NSUN2 
57 8112312 DIMT1 
58 8115765 FBXW11 
59 8115783 STK10 
60 8115895 KIAA1191 
61 8122672 TAB2 
62 8124022 DTNBP1 
63 8124950 LTB 
64 8125850 C6orf106 
65 8130383 MTRF1L 
66 8131044 GET4 
67 8132188 AVL9 
68 8134992 SRRT 
69 8135363 PIK3CG 
70 8136539 LUC7L2 
71 8139859 GUSB 
72 8142852 TNPO3 
73 8144586 MTMR9 
74 8145922 DDHD2 
75 8147785 DCAF13 
76 8150287 WHSC1L1 




78 8152628 DERL1 
79 8154012 KANK1 
80 8154856 UBE2R2 
81 8157945 ZBTB34 
82 8158686 FUBP3 
83 8161632 PTAR1 
84 8164587 TOR1A 
85 8167790 TSR2 
86 8177560 BDP1 
87 8178512 LTB 
88 8179768 LTB 
Cluster 22 
1 7900438 ZNF643 
2 7902166 MIER1 
3 7903369 SLC30A7 
4 7903893 CD53 
5 7906819 ATF6 
6 7907773 TOR1AIP1 
7 7909628 FLVCR1 
8 7912675 ZBTB17 
9 7914202 SNHG12 
10 7914214 SNORA44 
11 7916135 CC2D1B 
12 7917771 DNTTIP2 
13 7919888 CDC42SE1 
14 7920839 RIT1 
15 7921667 CD48 
16 7921970 ALDH9A1 
17 7924701 ACBD3 
18 7926021 RBM17 
19 7926836 RAB18 
20 7927513 FAM21C 
21 7927767 ADO 
22 7927972 VPS26A 
23 7928171 SGPL1 
24 7932885 ARHGAP12 
25 7934122 SAR1A 
26 7934459 NDST2 
27 7934812 WAPAL 
28 7936463 ABLIM1 
29 7938762 GTF2H1 
30 7947540 TRAF6 
31 7953021 ADIPOR2 
32 7959473 DENR 
33 7960134 ZNF26 
34 7962516 SLC38A1 
35 7966638 RBM19 
36 7967624 SLC15A4 
37 7967794 ANKLE2 
38 7970413 PSPC1 
39 7970696 USP12 
40 7972062 FBXL3 
41 7972828 ANKRD10 
42 7974249 ARF6 
43 7975645 ZNF410 
44 7975863 C14orf118 
45 7978628 PPP2R3C 
46 7979044 NIN 
47 7979223 DDHD1 
48 7980680 FOXN3 
49 7980833 SMEK1 
50 7986250 CHD2 
51 7986665 NIPA2 
52 7986675 NIPA1 
53 7989013 RSL24D1 
54 7991581 CHSY1 
55 7993159 C16orf72 
56 7993433 PDXDC1 
57 7994102 DCTN5 
58 7994518 SPNS1 
59 7996341 PDP2 
60 7996772 SLC7A6 
61 7997381 CENPN 
62 7998174 LUC7L 
63 8001841 DYNC1LI2 
64 8002878 TMEM170A 
65 8003758 PAFAH1B1 
66 8007885 NSF 
67 8008087 NFE2L1 
68 8008139 UBE2Z 
69 8013908 NUFIP2 
70 8015642 PSMC3IP 
71 8017711 GNA13 
72 8020149 NAPG 
73 8021113 C18orf25 
74 8022996 EPG5 
75 8042291 AFTPH 
76 8045398 RAB3GAP1 
77 8046726 SSFA2 
78 8047865 PIKFYVE 
79 8048752 MRPL44 
80 8049657 ASB1 
81 8050128 KIDINS220 
82 8050190 ADAM17 
83 8050719 ITSN2 
84 8052024 FBXO11 
85 8052680 RAB1A 
86 8053668 EIF2AK3 
87 8054227 REV1 
88 8054804 CCDC93 
89 8054997 MAP3K2 
90 8058182 FAM126B 
91 8068062 USP16 
92 8068919 PDXK 
93 8070269 DSCR3 




95 8075130 PITPNB 
96 8077450 ARL8B 
97 8077458 EDEM1 
98 8078350 TGFBR2 
99 8078569 GOLGA4 
100 8079021 CTNNB1 
101 8081055 CHMP2B 
102 8084717 ST6GAL1 
103 8087473 IP6K1 
104 8089299 CD47 
105 8089584 C3orf17 
106 8089999 KPNA1 
107 8090490 RPN1 
108 8092392 KLHL6 
109 8092849 ATP13A3 
110 8096938 LARP7 
111 8098414 SPCS3 
112 8099850 TMEM156 
113 8101013 RCHY1 
114 8103524 TMEM192 
115 8105681 ERBB2IP 
116 8107194 C5orf30 
117 8109062 FBXO38 
118 8109344 GM2A 
119 8109350 SLC36A1 
120 8110886 MED10 
121 8111129 ZNF622 
122 8113023 TMEM161B 
123 8113616 FEM1C 
124 8114083 AFF4 
125 8114326 FAM13B 
126 8114787 GNPDA1 
127 8114814 NR3C1 
128 8115022 CSNK1A1 
129 8122202 MYB 
130 8127425 LMBRD1 
131 8128260 MAP3K7 
132 8130071 C15orf29 
133 8131292 RBAK 
134 8132070 GARS 
135 8133176 RABGEF1 
136 8133914 DMTF1 
137 8135955 CALU 
138 8136259 MKLN1 
139 8137833 SNX8 
140 8138566 IGF2BP3 
141 8138592 TRA2A 
142 8138613 OSBPL3 
143 8139592 HUS1 
144 8139891 SBDS 
145 8140311 PMS2P3 
146 8143697 ZNF786 
147 8144516 ERI1 
148 8144658 NEIL2 
149 8147548 POP1 
150 8149258 MFHAS1 
151 8149707 BIN3 
152 8150126 PPP2CB 
153 8150797 ATP6V1H 
154 8152845 FAM49B 
155 8158560 TOR1B 
156 8162294 SPTLC1 
157 8167573 GAGE1 
158 8175360 MMGT1 
159 8176698 TXLNG2P 
160 8177137 UTY 
161 8180323 USP12 
Cluster 23 
1 7897322 PHF13 
2 7897774 CLCN6 
3 7899436 SESN2 
4 7901054 PLK3 
5 7902290 CTH 
6 7902400 SNORD45B 
7 7906564 PEA15 
8 7907171 BLZF1 
9 7910014 CNIH4 
10 7910427 GALNT2 
11 7911754 TNFRSF14 
12 7914212 SNORA61 
13 7915160 RRAGC 
14 7915392 HIVEP3 
15 7918157 VAV3 
16 7918902 CD58 
17 7923141 DENND1B 
18 7923406 PTPN7 
19 7924760 ITPKB 
20 7927146 CSGALNACT2 
21 7928308 DDIT4 
22 7930927 INPP5F 
23 7931353 PTPRE 
24 7931479 INPP5A 
25 7933877 JMJD1C 
26 7940160 DTX4 
27 7940191 STX3 
28 7942289 RNF121 
29 7943293 ENDOD1 
30 7948332 LPXN 
31 7948364 MPEG1 
32 7950743 RAB30 
33 7953878 CLEC2D 
34 7957665 ELK3 
35 7958884 OAS1 
36 7960637 LPAR5 
37 7960933 M6PR 




39 7961371 DUSP16 
40 7963174 CERS5 
41 7964460 DDIT3 
42 7965094 E2F7 
43 7965964 SLC41A2 
44 7968976 LRCH1 
45 7969060 FNDC3A 
46 7969651 DNAJC3 
47 7970844 KATNAL1 
48 7975068 ZBTB1 
49 7980547 SEL1L 
50 7982564 SPRED1 
51 7983828 TEX9 
52 7984112 RAB8B 
53 7985482 WHAMM 
54 7989069 PYGO1 
55 7990345 SEMA7A 
56 7992789 TNFRSF12A 
57 7993167 ATF7IP2 
58 7995895 HERPUD1 
59 7996022 CCL22 
60 7996954 NFAT5 
61 8000028 DCUN1D3 
62 8002322 PDXDC2P 
63 8003611 FAM57A 
64 8003875 SPNS2 
65 8005707 MAP2K3 
66 8005765 WSB1 
67 8006123 CPD 
68 8011875 DERL2 
69 8013071 FLCN 
70 8014233 SLFN11 
71 8014391 CCL3L1 
72 8014414 CCL3L1 
73 8016088 CCDC43 
74 8017843 SLC16A6 
75 8019308 MAFG 
76 8019731 CCL3L1 
77 8019796 MAFG 
78 8023646 BCL2 
79 8026272 IL27RA 
80 8027837 CD22 
81 8032410 MOB3A 
82 8035694 PBX4 
83 8040440 GEN1 
84 8042391 PLEK 
85 8042416 ARHGAP25 
86 8045289 RHOQ 
87 8047854 CCNYL1 
88 8050766 ADCY3 
89 8051547 PRKD3 
90 8056977 NFE2L2 
91 8058824 MREG 
92 8059361 WDFY1 
93 8059854 ARL4C 
94 8060344 TRIB3 
95 8060418 SIRPA 
96 8062964 SYS1 
97 8063923 SLCO4A1 
98 8064808 SLC23A2 
99 8064868 GPCPD1 
100 8067113 ZNF217 
101 8069532 HSPA13 
102 8071559 SDF2L1 
103 8076533 PACSIN2 
104 8079517 KLHL18 
105 8082075 DTX3L 
106 8083090 ZBTB38 
107 8084045 MFN1 
108 8084634 DNAJB11 
109 8090018 PARP9 
110 8096004 BMP2K 
111 8096675 TET2 
112 8097017 UGT8 
113 8099760 ARAP2 
114 8099897 UGDH 
115 8101925 LAMTOR3 
116 8102371 C4orf21 
117 8102389 C4orf21 
118 8103951 ACSL1 
119 8104499 ANKRD33B 
120 8105067 PTGER4 
121 8106252 HEXB 
122 8110569 SQSTM1 
123 8112409 SGTB 
124 8112428 CD180 
125 8113064 LYSMD3 
126 8113914 FNIP1 
127 8118137 LTA 
128 8118322 SNORD52 
129 8119088 CDKN1A 
130 8122343 HECA 
131 8122756 PLEKHG1 
132 8123181 IGF2R 
133 8123609 SERPINB9 
134 8123976 GFOD1 
135 8125461 HLA-DQB1 
136 8126542 ZNF318 
137 8126666 NFKBIE 
138 8128716 CD164 
139 8129804 MAP3K5 
140 8129861 IFNGR1 
141 8131265 KIAA0415 
142 8131479 MIOS 
143 8132305 EEPD1 




145 8135568 MDFIC 
146 8135576 TES 
147 8136591 ADCK2 
148 8137091 ZNF398 
149 8139003 HERPUD2 
150 8145136 PPP3CC 
151 8145954 TACC1 
152 8147344 PDP1 
153 8147439 PLEKHF2 
154 8149330 CTSB 
155 8149534 ASAH1 
156 8152041 RNF19A 
157 8153201 EIF2C2 
158 8155930 GCNT1 
159 8157524 TLR4 
160 8157933 ZBTB43 
161 8159554 UAP1L1 
162 8163825 TRAF1 
163 8164165 HSPA5 
164 8164343 FAM102A 
165 8164701 SETX 
166 8167006 RP2 
167 8168447 CXorf26 
168 8177976 LTA 
169 8179258 LTA 
Cluster 24 
1 7899310 TMEM222 
2 7900146 ZC3H12A 
3 7907690 TOR3A 
4 7912102 KLHL21 
5 7913357 ECE1 
6 7914021 SLC9A1 
7 7920944 SMG5 
8 7922717 RGS16 
9 7923394 ARL8A 
10 7926531 ARL5B 
11 7930074 NFKB2 
12 7948399 PATL1 
13 7958749 SH2B3 
14 7979813 ZFP36L1 
15 7980051 C14orf43 
16 7984952 C15orf39 
17 7995258 ZNF267 
18 8004671 KDM6B 
19 8004691 TMEM88 
20 8013312 FAM83G 
21 8014956 NR1D1 
22 8018937 USP36 
23 8024228 MIDN 
24 8026350 CLEC17A 
25 8026915 ARRDC2 
26 8030128 PPP1R15A 
27 8035703 LPAR2 
28 8036207 NFKBID 
29 8040103 ID2 
30 8049075 B3GNT7 
31 8053882 DUSP2 
32 8060427 STK35 
33 8063156 CD40 
34 8063583 RBM38 
35 8066905 ZNFX1 
36 8068280 IFNGR2 
37 8071899 ADORA2A 
38 8073960 PIM3 
39 8077728 LOC442075 
40 8082314 PLXNA1 
41 8086330 CSRNP1 
42 8091485 SIAH2 
43 8096635 NFKB1 
44 8103025 ZNF827 
45 8109201 HMGXB3 
46 8113761 ZNF608 
47 8115806 UBTD2 
48 8116559 IRF4 
49 8116983 CD83 
50 8123606 MGC39372 
51 8152215 KLF10 
52 8158147 SLC25A25 
53 8164336 DPM2 
Cluster 25 
1 7904361 FAM46C 
2 7906622 LY9 
3 7956287 NAB2 
4 7965040 PHLDA1 
5 7985493 TM6SF1 
6 8044766 INSIG2 
7 8082086 PARP15 
8 8100231 TEC 
9 8102800 SLC7A11 
10 8113073 ARRDC3 
11 8118142 TNF 
12 8122265 TNFAIP3 
13 8122334 CCRL1 
14 8128123 RRAGD 
15 8129677 SGK1 
16 8131844 GPNMB 
17 8151816 GEM 
18 8177983 TNF 
19 8179263 TNF 
Cluster 26 
1 7906613 SLAMF7 
Cluster 27 
1 7904726 TXNIP 
2 7909214 RASSF5 
3 7921625 SLAMF6 




5 7930139 TRIM8 
6 7931863 ASB13 
7 7947624 PHF21A 
8 7955589 NR4A1 
9 7963575 EIF4B 
10 7966183 ALKBH2 
11 7969677 MBNL2 
12 7975626 C14orf43 
13 7978644 NFKBIA 
14 7988212 ELL3 
15 7996571 FAM65A 
16 8008263 PDK2 
17 8028652 ZFP36 
18 8029693 FOSB 
19 8042811 TET3 
20 8075673 RBFOX2 
21 8084880 HES1 
22 8088142 CHDH 
23 8088180 WNT5A 
24 8094743 RHOH 
25 8108370 EGR1 
26 8116910 HIVEP1 
27 8117106 RNF144B 
28 8119161 PIM1 
29 8121850 HEY2 
30 8132819 IKZF1 
31 8149720 EGR3 
32 8151101 MYBL1 
33 8163629 TNFSF8 










Figure A-1 Bayesian Hierarchical Clustering reveals 27 clusters of genes bearing differential expression over time. α-IgM stimulation of BL2 cells was monitored with regard to 
gene expression changes on the whole genome level for a period of 8 hours. Three biological replicates were hybridized to Human Gene ST 1.0 microarray chips (Affymetrix). 
Bayesian hierarchical clustering identified 21 clusters of genes with an expression range > 0.5. Clusters of genes with less than 10 % significantly enriched genes (FDR < 0.05) 





Table A-2 Gene set enrichment analysis for manually picked clusters (cl 6, cl 8 and cl 11) 
GOBPID  Pvalue  OddsRatio  ExpCount  Count  Size  Term  
cluster 6 
GO:0044267  0.000  2.544  16  30  2926  cellular protein metabolic 
process  
GO:0043153  0.000  191.784  0  2  4  entrainment of circadian clock by 
photoperiod  
GO:0006464  0.000  2.492  12  24  2242  protein modification process  
GO:0009648  0.000  95.878  0  2  6  photoperiodism  
GO:0033235  0.001  76.697  0  2  7  positive regulation of protein 
sumoylation  
GO:0043412  0.001  2.373  12  24  2335  macromolecule modification  
GO:0033233  0.001  63.910  0  2  8  regulation of protein 
sumoylation  
GO:0043501  0.001  63.910  0  2  8  skeletal muscle adaptation  
GO:0009649  0.001  54.776  0  2  9  entrainment of circadian clock  
GO:0019538  0.001  2.153  18  31  3472  protein metabolic process  
GO:0071397  0.001  47.926  0  2  10  cellular response to cholesterol  
GO:0014888  0.002  38.335  0  2  12  striated muscle adaptation  
GO:0006486  0.004  5.136  1  5  197  protein glycosylation  
GO:0043413  0.004  5.136  1  5  197  macromolecule glycosylation  
GO:0070085  0.004  5.082  1  5  199  glycosylation  
GO:0050691  0.005  22.539  0  2  19  regulation of defense response 
to virus by host  
GO:0070723  0.005  22.539  0  2  19  response to cholesterol  
GO:0044260  0.005  1.858  32  44  6081  cellular macromolecule 
metabolic process  
GO:0006507  0.005  Inf  0  1  1  GPI anchor release  
GO:0046092  0.005  Inf  0  1  1  deoxycytidine metabolic process  
GO:0048213  0.005  Inf  0  1  1  Golgi vesicle prefusion complex 
stabilization  
GO:0051754  0.005  Inf  0  1  1  meiotic sister chromatid 
cohesion, centromeric  
GO:0061310  0.005  Inf  0  1  1  canonical Wnt receptor signaling 
pathway involved in cardiac 
neural crest cell differentiation 
involved in heart development  
GO:0070159  0.005  Inf  0  1  1  mitochondrial threonyl-tRNA 
aminoacylation  
GO:0071401  0.005  Inf  0  1  1  cellular response to triglyceride  
GO:0071609  0.005  Inf  0  1  1  chemokine (C-C motif) ligand 5 
production  
GO:0071612  0.005  Inf  0  1  1  IP-10 production  
GO:0071649  0.005  Inf  0  1  1  regulation of chemokine (C-C 
motif) ligand 5 production  
GO:0071651  0.005  Inf  0  1  1  positive regulation of chemokine 
(C-C motif) ligand 5 production  
GO:0071658  0.005  Inf  0  1  1  regulation of IP-10 production  





GO:0090219  0.005  Inf  0  1  1  negative regulation of lipid 
kinase activity  
GO:0097241  0.005  Inf  0  1  1  hematopoietic stem cell 
migration to bone marrow  
GO:1900037  0.005  Inf  0  1  1  regulation of cellular response to 
hypoxia  
GO:2000055  0.005  Inf  0  1  1  positive regulation of Wnt 
receptor signaling pathway 
involved in dorsal/ventral axis 
specification  
GO:2000148  0.005  Inf  0  1  1  regulation of planar cell polarity 
pathway involved in ventricular 
septum morphogenesis  
GO:2000149  0.005  Inf  0  1  1  negative regulation of planar cell 
polarity pathway involved in 
ventricular septum 
morphogenesis  
GO:2000150  0.005  Inf  0  1  1  regulation of planar cell polarity 
pathway involved in cardiac 
muscle tissue morphogenesis  
GO:2000151  0.005  Inf  0  1  1  negative regulation of planar cell 
polarity pathway involved in 
cardiac muscle tissue 
morphogenesis  
GO:2000159  0.005  Inf  0  1  1  regulation of planar cell polarity 
pathway involved in heart 
morphogenesis  
GO:2000160  0.005  Inf  0  1  1  negative regulation of planar cell 
polarity pathway involved in 
heart morphogenesis  
GO:2000161  0.005  Inf  0  1  1  regulation of planar cell polarity 
pathway involved in cardiac right 
atrium morphogenesis  
GO:2000162  0.005  Inf  0  1  1  negative regulation of planar cell 
polarity pathway involved in 
cardiac right atrium 
morphogenesis  
GO:2000163  0.005  Inf  0  1  1  regulation of planar cell polarity 
pathway involved in outflow 
tract morphogenesis  
GO:2000164  0.005  Inf  0  1  1  negative regulation of planar cell 
polarity pathway involved in 
outflow tract morphogenesis  
GO:2000165  0.005  Inf  0  1  1  regulation of planar cell polarity 
pathway involved in pericardium 
morphogenesis  
GO:2000166  0.005  Inf  0  1  1  negative regulation of planar cell 
polarity pathway involved in 
pericardium morphogenesis  
GO:2000167  0.005  Inf  0  1  1  regulation of planar cell polarity 





GO:2000168  0.005  Inf  0  1  1  negative regulation of planar cell 
polarity pathway involved in 
neural tube closure  
GO:0016925  0.006  20.164  0  2  21  protein sumoylation  
GO:0070887  0.006  2.306  7  15  1383  cellular response to chemical 
stimulus  
GO:0071310  0.007  2.466  5  12  1015  cellular response to organic 
substance  
GO:0006890  0.007  17.410  0  2  24  retrograde vesicle-mediated 
transport, Golgi to ER  
GO:0044092  0.007  2.849  3  9  648  negative regulation of molecular 
function  
GO:0019835  0.008  15.957  0  2  26  cytolysis  
GO:0071396  0.009  15.318  0  2  27  cellular response to lipid  
GO:0010907  0.010  14.728  0  2  28  positive regulation of glucose 
metabolic process  
GO:0034381  0.010  14.728  0  2  28  plasma lipoprotein particle 
clearance  
GO:0009101  0.010  4.094  1  5  245  glycoprotein biosynthetic 
process 
 
Table A-3 List of genes, taken for comparison of CD40 and BCR stimulated BL cells by testing for stationarity. 
 Gene ID Probe ID Gene Symbol Gene Name 
1 790 7906613 SLAMF7 SLAM family member 7 
1 587 7904361 FAM46C family with sequence similarity 46, member C 
1 762 7906339 CD1A CD1a molecule 
1 763 7906348 CD1C CD1c molecule 
1 1169 7911754 TNFRSF14 tumor necrosis factor receptor superfamily, member 
1 1216 7912496 MTHFR methylenetetrahydrofolate reductase (NAD(P)H) 
1 2072 7923917 FAIM3 Fas apoptotic inhibitory molecule 3 
1 2548 7930413 DUSP5 dual specificity phosphatase 5 
1 5066 7961891 BHLHE41 basic helix-loop-helix family, member e41 
1 5207 7963911 CD63 CD63 molecule 
1 5286 7965040 PHLDA1 pleckstrin homology-like domain, family A, member 
1 5790 7972557 GPR183 G protein-coupled receptor 183 
1 7130 7990345 SEMA7A semaphorin 7A, GPI membrane anchor (John Milton Ha 
1 7327 7992789 TNFRSF12A tumor necrosis factor receptor superfamily, member 
1 8388 8006608 CCL4L1 chemokine (C-C motif) ligand 4-like 1 
1 8389 8006621 CCL4L1 chemokine (C-C motif) ligand 4-like 1 
1 8623 8009476 MAP2K6 mitogen-activated protein kinase kinase 6 
1 9420 8019651 CCL4L1 chemokine (C-C motif) ligand 4-like 1 
1 10263 8030007 EMP3 epithelial membrane protein 3 
1 12534 8059854 ARL4C ADP-ribosylation factor-like 4C 
1 13836 8075886 IL2RB interleukin 2 receptor, beta 
1 14768 8088848 PDZRN3 PDZ domain containing ring finger 3 
1 15587 8100231 TEC tec protein tyrosine kinase 
1 17463 8125139 NEU1 sialidase 1 (lysosomal sialidase) 
1 18005 8132725 UPP1 uridine phosphorylase 1 




1 19304 8149330 CTSB cathepsin B 
1 19510 8151816 GEM GTP binding protein overexpressed in skeletal musc 
1 21675 8178676 NEU1 sialidase 1 (lysosomal sialidase) 
1 21798 8179851 NEU1 sialidase 1 (lysosomal sialidase) 
3 13173 8068022 MIR155HG MIR155 host gene (non-protein coding) 
3 1056 7910427 GALNT2 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-a 
3 1073 7910680 GPR137B G protein-coupled receptor 137B 
3 1347 7914202 SNHG12 small nucleolar RNA host gene 12 (non-protein codi 
3 1348 7914212 SNORA61 small nucleolar RNA, H/ACA box 61 
3 1601 7917754 BCAR3 breast cancer anti-estrogen resistance 3 
3 1677 7918902 CD58 CD58 molecule 
3 5457 7967624 SLC15A4 solute carrier family 15, member 4 
3 6922 7986665 NIPA2 non imprinted in Prader-Willi/Angelman syndrome 2 
3 7106 7989968 CALML4 calmodulin-like 4 
3 9034 8015031 CCR7 chemokine (C-C motif) receptor 7 
3 9716 8023646 BCL2 B-cell CLL/lymphoma 2 
3 9922 8026007 ZNF791 zinc finger protein 791 
3 10765 8035694 PBX4 pre-B-cell leukemia homeobox 4 
3 12770 8062964 SYS1 SYS1 Golgi-localized integral membrane protein hom 
3 13776 8075130 PITPNB phosphatidylinositol transfer protein, beta 
3 13965 8077450 ARL8B ADP-ribosylation factor-like 8B 
3 14296 8082086 PARP15 poly (ADP-ribose) polymerase family, member 15 
3 15864 8103951 ACSL1 acyl-CoA synthetase long-chain family member 1 
3 15939 8105067 PTGER4 prostaglandin E receptor 4 (subtype EP4) 
3 16336 8110569 SQSTM1 sequestosome 1 
3 16365 8110886 MED10 mediator complex subunit 10 
3 16424 8111941 HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble 
3 16530 8113305 CHD1 chromodomain helicase DNA binding protein 1 
3 16741 8116227 CLK4 CDC-like kinase 4 
3 17286 8123181 IGF2R insulin-like growth factor 2 receptor 
3 17482 8125447 HLA-DQB1 major histocompatibility complex, class II, DQ bet 
3 17583 8126666 NFKBIE nuclear factor of kappa light polypeptide gene enh 
3 19015 8145691 UBXN8 UBX domain protein 8 
3 21736 8179258 LTA lymphotoxin alpha (TNF superfamily, member 1) 
4 9890 8025601 ICAM1 intercellular adhesion molecule 1 
4 287 7900146 ZC3H12A zinc finger CCCH-type containing 12A 
4 606 7904702 NOTCH2NL notch 2 N-terminal like 
4 987 7909503 SERTAD4 SERTA domain containing 4 
4 1697 7919193 NUDT4P1 nudix (nucleoside diphosphate linked moiety X)-typ 
4 2071 7923907 IL10 interleukin 10 
4 2450 7929032 FAS Fas (TNF receptor superfamily, member 6) 
4 2525 7930074 NFKB2 nuclear factor of kappa light polypeptide gene enh 
4 2778 7933750 SLC16A9 solute carrier family 16, member 9 (monocarboxylic 
4 6047 7975793 BATF basic leucine zipper transcription factor, ATF-lik 
4 6149 7977018 TRAF3 TNF receptor-associated factor 3 
4 6493 7981530 GPR132 G protein-coupled receptor 132 
4 6946 7987048 MTMR10 myotubularin related protein 10 
4 7097 7989849 DENND4A DENN/MADD domain containing 4A 
4 7833 7999496 ZC3H7A zinc finger CCCH-type containing 7A 




4 8523 8008096 SNX11 sorting nexin 11 
4 9345 8018922 CYTH1 cytohesin 1 
4 9790 8024485 GADD45B growth arrest and DNA-damage-inducible, beta 
4 11145 8039545 NLRP11 NLR family, pyrin domain containing 11 
4 11467 8043583 LOC285033 hypothetical protein LOC285033 
4 12722 8062319 TGIF2 TGFB-induced factor homeobox 2 
4 13294 8069541 SAMSN1 SAM domain, SH3 domain and nuclear localization si 
4 14827 8089771 CD80 CD80 molecule 
4 15907 8104580 FAM105B family with sequence similarity 105, member B 
4 15908 8104590 LOC100130744 hypothetical LOC100130744 
4 16139 8108080 PHF15 PHD finger protein 15 
4 17270 8122933 TIAM2 T-cell lymphoma invasion and metastasis 2 
4 18253 8136067 TSPAN33 tetraspanin 33 
4 20028 8158918 GTF3C4 general transcription factor IIIC, polypeptide 4, 
5 16514 8113073 ARRDC3 arrestin domain containing 3 
5 908 7908409 RGS2 regulator of G-protein signaling 2, 24kDa 
5 2158 7925062 SIPA1L2 signal-induced proliferation-associated 1 like 2 
5 4441 7953532 ENO2 enolase 2 (gamma, neuronal) 
5 4992 7961075 CD69 CD69 molecule 
5 8963 8014063 EVI2B ecotropic viral integration site 2B 
5 8964 8014066 EVI2A ecotropic viral integration site 2A 
5 12671 8061564 ID1 inhibitor of DNA binding 1, dominant negative heli 
5 14645 8086961 PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatas 
5 15286 8095870 CCNG2 cyclin G2 
5 15296 8096070 BMP3 bone morphogenetic protein 3 
5 15668 8101322 MOP-1 MOP-1 
5 16475 8112615 ENC1 ectodermal-neural cortex 1 (with BTB-like domain) 
5 16810 8117020 MYLIP myosin regulatory light chain interacting protein 
5 17049 8119898 VEGFA vascular endothelial growth factor A 
5 17197 8121861 NCOA7 nuclear receptor coactivator 7 
5 17371 8124380 HIST1H1A histone cluster 1, H1a 
5 17884 8131069 GPER G protein-coupled estrogen receptor 1 
5 19666 8154100 VLDLR very low density lipoprotein receptor 
6 16808 8116983 CD83 CD83 molecule 
6 1992 7922717 RGS16 regulator of G-protein signaling 16 
6 2110 7924450 DUSP10 dual specificity phosphatase 10 
6 2654 7931914 IL2RA interleukin 2 receptor, alpha 
6 3136 7938329 SNORA23 small nucleolar RNA, H/ACA box 23 
6 3578 7943424 BIRC2 baculoviral IAP repeat-containing 2 
6 4202 7950743 RAB30 RAB30, member RAS oncogene family 
6 4515 7954436 LRMP lymphoid-restricted membrane protein 
6 6013 7975368 SRSF5 serine/arginine-rich splicing factor 5 
6 6751 7984364 SMAD3 SMAD family member 3 
6 7846 7999642 KIAA0430 KIAA0430 
6 10766 8035703 LPAR2 lysophosphatidic acid receptor 2 
6 10812 8036207 NFKBID nuclear factor of kappa light polypeptide gene enh 
6 12050 8052269 CCDC88A coiled-coil domain containing 88A 
6 12786 8063156 CD40 CD40 molecule, TNF receptor superfamily member 5 
6 12796 8063351 SLC9A8 solute carrier family 9 (sodium/hydrogen exchanger 




6 14291 8082035 CD86 CD86 molecule 
6 14449 8084219 KLHL24 kelch-like 24 (Drosophila) 
6 14763 8088776 FOXP1 forkhead box P1 
6 14942 8091485 SIAH2 seven in absentia homolog 2 (Drosophila) 
6 15555 8099760 ARAP2 ArfGAP with RhoGAP domain, ankyrin repeat and PH d 
6 16561 8113761 ZNF608 zinc finger protein 608 
6 17168 8121563 MARCKS myristoylated alanine-rich protein kinase C substr 
6 17232 8122343 HECA headcase homolog (Drosophila) 
6 17315 8123606 MGC39372 serpin peptidase inhibitor, clade B (ovalbumin), m 
6 17347 8123981 C6orf114 chromosome 6 open reading frame 114 
6 18983 8145136 PPP3CC protein phosphatase 3, catalytic subunit, gamma is 
6 19386 8150225 RAB11FIP1 RAB11 family interacting protein 1 (class I) 
6 21458 8176384 ZFY zinc finger protein, Y-linked 
8 14277 8081838 ARHGAP31 Rho GTPase activating protein 31 
8 785 7906564 PEA15 phosphoprotein enriched in astrocytes 15 
8 1956 7922343 TNFSF4 tumor necrosis factor (ligand) superfamily, member 
8 2819 7934367 ANXA7 annexin A7 
8 2875 7935146 NOC3L nucleolar complex associated 3 homolog (S. cerevis 
8 4468 7953873 OVOS ovostatin 
8 4988 7961026 OVOS ovostatin 
8 5147 7963235 CSRNP2 cysteine-serine-rich nuclear protein 2 
8 5377 7966356 HVCN1 hydrogen voltage-gated channel 1 
8 7363 7993185 NUBP1 nucleotide binding protein 1 (MinD homolog, E. col 
8 7968 8001185 DNAJA2 DnaJ (Hsp40) homolog, subfamily A, member 2 
8 8679 8010243 SYNGR2 synaptogyrin 2 
8 8735 8011027 MYO1C myosin IC 
8 9145 8016194 MAP3K14 mitogen-activated protein kinase kinase kinase 14 
8 9493 8020495 CABLES1 Cdk5 and Abl enzyme substrate 1 
8 9798 8024572 GNA15 guanine nucleotide binding protein (G protein), al 
8 11850 8049271 ATG16L1 ATG16 autophagy related 16-like 1 (S. cerevisiae) 
8 12201 8054192 MITD1 MIT, microtubule interacting and transport, domain 
8 12503 8059413 DOCK10 dedicator of cytokinesis 10 
8 14674 8087473 IP6K1 inositol hexakisphosphate kinase 1 
8 15291 8096004 BMP2K BMP2 inducible kinase 
8 16766 8116548 DUSP22 dual specificity phosphatase 22 
8 16908 8117890 HLA-E major histocompatibility complex, class I, E 
8 17325 8123717 RPP40 ribonuclease P/MRP 40kDa subunit 
8 18070 8133459 CLIP2 CAP-GLY domain containing linker protein 2 
8 20111 8159984 C9orf46 chromosome 9 open reading frame 46 
8 20513 8164967 VAV2 vav 2 guanine nucleotide exchange factor 
8 21197 8173444 IL2RG interleukin 2 receptor, gamma 
8 21584 8177788 HLA-E major histocompatibility complex, class I, E 
8 21721 8179103 HLA-E major histocompatibility complex, class I, E 
9 8447 8007228 ATP6V0A1 ATPase, H+ transporting, lysosomal V0 subunit a1 
9 1075 7910706 LGALS8 lectin, galactoside-binding, soluble, 8 
9 3655 7944560 ARHGEF12 Rho guanine nucleotide exchange factor (GEF) 12 
9 4023 7948667 AHNAK AHNAK nucleoprotein 
9 4255 7951351 PDGFD platelet derived growth factor D 
9 4444 7953569 PTPN6 protein tyrosine phosphatase, non-receptor type 6 




9 6422 7980547 SEL1L sel-1 suppressor of lin-12-like (C. elegans) 
9 6443 7980958 LGMN legumain 
9 6474 7981290 WARS tryptophanyl-tRNA synthetase 
9 7051 7989037 CCPG1 cell cycle progression 1 
9 8350 8006123 CPD carboxypeptidase D 
9 10652 8034304 ACP5 acid phosphatase 5, tartrate resistant 
9 12500 8059361 WDFY1 WD repeat and FYVE domain containing 1 
9 13957 8077270 CHL1 cell adhesion molecule with homology to L1CAM (clo 
9 14367 8083092 ZBTB38 zinc finger and BTB domain containing 38 
9 14471 8084634 DNAJB11 DnaJ (Hsp40) homolog, subfamily B, member 11 
9 15358 8097017 UGT8 UDP glycosyltransferase 8 
9 15434 8098121 RAPGEF2 Rap guanine nucleotide exchange factor (GEF) 2 
9 16022 8106252 HEXB hexosaminidase B (beta polypeptide) 
9 16160 8108378 CTNNA1 catenin (cadherin-associated protein), alpha 1, 10 
9 16492 8112841 HOMER1 homer homolog 1 (Drosophila) 
9 17145 8121257 PRDM1 PR domain containing 1, with ZNF domain 
9 17231 8122336 C6orf115 chromosome 6 open reading frame 115 
9 17345 8123961 TBC1D7 TBC1 domain family, member 7 
9 17683 8128123 RRAGD Ras-related GTP binding D 
9 17784 8129804 MAP3K5 mitogen-activated protein kinase kinase kinase 5 
9 17787 8129861 IFNGR1 interferon gamma receptor 1 
9 19810 8155930 GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2 
9 20881 8169541 DOCK11 dedicator of cytokinesis 11 
10 1973 7922474 KIAA0040 KIAA0040 
10 42 7897210 DFFB DNA fragmentation factor, 40kDa, beta polypeptide 
10 354 7901102 MMACHC methylmalonic aciduria (cobalamin deficiency) cblC 
10 661 7905299 PRUNE prune homolog (Drosophila) 
10 1312 7913787 C1orf201 chromosome 1 open reading frame 201 
10 1646 7918457 KCNA3 potassium voltage-gated channel, shaker-related su 
10 2529 7930139 TRIM8 tripartite motif-containing 8 
10 3396 7941104 ARL2 ADP-ribosylation factor-like 2 
10 3505 7942562 NEU3 sialidase 3 (membrane sialidase) 
10 3762 7945875 FAM86C family with sequence similarity 86, member C 
10 4138 7949948 C11orf24 chromosome 11 open reading frame 24 
10 4931 7960320 DCP1B DCP1 decapping enzyme homolog B (S. cerevisiae) 
10 6055 7975926 KIAA1737 KIAA1737 
10 6343 7979505 SIX1 SIX homeobox 1 
10 6910 7986463 LRRK1 leucine-rich repeat kinase 1 
10 7308 7992594 CCNF cyclin F 
10 7736 7998336 NARFL nuclear prelamin A recognition factor-like 
10 8540 8008297 XYLT2 xylosyltransferase II 
10 8543 8008339 RSAD1 radical S-adenosyl methionine domain containing 1 
10 8764 8011396 SHPK sedoheptulokinase 
10 9234 8017186 HEATR6 HEAT repeat containing 6 
10 9986 8026712 ANKLE1 ankyrin repeat and LEM domain containing 1 
10 16165 8108447 CXXC5 CXXC finger 5 
10 17196 8121850 HEY2 hairy/enhancer-of-split related with YRPW motif 2 
10 18410 8138088 C7orf70 chromosome 7 open reading frame 70 
10 20320 8162438 BICD2 bicaudal D homolog 2 (Drosophila) 




10 20461 8164314 ST6GALNAC4 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl 
10 20489 8164644 FAM78A family with sequence similarity 78, member A 
10 21991 8180413 ST6GALNAC4 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl 
11 19176 8148059 DEPDC6 DEP domain containing 6 
11 405 7901788 NFIA nuclear factor I/A 
11 771 7906386 PYHIN1 pyrin and HIN domain family, member 1 
11 943 7908924 PRELP proline/arginine-rich end leucine-rich repeat prot 
11 1307 7913705 CNR2 cannabinoid receptor 2 (macrophage) 
11 2311 7927215 ALOX5 arachidonate 5-lipoxygenase 
11 3096 7938035 TRIM22 tripartite motif-containing 22 
11 4061 7949021 RCOR2 REST corepressor 2 
11 4168 7950307 UCP2 uncoupling protein 2 (mitochondrial, proton carrie 
11 4208 7950810 SYTL2 synaptotagmin-like 2 
11 4809 7958466 ACACB acetyl-CoA carboxylase beta 
11 5003 7961175 KLRC3 killer cell lectin-like receptor subfamily C, memb 
11 6172 7977319 PLD4 phospholipase D family, member 4 
11 6263 7978376 STXBP6 syntaxin binding protein 6 (amisyn) 
11 6460 7981142 CLMN calmin (calponin-like, transmembrane) 
11 7111 7990033 TLE3 transducin-like enhancer of split 3 (E(sp1) homolo 
11 7847 7999674 MYH11 myosin, heavy chain 11, smooth muscle 
11 9261 8017599 PECAM1 platelet/endothelial cell adhesion molecule 
11 10571 8033233 TUBB4 tubulin, beta 4 
11 10909 8037205 CEACAM1 carcinoembryonic antigen-related cell adhesion mol 
11 11579 8045182 PTPN18 protein tyrosine phosphatase, non-receptor type 18 
11 12387 8057418 ZNF385B zinc finger protein 385B 
11 13106 8067185 BMP7 bone morphogenetic protein 7 
11 13692 8074237 CECR1 cat eye syndrome chromosome region, candidate 1 
11 14484 8084742 LPP LIM domain containing preferred translocation part 
11 16031 8106411 S100Z S100 calcium binding protein Z 
11 16542 8113504 C5orf13 chromosome 5 open reading frame 13 
11 17432 8124806 NRM nurim (nuclear envelope membrane protein) 
11 19841 8156321 SYK spleen tyrosine kinase 
11 21058 8171493 CTPS2 CTP synthase II 
12 9656 8022817 KLHL14 kelch-like 14 (Drosophila) 
12 1867 7921319 FCRL1 Fc receptor-like 1 
12 2779 7933760 CCDC6 coiled-coil domain containing 6 
12 2780 7933772 ANK3 ankyrin 3, node of Ranvier (ankyrin G) 
12 4014 7948565 CYBASC3 cytochrome b, ascorbate dependent 3 
12 4491 7954104 ATF7IP activating transcription factor 7 interacting prot 
12 5077 7962151 DENND5B DENN/MADD domain containing 5B 
12 5323 7965541 FGD6 FYVE, RhoGEF and PH domain containing 6 
12 5596 7969677 MBNL2 muscleblind-like 2 (Drosophila) 
12 5972 7974653 KIAA0586 KIAA0586 
12 6431 7980744 RPS6KA5 ribosomal protein S6 kinase, 90kDa, polypeptide 5 
12 6900 7986383 IGF1R insulin-like growth factor 1 receptor 
12 6995 7987892 ZFP106 zinc finger protein 106 homolog (mouse) 
12 8469 8007471 NBR1 neighbor of BRCA1 gene 1 
12 9186 8016546 ZNF652 zinc finger protein 652 
12 11738 8047565 FAM117B family with sequence similarity 117, member B 




12 14794 8089261 CBLB Cas-Br-M (murine) ecotropic retroviral transformin 
12 15401 8097657 SMAD1 SMAD family member 1 
12 16038 8106516 JMY junction mediating and regulatory protein, p53 cof 
12 16437 8112107 PPAP2A phosphatidic acid phosphatase type 2A 
12 17003 8119161 PIM1 pim-1 oncogene 
12 17209 8122071 ENPP3 ectonucleotide pyrophosphatase/phosphodiesterase 3 
12 18799 8142930 TSGA14 testis specific, 14 
12 20331 8162533 PTCH1 patched 1 
12 20348 8162719 HEMGN hemogen 
12 20648 8166730 CYBB cytochrome b-245, beta polypeptide 
12 21096 8172088 BCOR BCL6 corepressor 
12 21127 8172471 PIM2 pim-2 oncogene 
12 21228 8173869 POF1B premature ovarian failure, 1B 
13 20406 8163629 TNFSF8 tumor necrosis factor (ligand) superfamily, member 
13 265 7899870 ZNF362 zinc finger protein 362 
13 623 7904907 BCL9 B-cell CLL/lymphoma 9 
13 2364 7927876 TET1 tet oncogene 1 
13 2650 7931863 ASB13 ankyrin repeat and SOCS box-containing 13 
13 2655 7931930 PRKCQ protein kinase C, theta 
13 2904 7935660 DNMBP dynamin binding protein 
13 3922 7947624 PHF21A PHD finger protein 21A 
13 4073 7949206 MEN1 multiple endocrine neoplasia I 
13 4163 7950248 FCHSD2 FCH and double SH3 domains 2 
13 4704 7956878 IRAK3 interleukin-1 receptor-associated kinase 3 
13 4720 7957126 KCNMB4 potassium large conductance calcium-activated chan 
13 4807 7958439 USP30 ubiquitin specific peptidase 30 
13 4838 7958960 TPCN1 two pore segment channel 1 
13 4843 7959025 RNFT2 ring finger protein, transmembrane 2 
13 5277 7964852 BEST3 bestrophin 3 
13 5363 7966183 ALKBH2 alkB, alkylation repair homolog 2 (E. coli) 
13 5688 7971015 SMAD9 SMAD family member 9 
13 7059 7989159 ZNF280D zinc finger protein 280D 
13 10640 8034130 KANK2 KN motif and ankyrin repeat domains 2 
13 11313 8041617 MTA3 metastasis associated 1 family, member 3 
13 12515 8059650 SP110 SP110 nuclear body protein 
13 13235 8068671 BACE2 beta-site APP-cleaving enzyme 2 
13 13820 8075673 RBM9 RNA binding motif protein 9 
13 14721 8088142 CHDH choline dehydrogenase 
13 16500 8112940 SSBP2 single-stranded DNA binding protein 2 
13 16854 8117476 BTN3A3 butyrophilin, subfamily 3, member A3 
13 17590 8126770 CYP39A1 cytochrome P450, family 39, subfamily A, polypepti 
13 19533 8152133 RRM2B ribonucleotide reductase M2 B (TP53 inducible) 
13 21179 8173208 SPIN4 spindlin family, member 4 
16 16265 8109649 NA NA 
16 81 7897774 CLCN6 chloride channel 6 
16 1082 7910950 KMO kynurenine 3-monooxygenase (kynurenine 3-hydroxyla 
16 2785 7933877 JMJD1C jumonji domain containing 1C 
16 4469 7953878 CLEC2D C-type lectin domain family 2, member D 
16 5000 7961151 KLRK1 killer cell lectin-like receptor subfamily K, memb 




16 6023 7975545 PSEN1 presenilin 1 
16 6843 7985482 WHAMM WAS protein homolog associated with actin, golgi m 
16 7552 7995895 HERPUD1 homocysteine-inducible, endoplasmic reticulum stre 
16 8319 8005765 WSB1 WD repeat and SOCS box-containing 1 
16 9576 8021653 SERPINB8 serpin peptidase inhibitor, clade B (ovalbumin), m 
16 11228 8040340 LPIN1 lipin 1 
16 11234 8040440 GEN1 Gen homolog 1, endonuclease (Drosophila) 
16 11300 8041447 CRIM1 cysteine rich transmembrane BMP regulator 1 (chord 
16 12920 8064868 GPCPD1 glycerophosphocholine phosphodiesterase GDE1 homol 
16 13182 8068105 BACH1 BTB and CNC homology 1, basic leucine zipper trans 
16 14333 8082607 ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 
16 15718 8101992 SLC39A8 solute carrier family 39 (zinc transporter), membe 
16 15744 8102389 C4orf21 chromosome 4 open reading frame 21 
16 15974 8105506 ZSWIM6 zinc finger, SWIM-type containing 6 
16 16569 8113914 FNIP1 folliculin interacting protein 1 
16 18369 8137526 INSIG1 insulin induced gene 1 
16 19031 8145954 TACC1 transforming, acidic coiled-coil containing protei 
16 19076 8146550 SDCBP syndecan binding protein (syntenin) 
16 19905 8157216 UGCG UDP-glucose ceramide glucosyltransferase 
16 19926 8157524 TLR4 toll-like receptor 4 
16 20355 8162833 ERP44 endoplasmic reticulum protein 44 
16 20495 8164701 SETX senataxin 
16 21856 8180268 CYP51A1 cytochrome P450, family 51, subfamily A, polypepti 
 
Table A-4 Testing for stationarity reveals 5 distinct and disjoint groups of genes, changing their expression 
after sCD40L stimulation. 
 Gene ID Probe ID Gene Symbol Gene Name 
2 16514 8113073     ARRDC3 arrestin domain containing 3 
2 903 7908376      RGS18 regulator of G-protein signaling 18 
2 905 7908388       RGS1 regulator of G-protein signaling 1 
2 908 7908409       RGS2 regulator of G-protein signaling 2, 24kDa 
2 1897 7921625     SLAMF6 SLAM family member 6 
2 2985 7936884     FAM53B family with sequence similarity 53, member B 
2 4441 7953532       ENO2 enolase 2 (gamma, neuronal) 
2 4545 7954926     PDZRN4 PDZ domain containing ring finger 4 
2 4992 7961075       CD69 CD69 molecule 
2 5363 7966183     ALKBH2 alkB, alkylation repair homolog 2 (E. coli) 
2 8674 8010139    SEC14L1 SEC14-like 1 (S. cerevisiae) 
2 9011 8014706      PCGF2 polycomb group ring finger 2 
2 12671 8061564        ID1 inhibitor of DNA binding 1, dominant negative heli 
2 13494 8071691        BCR breakpoint cluster region 
2 14598 8086330     CSRNP1 cysteine-serine-rich nuclear protein 1 
2 15035 8092691       BCL6 B-cell CLL/lymphoma 6 
2 15296 8096070       BMP3 bone morphogenetic protein 3 
2 15668 8101322      MOP-1 MOP-1 




2 15806 8103226    TMEM154 transmembrane protein 154 
2 16475 8112615       ENC1 ectodermal-neural cortex 1 (with BTB-like domain) 
2 16684 8115490     ADAM19 ADAM metallopeptidase domain 19 
2 16818 8117120        ID4 inhibitor of DNA binding 4, dominant negative heli 
2 17371 8124380   HIST1H1A histone cluster 1, H1a 
2 17776 8129666    SLC2A12 solute carrier family 2 (facilitated glucose trans 
2 19303 8149324    FAM167A family with sequence similarity 167, member A 
2 19666 8154100      VLDLR very low density lipoprotein receptor 
2 20566 8165711     PLCXD1 phosphatidylinositol-specific phospholipase C, X d 
2 21237 8173999       XKRX XK, Kell blood group complex subunit-related, X-li 
2 21450 8176286     PLCXD1 phosphatidylinositol-specific phospholipase C, X d 
4 9890 8025601      ICAM1 intercellular adhesion molecule 1 
4 287 7900146    ZC3H12A zinc finger CCCH-type containing 12A 
4 606 7904702   NOTCH2NL notch 2 N-terminal like 
4 1348 7914212    SNORA61 small nucleolar RNA, H/ACA box 61 
4 1601 7917754      BCAR3 breast cancer anti-estrogen resistance 3 
4 1697 7919193    NUDT4P1 nudix (nucleoside diphosphate linked moiety X)-typ 
4 2287 7926900     MAP3K8 mitogen-activated protein kinase kinase kinase 8 
4 2450 7929032        FAS Fas (TNF receptor superfamily, member 6) 
4 4745 7957478      TMTC3 transmembrane and tetratricopeptide repeat contain 
4 5448 7967456     RILPL2 Rab interacting lysosomal protein-like 2 
4 5664 7970696      USP12 ubiquitin specific peptidase 12 
4 7434 7994292      IL21R interleukin 21 receptor 
4 7833 7999496     ZC3H7A zinc finger CCCH-type containing 7A 
4 9034 8015031       CCR7 chemokine (C-C motif) receptor 7 
4 9790 8024485    GADD45B growth arrest and DNA-damage-inducible, beta 
4 11145 8039545     NLRP11 NLR family, pyrin domain containing 11 
4 13173 8068022   MIR155HG MIR155 host gene (non-protein coding) 
4 13294 8069541     SAMSN1 SAM domain, SH3 domain and nuclear localization si 
4 15333 8096635      NFKB1 nuclear factor of kappa light polypeptide gene enh 
4 15907 8104580    FAM105B family with sequence similarity 105, member B 
4 15908 8104590 LOC100130744 hypothetical LOC100130744 
4 15939 8105067     PTGER4 prostaglandin E receptor 4 (subtype EP4) 
4 16365 8110886      MED10 mediator complex subunit 10 
4 16741 8116227       CLK4 CDC-like kinase 4 
4 17221 8122202        MYB v-myb myeloblastosis viral oncogene homolog (avian 
4 17353 8124059     NUP153 nucleoporin 153kDa 
4 17583 8126666     NFKBIE nuclear factor of kappa light polypeptide gene enh 
4 17901 8131292       RBAK RB-associated KRAB zinc finger 
4 18882 8143957       RHEB Ras homolog enriched in brain 
4 21908 8180323      USP12 ubiquitin specific peptidase 12 
5 16808 8116983       CD83 CD83 molecule 
5 191 7899018     TMEM57 transmembrane protein 57 
5 571 7904086      LRIG2 leucine-rich repeats and immunoglobulin-like domai 




5 4515 7954436       LRMP lymphoid-restricted membrane protein 
5 6751 7984364      SMAD3 SMAD family member 3 
5 6825 7985259     ZFAND6 zinc finger, AN1-type domain 6 
5 7846 7999642   KIAA0430 KIAA0430 
5 9656 8022817     KLHL14 kelch-like 14 (Drosophila) 
5 10766 8035703      LPAR2 lysophosphatidic acid receptor 2 
5 10812 8036207     NFKBID nuclear factor of kappa light polypeptide gene enh 
5 11925 8050190     ADAM17 ADAM metallopeptidase domain 17 
5 12050 8052269    CCDC88A coiled-coil domain containing 88A 
5 12074 8052689     SPRED2 sprouty-related, EVH1 domain containing 2 
5 12786 8063156       CD40 CD40 molecule, TNF receptor superfamily member 5 
5 12796 8063351     SLC9A8 solute carrier family 9 (sodium/hydrogen exchanger 
5 14291 8082035       CD86 CD86 molecule 
5 14449 8084219     KLHL24 kelch-like 24 (Drosophila) 
5 14752 8088550   PRICKLE2 prickle homolog 2 (Drosophila) 
5 14763 8088776      FOXP1 forkhead box P1 
5 16637 8114814      NR3C1 nuclear receptor subfamily 3, group C, member 1 (g 
5 17209 8122071      ENPP3 ectonucleotide pyrophosphatase/phosphodiesterase 3 
5 17347 8123981   C6orf114 chromosome 6 open reading frame 114 
5 18983 8145136     PPP3CC protein phosphatase 3, catalytic subunit, gamma is 
5 19342 8149720       EGR3 early growth response 3 
5 19514 8151890   TP53INP1 tumor protein p53 inducible nuclear protein 1 
5 19876 8156848      NR4A3 nuclear receptor subfamily 4, group A, member 3 
5 20354 8162827       ALG2 asparagine-linked glycosylation 2, alpha-1,3-manno 
5 21127 8172471       PIM2 pim-2 oncogene 
5 21458 8176384        ZFY zinc finger protein, Y-linked 
7 14277 8081838   ARHGAP31 Rho GTPase activating protein 31 
7 65 7897482     PIK3CD phosphoinositide-3-kinase, catalytic, delta polype 
7 533 7903592   KIAA1324 KIAA1324 
7 785 7906564      PEA15 phosphoprotein enriched in astrocytes 15 
7 1956 7922343     TNFSF4 tumor necrosis factor (ligand) superfamily, member 
7 2819 7934367      ANXA7 annexin A7 
7 4468 7953873       OVOS ovostatin 
7 5122 7962884       RND1 Rho family GTPase 1 
7 5147 7963235     CSRNP2 cysteine-serine-rich nuclear protein 2 
7 5377 7966356      HVCN1 hydrogen voltage-gated channel 1 
7 6099 7976556  C14orf132 chromosome 14 open reading frame 132 
7 8934 8013633     UNC119 unc-119 homolog (C. elegans) 
7 9798 8024572      GNA15 guanine nucleotide binding protein (G protein), al 
7 10628 8033996       TYK2 tyrosine kinase 2 
7 11728 8047381      CFLAR CASP8 and FADD-like apoptosis regulator 
7 12201 8054192      MITD1 MIT, microtubule interacting and transport, domain 
7 12503 8059413     DOCK10 dedicator of cytokinesis 10 
7 12914 8064790     RASSF2 Ras association (RalGDS/AF-6) domain family member 




7 13575 8072757     CSF2RB colony stimulating factor 2 receptor, beta, low-af 
7 14725 8088180      WNT5A wingless-type MMTV integration site family, member 
7 15291 8096004      BMP2K BMP2 inducible kinase 
7 16002 8105949     SERF1A small EDRK-rich factor 1A (telomeric) 
7 16007 8105997     SERF1A small EDRK-rich factor 1A (telomeric) 
7 18070 8133459      CLIP2 CAP-GLY domain containing linker protein 2 
7 19590 8153043       ZFAT zinc finger and AT hook domain containing 
7 20513 8164967       VAV2 vav 2 guanine nucleotide exchange factor 
7 21565 8177658     SERF1A small EDRK-rich factor 1A (telomeric) 
7 21689 8178826         NA NA 
7 21810 8180022         NA NA 
8 15667 8101304   RASGEF1B RasGEF domain family, member 1B 
8 430 7902227    GADD45A growth arrest and DNA-damage-inducible, alpha 
8 974 7909332       CD55 CD55 molecule, decay accelerating factor for compl 
8 1992 7922717      RGS16 regulator of G-protein signaling 16 
8 3740 7945652   KRTAP5-3 keratin associated protein 5-3 
8 5000 7961151      KLRK1 killer cell lectin-like receptor subfamily K, memb 
8 5101 7962537    SLC38A2 solute carrier family 38, member 2 
8 5313 7965423       BTG1 B-cell translocation gene 1, anti-proliferative 
8 6135 7976844         NA NA 
8 6366 7979813    ZFP36L1 zinc finger protein 36, C3H type-like 1 
8 9540 8021183   SCARNA17 small Cajal body-specific RNA 17 
8 9935 8026163       IER2 immediate early response 2 
8 11377 8042503       MXD1 MAX dimerization protein 1 
8 11866 8049530    LRRFIP1 leucine rich repeat (in FLII) interacting protein  
8 12150 8053576     RNF103 ring finger protein 103 
8 12159 8053668    EIF2AK3 eukaryotic translation initiation factor 2-alpha k 
8 12343 8056359     COBLL1 COBL-like 1 
8 15560 8099834       TLR1 toll-like receptor 1 
8 15741 8102362       TIFA TRAF-interacting protein with forkhead-associated  
8 16292 8110032    C5orf41 chromosome 5 open reading frame 41 
8 17751 8129317    SERINC1 serine incorporator 1 
8 17832 8130539      TAGAP T-cell activation RhoGTPase activating protein 
8 18203 8135392       HBP1 HMG-box transcription factor 1 
8 18750 8142307     PNPLA8 patatin-like phospholipase domain containing 8 
8 19111 8147040     ZBTB10 zinc finger and BTB domain containing 10 
8 19147 8147573       OSR2 odd-skipped related 2 (Drosophila) 
8 19380 8150186     RNF122 ring finger protein 122 
8 20215 8161224      ZBTB5 zinc finger and BTB domain containing 5 
8 20368 8162940      ABCA1 ATP-binding cassette, sub-family A (ABC1), member  





Table A-5 Testing for stationarity reveals 15 distinct and disjoint groups of genes in BCR-resolved time series 
analysis. Each group contains 30 genes, which are listed below. Each group of genes displays a unique 
expression course. 
 Gene ID Probe ID Gene Symbol Gene Name 
1 790 7906613     SLAMF7 SLAM family member 7 
1 587 7904361     FAM46C family with sequence similarity 46, member C 
1 762 7906339       CD1A CD1a molecule 
1 763 7906348       CD1C CD1c molecule 
1 1056 7910427     GALNT2 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-a 
1 1169 7911754   TNFRSF14 tumor necrosis factor receptor superfamily, member 
1 3735 7945620     TOLLIP toll interacting protein 
1 3995 7948332       LPXN leupaxin 
1 5286 7965040     PHLDA1 pleckstrin homology-like domain, family A, member  
1 6630 7982564     SPRED1 sprouty-related, EVH1 domain containing 1 
1 6730 7984112      RAB8B RAB8B, member RAS oncogene family 
1 7381 7993433     PDXDC1 pyridoxal-dependent decarboxylase domain containin 
1 8319 8005765       WSB1 WD repeat and SOCS box-containing 1 
1 8623 8009476     MAP2K6 mitogen-activated protein kinase kinase 6 
1 9716 8023646       BCL2 B-cell CLL/lymphoma 2 
1 12007 8051547      PRKD3 protein kinase D3 
1 12017 8051707     MAP4K3 mitogen-activated protein kinase kinase kinase kin 
1 12534 8059854      ARL4C ADP-ribosylation factor-like 4C 
1 14295 8082075      DTX3L deltex 3-like (Drosophila) 
1 14296 8082086     PARP15 poly (ADP-ribose) polymerase family, member 15 
1 14768 8088848     PDZRN3 PDZ domain containing ring finger 3 
1 15587 8100231        TEC tec protein tyrosine kinase 
1 17286 8123181      IGF2R insulin-like growth factor 2 receptor 
1 17428 8124742       GNL1 guanine nucleotide binding protein-like 1 
1 18005 8132725       UPP1 uridine phosphorylase 1 
1 18360 8137404      CHPF2 chondroitin polymerizing factor 2 
1 18952 8144658      NEIL2 nei endonuclease VIII-like 2 (E. coli) 
1 19304 8149330       CTSB cathepsin B 
1 19510 8151816        GEM GTP binding protein overexpressed in skeletal musc 
1 20495 8164701       SETX senataxin 
2 9034 8015031       CCR7 chemokine (C-C motif) receptor 7 
2 791 7906622        LY9 lymphocyte antigen 9 
2 2110 7924450     DUSP10 dual specificity phosphatase 10 
2 2548 7930413      DUSP5 dual specificity phosphatase 5 
2 4668 7956287       NAB2 NGFI-A binding protein 2 (EGR1 binding protein 2) 
2 5377 7966356      HVCN1 hydrogen voltage-gated channel 1 
2 5409 7966929      RAB35 RAB35, member RAS oncogene family 
2 7405 7993825    RUNDC2B RUN domain containing 2B 
2 7452 7994576    RUNDC2C RUN domain containing 2C 
2 8886 8013071       FLCN folliculin 




2 9440 8019796       MAFG v-maf musculoaponeurotic fibrosarcoma oncogene hom 
2 9947 8026300       CD97 CD97 molecule 
2 11228 8040340      LPIN1 lipin 1 
2 12770 8062964       SYS1 SYS1 Golgi-localized integral membrane protein hom 
2 13394 8070720     ICOSLG inducible T-cell co-stimulator ligand 
2 13964 8077441    BHLHE40 basic helix-loop-helix family, member e40 
2 14505 8084951     LRRC33 leucine rich repeat containing 33 
2 15939 8105067     PTGER4 prostaglandin E receptor 4 (subtype EP4) 
2 16336 8110569     SQSTM1 sequestosome 1 
2 16569 8113914      FNIP1 folliculin interacting protein 1 
2 16572 8114010       IRF1 interferon regulatory factor 1 
2 16748 8116316     MGAT4B mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acet 
2 17583 8126666     NFKBIE nuclear factor of kappa light polypeptide gene enh 
2 17677 8128043       CNR1 cannabinoid receptor 1 (brain) 
2 18369 8137526     INSIG1 insulin induced gene 1 
2 19031 8145954      TACC1 transforming, acidic coiled-coil containing protei 
2 19589 8153021    ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 
2 19677 8154233      CD274 CD274 molecule 
2 19905 8157216       UGCG UDP-glucose ceramide glucosyltransferase 
3 18760 8142452       TFEC transcription factor EC 
3 716 7905789       IL6R interleukin 6 receptor 
3 1601 7917754      BCAR3 breast cancer anti-estrogen resistance 3 
3 1864 7921259      FCRL4 Fc receptor-like 4 
3 4755 7957570     PLXNC1 plexin C1 
3 5544 7968976      LRCH1 leucine-rich repeats and calponin homology (CH) do 
3 5549 7969060     FNDC3A fibronectin type III domain containing 3A 
3 7869 8000028    DCUN1D3 DCN1, defective in cullin neddylation 1, domain co 
3 9930 8026106       CALR calreticulin 
3 10652 8034304       ACP5 acid phosphatase 5, tartrate resistant 
3 11686 8046726      SSFA2 sperm specific antigen 2 
3 12500 8059361      WDFY1 WD repeat and FYVE domain containing 1 
3 13383 8070584    TMPRSS3 transmembrane protease, serine 3 
3 14155 8080084       MANF mesencephalic astrocyte-derived neurotrophic facto 
3 14471 8084634    DNAJB11 DnaJ (Hsp40) homolog, subfamily B, member 11 
3 14874 8090490       RPN1 ribophorin I 
3 15291 8096004      BMP2K BMP2 inducible kinase 
3 15358 8097017       UGT8 UDP glycosyltransferase 8 
3 15561 8099841       TLR6 toll-like receptor 6 
3 16022 8106252       HEXB hexosaminidase B (beta polypeptide) 
3 16095 8107474      DMXL1 Dmx-like 1 
3 16160 8108378     CTNNA1 catenin (cadherin-associated protein), alpha 1, 10 
3 17551 8126303      TREM1 triggering receptor expressed on myeloid cells 1 
3 17683 8128123      RRAGD Ras-related GTP binding D 
3 17784 8129804     MAP3K5 mitogen-activated protein kinase kinase kinase 5 




3 18217 8135576        TES testis derived transcript (3 LIM domains) 
3 19933 8157650      PTGS1 prostaglandin-endoperoxide synthase 1 (prostagland 
3 20270 8161701      TMEM2 transmembrane protein 2 
3 20448 8164165      HSPA5 heat shock 70kDa protein 5 (glucose-regulated prot 
4 20135 8160332      MLLT3 myeloid/lymphoid or mixed-lineage leukemia (tritho 
4 771 7906386     PYHIN1 pyrin and HIN domain family, member 1 
4 943 7908924      PRELP proline/arginine-rich end leucine-rich repeat prot 
4 2243 7926170     DHTKD1 dehydrogenase E1 and transketolase domain containi 
4 2655 7931930      PRKCQ protein kinase C, theta 
4 4208 7950810      SYTL2 synaptotagmin-like 2 
4 4478 7953981       ETV6 ets variant 6 
4 4720 7957126     KCNMB4 potassium large conductance calcium-activated chan 
4 4843 7959025      RNFT2 ring finger protein, transmembrane 2 
4 6735 7984174      SNX22 sorting nexin 22 
4 6747 7984298      DIS3L DIS3 mitotic control homolog (S. cerevisiae)-like 
4 7012 7988212       ELL3 elongation factor RNA polymerase II-like 3 
4 10640 8034130      KANK2 KN motif and ankyrin repeat domains 2 
4 10909 8037205    CEACAM1 carcinoembryonic antigen-related cell adhesion mol 
4 11456 8043465       IGKC immunoglobulin kappa constant 
4 12914 8064790     RASSF2 Ras association (RalGDS/AF-6) domain family member 
4 13737 8074780      YPEL1 yippee-like 1 (Drosophila) 
4 13820 8075673       RBM9 RNA binding motif protein 9 
4 14179 8080562     IL17RB interleukin 17 receptor B 
4 14721 8088142       CHDH choline dehydrogenase 
4 16031 8106411      S100Z S100 calcium binding protein Z 
4 16829 8117243    LRRC16A leucine rich repeat containing 16A 
4 18441 8138489     CDCA7L cell division cycle associated 7-like 
4 18647 8140955       CDK6 cyclin-dependent kinase 6 
4 18719 8141768      RASA4 RAS p21 protein activator 4 
4 18722 8141803      RASA4 RAS p21 protein activator 4 
4 19845 8156393      SUSD3 sushi domain containing 3 
4 19953 8157804    OLFML2A olfactomedin-like 2A 
4 20348 8162719      HEMGN hemogen 
4 20526 8165156    SDCCAG3 serologically defined colon cancer antigen 3 
5 19876 8156848      NR4A3 nuclear receptor subfamily 4, group A, member 3 
5 109 7898070      PRDM2 PR domain containing 2, with ZNF domain 
5 300 7900365     MFSD2A major facilitator superfamily domain containing 2A 
5 1047 7910261    C1orf69 chromosome 1 open reading frame 69 
5 1992 7922717      RGS16 regulator of G-protein signaling 16 
5 2398 7928429       PLAU plasminogen activator, urokinase 
5 2643 7931810       KLF6 Kruppel-like factor 6 
5 5789 7972548      GPR18 G protein-coupled receptor 18 
5 6366 7979813    ZFP36L1 zinc finger protein 36, C3H type-like 1 
5 6386 7980051   C14orf43 chromosome 14 open reading frame 43 




5 9935 8026163       IER2 immediate early response 2 
5 10003 8026915     ARRDC2 arrestin domain containing 2 
5 10277 8030128   PPP1R15A protein phosphatase 1, regulatory (inhibitor) subu 
5 10744 8035445       JUND jun D proto-oncogene 
5 10812 8036207     NFKBID nuclear factor of kappa light polypeptide gene enh 
5 11834 8049075     B3GNT7 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltr 
5 12107 8053022       EGR4 early growth response 4 
5 12179 8053882      DUSP2 dual specificity phosphatase 2 
5 13671 8073960       PIM3 pim-3 oncogene 
5 14495 8084880       HES1 hairy and enhancer of split 1, (Drosophila) 
5 14598 8086330     CSRNP1 cysteine-serine-rich nuclear protein 1 
5 15667 8101304   RASGEF1B RasGEF domain family, member 1B 
5 16808 8116983       CD83 CD83 molecule 
5 16819 8117128       E2F3 E2F transcription factor 3 
5 17039 8119712        SRF serum response factor (c-fos serum response elemen 
5 17226 8122265    TNFAIP3 tumor necrosis factor, alpha-induced protein 3 
5 19535 8152215      KLF10 Kruppel-like factor 10 
5 20194 8160912   C9orf131 chromosome 9 open reading frame 131 
5 21196 8173437    CXorf65 chromosome X open reading frame 65 
6 19176 8148059     DEPDC6 DEP domain containing 6 
6 405 7901788       NFIA nuclear factor I/A 
6 533 7903592   KIAA1324 KIAA1324 
6 963 7909188      IKBKE inhibitor of kappa light polypeptide gene enhancer 
6 1302 7913644       E2F2 E2F transcription factor 2 
6 1307 7913705       CNR2 cannabinoid receptor 2 (macrophage) 
6 1816 7920552      KCNN3 potassium intermediate/small conductance calcium-a 
6 1867 7921319      FCRL1 Fc receptor-like 1 
6 1945 7922219       SELL selectin L 
6 5046 7961540       RERG RAS-like, estrogen-regulated, growth inhibitor 
6 6464 7981183      TCL1A T-cell leukemia/lymphoma 1A 
6 7058 7989146       MNS1 meiosis-specific nuclear structural 1 
6 8905 8013319       GRAP GRB2-related adaptor protein 
6 9993 8026787    FAM129C family with sequence similarity 129, member C 
6 12385 8057377    CCDC141 coiled-coil domain containing 141 
6 12678 8061668        HCK hemopoietic cell kinase 
6 12980 8065569     BCL2L1 BCL2-like 1 
6 13106 8067185       BMP7 bone morphogenetic protein 7 
6 13492 8071671       GNAZ guanine nucleotide binding protein (G protein), al 
6 14419 8083749      PPM1L protein phosphatase, Mg2+/Mn2+ dependent, 1L 
6 14487 8084766       TP63 tumor protein p63 
6 14576 8085984    OSBPL10 oxysterol binding protein-like 10 
6 16081 8107307      CAMK4 calcium/calmodulin-dependent protein kinase IV 
6 16139 8108080      PHF15 PHD finger protein 15 
6 16542 8113504    C5orf13 chromosome 5 open reading frame 13 




6 17721 8128818      WASF1 WAS protein family, member 1 
6 19841 8156321        SYK spleen tyrosine kinase 
6 21437 8176174       MPP1 membrane protein, palmitoylated 1, 55kDa 
6 21884 8180299      PSIP1 PC4 and SFRS1 interacting protein 1 
7 17196 8121850       HEY2 hairy/enhancer-of-split related with YRPW motif 2 
7 661 7905299      PRUNE prune homolog (Drosophila) 
7 1633 7918300      PSRC1 proline/serine-rich coiled-coil 1 
7 1646 7918457      KCNA3 potassium voltage-gated channel, shaker-related su 
7 1973 7922474   KIAA0040 KIAA0040 
7 2529 7930139      TRIM8 tripartite motif-containing 8 
7 3627 7944152     IL10RA interleukin 10 receptor, alpha 
7 4536 7954717      BICD1 bicaudal D homolog 1 (Drosophila) 
7 5723 7971486   C13orf18 chromosome 13 open reading frame 18 
7 6012 7975361   KIAA0247 KIAA0247 
7 6968 7987385      MEIS2 Meis homeobox 2 
7 7736 7998336      NARFL nuclear prelamin A recognition factor-like 
7 8540 8008297      XYLT2 xylosyltransferase II 
7 8947 8013804     DHRS13 dehydrogenase/reductase (SDR family) member 13 
7 9001 8014551      SYNRG synergin, gamma 
7 9103 8015655    FAM134C family with sequence similarity 134, member C 
7 11798 8048489     ANKZF1 ankyrin repeat and zinc finger domain containing 1 
7 12072 8052669    SERTAD2 SERTA domain containing 2 
7 12622 8060977   C20orf94 chromosome 20 open reading frame 94 
7 14725 8088180      WNT5A wingless-type MMTV integration site family, member 
7 15296 8096070       BMP3 bone morphogenetic protein 3 
7 15382 8097417      PHF17 PHD finger protein 17 
7 15454 8098423      NEIL3 nei endonuclease VIII-like 3 (E. coli) 
7 15806 8103226    TMEM154 transmembrane protein 154 
7 15931 8104901       IL7R interleukin 7 receptor 
7 16155 8108301     KIF20A kinesin family member 20A 
7 16602 8114365       BRD8 bromodomain containing 8 
7 16817 8117106    RNF144B ring finger protein 144B 
7 16821 8117165       SOX4 SRY (sex determining region Y)-box 4 
7 20457 8164252     SH2D3C SH2 domain containing 3C 
9 11444 8043363 NCRNA00152 non-protein coding RNA 152 
9 540 7903703      GNAI3 guanine nucleotide binding protein (G protein), al 
9 555 7903893       CD53 CD53 molecule 
9 838 7907171      BLZF1 basic leucine zipper nuclear factor 1 
9 4515 7954436       LRMP lymphoid-restricted membrane protein 
9 5501 7968297       POMP proteasome maturation protein 
9 6023 7975545      PSEN1 presenilin 1 
9 6324 7979260       GMFB glia maturation factor, beta 
9 6712 7983828       TEX9 testis expressed 9 
9 6954 7987172   C15orf24 chromosome 15 open reading frame 24 




9 8087 8002878   TMEM170A transmembrane protein 170A 
9 8583 8008870     TMEM49 transmembrane protein 49 
9 13298 8069574   C21orf91 chromosome 21 open reading frame 91 
9 14333 8082607     ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 
9 14439 8084045       MFN1 mitofusin 1 
9 16532 8113358    ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltra 
9 16600 8114326     FAM13B family with sequence similarity 13, member B 
9 17231 8122336   C6orf115 chromosome 6 open reading frame 115 
9 17345 8123961     TBC1D7 TBC1 domain family, member 7 
9 17484 8125463   HLA-DQB2 major histocompatibility complex, class II, DQ bet 
9 17714 8128716      CD164 CD164 molecule, sialomucin 
9 19076 8146550      SDCBP syndecan binding protein (syntenin) 
9 20355 8162833      ERP44 endoplasmic reticulum protein 44 
9 20623 8166469       SAT1 spermidine/spermine N1-acetyltransferase 1 
9 21243 8174076        GLA galactosidase, alpha 
9 21688 8178811         NA NA 
9 21809 8180003         NA NA 
9 21811 8180029   HLA-DQB2 major histocompatibility complex, class II, DQ bet 
9 21856 8180268    CYP51A1 cytochrome P450, family 51, subfamily A, polypepti 
10 10233 8029693       FOSB FBJ murine osteosarcoma viral oncogene homolog B 
10 357 7901140      MAST2 microtubule associated serine/threonine kinase 2 
10 535 7903632     CELSR2 cadherin, EGF LAG seven-pass G-type receptor 2 (fl 
10 1511 7916403      SSBP3 single stranded DNA binding protein 3 
10 2234 7926037     PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatas 
10 3064 7937823      KCNQ1 potassium voltage-gated channel, KQT-like subfamil 
10 6045 7975779        FOS FBJ murine osteosarcoma viral oncogene homolog 
10 6175 7977344      PACS2 phosphofurin acidic cluster sorting protein 2 
10 6280 7978644     NFKBIA nuclear factor of kappa light polypeptide gene enh 
10 6494 7981538       JAG2 jagged 2 
10 7111 7990033       TLE3 transducin-like enhancer of split 3 (E(sp1) homolo 
10 8751 8011262        MNT MAX binding protein 
10 8771 8011516     ATP2A3 ATPase, Ca++ transporting, ubiquitous 
10 9094 8015526      KAT2A K(lysine) acetyltransferase 2A 
10 9790 8024485    GADD45B growth arrest and DNA-damage-inducible, beta 
10 9926 8026047       JUNB jun B proto-oncogene 
10 10696 8034783      LPHN1 latrophilin 1 
10 11238 8040473       RHOB ras homolog gene family, member B 
10 11322 8041763      PRKCE protein kinase C, epsilon 
10 11474 8043657      CNNM4 cyclin M4 
10 12024 8051814    ZFP36L2 zinc finger protein 36, C3H type-like 2 
10 12269 8055130     HS6ST1 heparan sulfate 6-O-sulfotransferase 1 
10 16719 8115927      RNF44 ring finger protein 44 
10 17003 8119161       PIM1 pim-1 oncogene 
10 17131 8121076      PNRC1 proline-rich nuclear receptor coactivator 1 




10 19111 8147040     ZBTB10 zinc finger and BTB domain containing 10 
10 19342 8149720       EGR3 early growth response 3 
10 19848 8156452    FAM120A family with sequence similarity 120A 
10 20985 8170704      ABCD1 ATP-binding cassette, sub-family D (ALD), member 1 
11 6845 7985493     TM6SF1 transmembrane 6 superfamily member 1 
11 1624 7918157       VAV3 vav 3 guanine nucleotide exchange factor 
11 1660 7918634      PHTF1 putative homeodomain transcription factor 1 
11 2388 7928308      DDIT4 DNA-damage-inducible transcript 4 
11 2531 7930162   C10orf26 chromosome 10 open reading frame 26 
11 3218 7939465   HSD17B12 hydroxysteroid (17-beta) dehydrogenase 12 
11 3840 7946504    TMEM41B transmembrane protein 41B 
11 4255 7951351      PDGFD platelet derived growth factor D 
11 6422 7980547      SEL1L sel-1 suppressor of lin-12-like (C. elegans) 
11 6474 7981290       WARS tryptophanyl-tRNA synthetase 
11 7051 7989037      CCPG1 cell cycle progression 1 
11 7362 7993167    ATF7IP2 activating transcription factor 7 interacting prot 
11 8563 8008646     SCPEP1 serine carboxypeptidase 1 
11 9189 8016578    SLC35B1 solute carrier family 35, member B1 
11 9560 8021453     SEC11C SEC11 homolog C (S. cerevisiae) 
11 12435 8058295       ALS2 amyotrophic lateral sclerosis 2 (juvenile) 
11 13293 8069532     HSPA13 heat shock protein 70kDa family, member 13 
11 13346 8070083    TMEM50B transmembrane protein 50B 
11 13604 8073088   APOBEC3G apolipoprotein B mRNA editing enzyme, catalytic po 
11 13688 8074204       XKR3 XK, Kell blood group complex subunit-related famil 
11 14339 8082745      CCRL1 chemokine (C-C motif) receptor-like 1 
11 14893 8090737      NPHP3 nephronophthisis 3 (adolescent) 
11 15565 8099897       UGDH UDP-glucose 6-dehydrogenase 
11 15853 8103834        AGA aspartylglucosaminidase 
11 15924 8104760       TARS threonyl-tRNA synthetase 
11 17787 8129861     IFNGR1 interferon gamma receptor 1 
11 18115 8134091     CLDN12 claudin 12 
11 18474 8138789      JAZF1 JAZF zinc finger 1 
11 19697 8154531    DENND4C DENN/MADD domain containing 4C 
11 20881 8169541     DOCK11 dedicator of cytokinesis 11 
12 1897 7921625     SLAMF6 SLAM family member 6 
12 903 7908376      RGS18 regulator of G-protein signaling 18 
12 964 7909214     RASSF5 Ras association (RalGDS/AF-6) domain family member 
12 2384 7928208    SLC29A3 solute carrier family 29 (nucleoside transporters) 
12 3120 7938183     ZNF215 zinc finger protein 215 
12 3698 7945132       FLI1 Friend leukemia virus integration 1 
12 3762 7945875     FAM86C family with sequence similarity 86, member C 
12 4451 7953651       PEX5 peroxisomal biogenesis factor 5 
12 4807 7958439      USP30 ubiquitin specific peptidase 30 
12 4873 7959354      BCL7A B-cell CLL/lymphoma 7A 




12 6046 7975787       JDP2 Jun dimerization protein 2 
12 6055 7975926   KIAA1737 KIAA1737 
12 6224 7977868   C14orf93 chromosome 14 open reading frame 93 
12 7059 7989159    ZNF280D zinc finger protein 280D 
12 8674 8010139    SEC14L1 SEC14-like 1 (S. cerevisiae) 
12 9654 8022803     FAM59A family with sequence similarity 59, member A 
12 10907 8037186       LIPE lipase, hormone-sensitive 
12 12455 8058570    C2orf67 chromosome 2 open reading frame 67 
12 14123 8079598     ZNF589 zinc finger protein 589 
12 15401 8097657      SMAD1 SMAD family member 1 
12 15518 8099200    JAKMIP1 janus kinase and microtubule interacting protein 1 
12 16165 8108447      CXXC5 CXXC finger 5 
12 16850 8117435     BTN3A2 butyrophilin, subfamily 3, member A2 
12 16854 8117476     BTN3A3 butyrophilin, subfamily 3, member A3 
12 17528 8126018      STK38 serine/threonine kinase 38 
12 18011 8132819      IKZF1 IKAROS family zinc finger 1 (Ikaros) 
12 19193 8148317        MYC v-myc myelocytomatosis viral oncogene homolog (avi 
12 20566 8165711     PLCXD1 phosphatidylinositol-specific phospholipase C, X d 
12 21450 8176286     PLCXD1 phosphatidylinositol-specific phospholipase C, X d 
13 16874 8117630     ZNF165 zinc finger protein 165 
13 53 7897322      PHF13 PHD finger protein 13 
13 306 7900438     ZNF643 zinc finger protein 643 
13 869 7907690      TOR3A torsin family 3, member A 
13 1899 7921652     SLAMF1 signaling lymphocytic activation molecule family m 
13 2654 7931914      IL2RA interleukin 2 receptor, alpha 
13 3247 7939839      PTPRJ protein tyrosine phosphatase, receptor type, J 
13 3306 7940118 ZFP91-CNTF ZFP91-CNTF readthrough transcript 
13 4625 7955943      PDE1B phosphodiesterase 1B, calmodulin-dependent 
13 7053 7989069      PYGO1 pygopus homolog 1 (Drosophila) 
13 7145 7990555       NRG4 neuregulin 4 
13 7417 7994058     SCNN1G sodium channel, nonvoltage-gated 1, gamma 
13 8147 8003611     FAM57A family with sequence similarity 57, member A 
13 8977 8014233     SLFN11 schlafen family member 11 
13 9135 8016088     CCDC43 coiled-coil domain containing 43 
13 9269 8017711      GNA13 guanine nucleotide binding protein (G protein), al 
13 9951 8026350    CLEC17A C-type lectin domain family 17, member A 
13 10765 8035694       PBX4 pre-B-cell leukemia homeobox 4 
13 10766 8035703      LPAR2 lysophosphatidic acid receptor 2 
13 11708 8047086       NAB1 NGFI-A binding protein 1 (EGR1 binding protein 1) 
13 12581 8060418      SIRPA signal-regulatory protein alpha 
13 15333 8096635      NFKB1 nuclear factor of kappa light polypeptide gene enh 
13 15555 8099760      ARAP2 ArfGAP with RhoGAP domain, ankyrin repeat and PH d 
13 16707 8115806      UBTD2 ubiquitin domain containing 2 
13 16929 8118137        LTA lymphotoxin alpha (TNF superfamily, member 1) 




13 17259 8122756    PLEKHG1 pleckstrin homology domain containing, family G (w 
13 18983 8145136     PPP3CC protein phosphatase 3, catalytic subunit, gamma is 
13 21600 8177976        LTA lymphotoxin alpha (TNF superfamily, member 1) 
13 21736 8179258        LTA lymphotoxin alpha (TNF superfamily, member 1) 
14 453 7902512     DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4 
14 197 7899087     PDIK1L PDLIM1 interacting kinase 1 like 
14 612 7904755     PEX11B peroxisomal biogenesis factor 11 beta 
14 1322 7913883     PAFAH2 platelet-activating factor acetylhydrolase 2, 40kD 
14 1617 7918008        DBT dihydrolipoamide branched chain transacylase E2 
14 1745 7919780    GOLPH3L golgi phosphoprotein 3-like 
14 1991 7922707     RNASEL ribonuclease L (2',5'-oligoisoadenylate synthetase 
14 2064 7923812     RAB7L1 RAB7, member RAS oncogene family-like 1 
14 2720 7933092     ZNF248 zinc finger protein 248 
14 2770 7933638   FLJ31958 hypothetical LOC143153 
14 2860 7934945      PANK1 pantothenate kinase 1 
14 4463 7953765     RIMKLB ribosomal modification protein rimK-like family me 
14 5288 7965060      BBS10 Bardet-Biedl syndrome 10 
14 5577 7969374   C13orf34 chromosome 13 open reading frame 34 
14 6768 7984626      SENP8 SUMO/sentrin specific peptidase family member 8 
14 7373 7993298      ERCC4 excision repair cross-complementing rodent repair  
14 10902 8037144      DEDD2 death effector domain containing 2 
14 11666 8046502      SCRN3 secernin 3 
14 12185 8053975     LMAN2L lectin, mannose-binding 2-like 
14 12454 8058552       IDH1 isocitrate dehydrogenase 1 (NADP+), soluble 
14 12927 8064967       MKKS McKusick-Kaufman syndrome 
14 15551 8099696    SEPSECS Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tR 
14 15741 8102362       TIFA TRAF-interacting protein with forkhead-associated  
14 16759 8116494      ZFP62 zinc finger protein 62 homolog (mouse) 
14 16881 8117685    ZKSCAN3 zinc finger with KRAB and SCAN domains 3 
14 16991 8119000     MAPK14 mitogen-activated protein kinase 14 
14 17767 8129590       STX7 syntaxin 7 
14 20547 8165486    TMEM203 transmembrane protein 203 
14 20561 8165642    TMEM203 transmembrane protein 203 
14 21087 8171896    CXorf21 chromosome X open reading frame 21 
17 20331 8162533      PTCH1 patched 1 
17 265 7899870     ZNF362 zinc finger protein 362 
17 2924 7935968       LDB1 LIM domain binding 1 
17 3452 7941797     ADRBK1 adrenergic, beta, receptor kinase 1 
17 3466 7942007       LRP5 low density lipoprotein receptor-related protein 5 
17 4073 7949206       MEN1 multiple endocrine neoplasia I 
17 4075 7949264       EHD1 EH-domain containing 1 
17 5108 7962659      HDAC7 histone deacetylase 7 
17 6899 7986359      IGF1R insulin-like growth factor 1 receptor 
17 7421 7994109       PLK1 polo-like kinase 1 




17 8452 8007302      TUBG1 tubulin, gamma 1 
17 9329 8018708      UBE2O ubiquitin-conjugating enzyme E2O 
17 9330 8018731     RHBDF2 rhomboid 5 homolog 2 (Drosophila) 
17 9439 8019778      PCYT2 phosphate cytidylyltransferase 2, ethanolamine 
17 9973 8026533      HSH2D hematopoietic SH2 domain containing 
17 10166 8028930      RAB4B RAB4B, member RAS oncogene family 
17 10582 8033362       INSR insulin receptor 
17 11854 8049317       DGKD diacylglycerol kinase, delta 130kDa 
17 13486 8071566      PPIL2 peptidylprolyl isomerase (cyclophilin)-like 2 
17 13800 8075430      MORC2 MORC family CW-type zinc finger 2 
17 14078 8079037      TRAK1 trafficking protein, kinesin binding 1 
17 14177 8080487      PRKCD protein kinase C, delta 
17 15732 8102232       LEF1 lymphoid enhancer-binding factor 1 
17 17465 8125172      EHMT2 euchromatic histone-lysine N-methyltransferase 2 
17 18184 8135149      SH2B2 SH2B adaptor protein 2 
17 19665 8154059    SMARCA2 SWI/SNF related, matrix associated, actin dependen 
17 20529 8165217     NOTCH1 notch 1 
17 21198 8173457      ZMYM3 zinc finger, MYM-type 3 
17 21800 8179884      EHMT2 euchromatic histone-lysine N-methyltransferase 2 
19 4234 7951077      SESN3 sestrin 3 
19 525 7903507    FAM102B family with sequence similarity 102, member B 
19 889 7908041      LAMC1 laminin, gamma 1 (formerly LAMB2) 
19 920 7908543       NEK7 NIMA (never in mitosis gene a)-related kinase 7 
19 1629 7918255      CLCC1 chloride channel CLIC-like 1 
19 2217 7925792    ZMYND11 zinc finger, MYND domain containing 11 
19 2465 7929282       HHEX hematopoietically expressed homeobox 
19 2674 7932227       NMT2 N-myristoyltransferase 2 
19 2689 7932512     DNAJC1 DnaJ (Hsp40) homolog, subfamily C, member 1 
19 2901 7935627       GOT1 glutamic-oxaloacetic transaminase 1, soluble (aspa 
19 5095 7962455      NELL2 NEL-like 2 (chicken) 
19 7055 7989094      NEDD4 neural precursor cell expressed, developmentally d 
19 8525 8008113   CALCOCO2 calcium binding and coiled-coil domain 2 
19 9621 8022356     SPIRE1 spire homolog 1 (Drosophila) 
19 11271 8040927      NRBP1 nuclear receptor binding protein 1 
19 11833 8049044      ARMC9 armadillo repeat containing 9 
19 13074 8066716      ELMO2 engulfment and cell motility 2 
19 14105 8079334      LIMD1 LIM domains containing 1 
19 14422 8083779   SERPINI1 serpin peptidase inhibitor, clade I (neuroserpin), 
19 14427 8083839     GPR160 G protein-coupled receptor 160 
19 16557 8113691      DTWD2 DTW domain containing 2 
19 16945 8118310     HSPA1A heat shock 70kDa protein 1A 
19 17352 8124040      ATXN1 ataxin 1 
19 17729 8128956        FYN FYN oncogene related to SRC, FGR, YES 
19 18711 8141688      PLOD3 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 




19 19050 8146243      HOOK3 hook homolog 3 (Drosophila) 
19 19356 8149877      PNMA2 paraneoplastic antigen MA2 
19 19675 8154178       JAK2 Janus kinase 2 
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